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ABSTRACT 
Periodontal disease describes a chronic bacterial infection affecting the gums and bone supporting the 
teeth. Bacteria present in plaque produce toxins, which lead to a cascade of inflammatory events that 
if left untreated may lead to permanent tooth loss. A periodontal pocket forms when the free gingiva 
moves away from the tooth surface.  
Periodontal disease is prevalent worldwide and has risk factors such as HIV and diabetes with 
possible links to socio-economic status. This places a large portion of the South African population at 
risk in an already burdened health care system.   
Scaling and root planning (SRP) forms the keystone of periodontal therapy, involving the removal of 
calculus and plaque. Multiple clinical trials have proved SRP leads to improved clinical outcomes. 
However, it often leaves behind microorganisms leading to recolonisation. Administration of 
pharmacological therapy is used in combination with SRP delivering one or more drugs. Subgingival 
treatment of periodontal disease involves the placement of a drug delivery device within the 
periodontal pocket releasing model drugs over a prolonged period of time. Targeted drug delivery 
devices have been the focus of periodontal research over the past two decades. To date there are no 
commercially available local drug delivery devices in South Africa for the treatment of periodontal 
disease.  
The aim of this study was to design, formulate and evaluate (in vitro) a novel polymeric fibre system to 
locally deliver an antimicrobial and an anti-inflammatory drug over 10 days to the periodontal pocket 
for the treatment of periodontal disease. The design of a flexible fibre would easily fit within the 
periodontal pocket evenly delivering the model drugs to the affected site. Alginate combined with 
glycerol was crosslinked with barium cations forming a monolithic fibre incorporating ciprofloxacin and 
diclofenac sodium, as the model antimicrobial and anti-inflammatory agents respectively. A 3-Factor 
Box-Behnken Design was employed to statistically optimise the fibres according to their tensile 
properties and drug release. The optimised formulation (3.14%w/v alginate, 22.54mL glycerol and 
10.00w/v barium chloride) was evaluated for its drug release and hydration behaviour at pH 4 and 6.8, 
vibrational transitions and tensile properties as well as antimicrobial assays, characterising the in vitro 
behaviour of the device. The pH of the periodontal pocket varies from pH 2-9. Crosslinked alginate 
matrices demonstrate pH-responsive behaviour, therefore the polymeric fibre device was tested at pH 
4 and 6.8. Drug release at pH 4 occurred as a result of drug diffusing through the polymeric fibres. 
However, at pH 6.8 the disruption of the fibre structure led to drug release as a consequence of the 
swelling and erosion of the matrix. Ciprofloxacin was sufficiently released from the drug-loaded fibres 
inhibiting growth of Escherichia coli, Enterococcus faecalis and Streptococcus mutans over 10 days. 
The physicomechanical and physicochemical properties were related to the degree of crosslinking, the 
effect of the plasticiser and the interaction of formulation components. The polymeric fibre device 
formed a strong yet flexible biodegradable matrix which simultaneously released an antimicrobial and 
anti-inflammatory agents in phosphate buffer solution pH 6.8 over 10 days.  The promising in vitro 
results advocate for further analysis of the fibres.  
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(b) E. faecailis and (c) S. Mutans 
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Figure 6.5 MIC plates inoculated with E.coli, wells which changed colour to red 
after addition of INT represented growth of bacteria while wells which 
remained colourless represented no bacterial growth, (a) dissolution 
samples in PBS pH 4 and 6.8 over 10 days (b) controls used for 
verification of results 
 
 
 
 
137 
 
 
 
 
 
 
 
 
 
XVIII 
 
LIST OF TABLES 
Table 1.1 Administration of antimicrobial agents to the periodontal pocket via 
four modes of application (Ryan, 2005) 
 
5 
   
Table 2.1 Advantages and disadvantages associated with oral mucosal delivery 
relating to the treatment of PD (Adapted from Hearnden et al., 2011; 
Sankar et al., 2011) 
 
 
12 
Table 2.2 Risk factors associated with PD 13 
Table 2.3 Local drug delivery devices containing anti-inflammatory agents 17 
Table 2.4 Mechanism of action of antimicrobial agents frequently used in the 
treatment of PD including sensitivity of periodontal pathogens to 
specific antimicrobials  
 
20 
Table 2.5 Local drug delivery devices containing antimicrobial agents 21 
Table 2.6 Local drug delivery devices loaded with chlorhexidine 25 
Table 2.7 Local drug delivery devices containing two or more drugs 26 
Table 2.8 Polymers frequently used in the formulation of drug delivery devices 
placed within the periodontal pocket 
 
31 
   
Table 3.1 Comparison of fibres formulated for the treatment of PD 34 
Table 3.2 Fibre formulations incorporating either triethanolamine or glycerol at 
varying concentrations 
 
39 
Table 3.3 TA.XTplus Texture Analyzer settings for elastic analysis of fibres 40 
Table 3.4 Standard NT transducer settings 43 
Table 3.5 Comparison of breaking force and extension distance of fibres 
incorporating triethanolamine or glycerol as a plasticiser (N=5) 
 
46 
Table 3.6 Comparison of in vitro dissolution test apparatus for drug delivery 
systems intended for placement in the periodontal pocket 
 
51 
Table 3.7 Creep-load analysis of fibres at constant load limit of 2000 and 
2100mN with the applied stress at 5.92MPa and 6.21MPa 
respectively (N=5) 
 
 
57 
Table 3.8 Dynamic-load analysis of fibres with oscillating load between 1000mN 
and 1500mN and the mean stress of 7.4MPa (N=5) 
 
58 
Table 3.9 Tensile-load analysis (N=5) of fibres at a constant velocity rate of 
20µmsec-1 
 
59 
Table 3.10 Effect of formulation components alginate, barium chloride and 
glycerol on observed fibre formation 
 
 
60 
XIX 
 
Table 4.1 Upper and lower limits of the independent variables; polymer 
concentration, crosslinking salt concentration and plasticiser 
concentration 
 
 
64 
Table 4.2 The 3-factor Box-Behnken Design generated for optimisation of the 
fibres 
 
65 
Table 4.3 Cross-sectional area of the experimental design formulations (N=5) 78 
Table 4.4 Correlation between experimental and predicted values for Young’s 
modulus, ultimate strain and MDT10 days for the release of diclofenac 
sodium and ciprofloxacin 
 
 
86 
Table 4.5 Probability of the test (p-test) obtaining the measured responses, 
highlighted are the significant values (<0.05) 
 
87 
Table 4.6 Experimental and predicted values for optimised formulation 1 and 2 95 
   
Table 5.1 Formulation components for optimised fibres prepared 97 
Table 5.2 Gradient method used in the separation of ciprofloxacin and 
diclofenac sodium indicating mobile phase concentrations and flow 
rate at various time periods over the 3 minute run time 
 
 
97 
Table 5.3 MDT10 days for ciprofloxacin and diclofenac release in PBS pH 4 and 
pH 6.8 
109 
Table 5.4 Tensile analysis results comparing drug-free fibres to drug-loaded 
fibres (N=5) 
111 
Table 5.5 Calculated energy parameters (kcal/mol) of polymer-plasticiser, 
polymer-crosslinker and crosslinked-plasticised polymer assemblies 
 
118 
Table 5.6 Calculated energy parameters (kcal/mol) of polymer-drug assemblies 123 
   
Table 6.1 Composition of optimised formulations 130 
Table 6.2 Microbial test organisms with corresponding Gram stains, incubation 
conditions and reference strains 
 
131 
Table 6.3 Controls used to verify MIC results 134 
Table 6.4 Mean zone of inhibition measurements for test organisms (N=3) 134 
Table 6.5 MIC results for ciprofloxacin-loaded and ciprofloxacin/diclofenac-
loaded fibres dissolution samples in PBS pH 4 over 10 days (NI – no 
inhibition) (NG – no growth) 
 
 
138 
Table 6.6 MIC results for ciprofloxacin-loaded and ciprofloxacin/diclofenac-
loaded fibres dissolution samples in PBS pH 6.8 over 10 days (NI – 
no inhibition) (NG – no growth)  
 
 
138 
  
1 
 
CHAPTER 1 
INTRODUCTION 
1.1. Defining and Classifying Periodontal Disease 
Periodontal disease (PD) describes a chronic bacterial infection affecting the gums and bone 
supporting the teeth. It refers to a broad category of oral manifestations that can be further 
classified as the following: gingival diseases, chronic periodontitis, aggressive periodontitis, 
periodontitis as a manifestation of systemic diseases, necrotising periodontal diseases, 
abscesses of the periodontium, periodontitis associated with endodontic lesions and 
developmental or acquired deformities and conditions (Figure 1.1) (Armitage, 1999). PD is 
prevalent worldwide, with 10-15% of adults presenting with advanced signs of the disease, 
which is periodontal pockets greater than 6mm in depth (Perterson and Ogawa, 2005).  
Poor oral hygiene can lead to gingivitis, characterised by red swollen gums that bleed easily. 
Gingivitis affects a large portion of the world’s population (Pihlstrom et al., 2005) and if left 
untreated may advance to periodontitis (Figure 1.2). Bacteria present in plaque, produce 
toxins that lead to a cascade of inflammatory events, resulting in the breakdown of tissues 
and bones supporting the teeth, and the formation of a pocket. Pockets are formed as the 
gum separates from the tooth forming a reservoir that may support the growth of 
microorganisms. Pocket depth is a clinical measurement indicative of the severity of 
periodontitis. As more tissue and bone are destroyed, permanent tooth loss may result. The 
formation of plaque leading to development of gingivitis and the subsequent progression to 
periodontitis is outlined in Figure 1.2.   
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Classification of Periodontal Diseases and Conditions
Gingival Diseases (GD)
Dental plaque 
induced GD
1. Gingivitis 
associated with 
plaque only 
2. GD modified by 
systemic factors
3. GD modified by 
medications
4. GD modified by 
malnutrition 
Non plaque 
induced gingival 
lesions
1. GD of specific 
bacterial / viral / 
fungal origin
2. Gingival lesions 
of genetic origin
3. Gingival 
manifestations of  
systemic diseases
4. Traumatic 
lesions
5. Foreign body 
reacttions
6. Not otherwise 
specified 
Chronic 
Periodontitis
Generalised 
Localised 
Necrotising 
Periodontal 
Diseases
Generalised 
Localised 
Abscesses of 
the 
Periodontum 
Associated with 
hematological 
disorders 
Associated with 
genetic disorders 
Not otherwise 
specified 
1. Aquired 
neutropenia
2. Leukemia's
3. Others 
12 genetic  
classifications
Periodontitis 
associated with 
Endotic 
Lesions
Necrotising 
ulcerative 
gingivitis
Necrotising 
ulcerative 
periodontitis 
Developmental 
or Aquired 
Deformaties and 
Conditions
Gingival absess
Periodontal 
abcess
Pericoronal 
abcess
1. Vertical &/ 
horizontal ridge 
deficiency 
2. Lack of 
gingiva/kertinised 
tissue
3. Gingival/soft 
tissue enlargement 
4. Aberrant 
frenum/muscle 
position
5. Decreased 
vestibular depth 
6. Abnormal colour
Aggressive 
Periodontitis
Combined periodontic-
endontic lesions
1. Primary 
2. Secondary 
Periodontitis as a 
Manifestation of  
Systemic 
Diseases
Localised tooth related 
factors
Mucogingival 
deformaties and 
conditions around 
teeth 
Mucogingival 
deformaties and 
and conditions 
on edentulous  
ridges
Occlusal trauma
1. Tooth anatomic 
factors
2. Dental 
resorations & 
appliances
3. Root fractures
4. Cervical root 
resoations & 
cememtal tears
1. Gingival/soft 
tissue recessions
2. Lack of 
keratinised gingiva 
3. Decreased 
vestibular depth 
4. Aberrent 
frenum/muscle 
potition
5.  Gingival excess 
6. Abnormal colour 
Figure 1.1: Classification of PD and conditions as decided upon at the international workshop held in October/November 1999 
(Adapted from Armitage, 1999)  
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Tooth surface 
↓ 
Adsorption of salivary polypeptide and glycol-proteins 
↓ 
Bacterial invasions in periodontum/surrounding tissues 
Bacterial adhesion and co-aggregation 
↓ 
Calcification of Plaque 
↓ 
Production of bacterial enzymes, exotoxins/endotoxins 
Pathological tissue changes and inflammation 
↓ 
Bacterial and minocytes/lymphocytes interaction 
Release of inflammatory mediators (cytotoxins) 
Inflammation, bleeding and bad breath 
↓ 
Degeneration of collagen and periodontal ligament 
Alveolar bone degeneration 
↓ 
Deepening of the gingival sulcus 
Periodontal tissue destruction and teeth loosening 
↓ 
Loss of teeth 
 
Figure 1.2: Flow chart of the possible pathogenic mechanism of PD (Jain et al., 2008) 
The two distinctive features of PD are the presence of microorganisms and inflammatory 
mediators, as presented in Figure 1.2. The interaction between bacteria and the 
immunoinflammatory response may lead to periodontal tissue destruction (Vardar et al., 
2003) which forms the rationale for the treatment with anti-inflammatory and/or antimicrobial 
agents.  
Normally healthy oral mucosa is host to both aerobic and anaerobic bacteria forming a 
symbiotic relationship (Pihlstrom et al., 2005). It is estimated that 200–500 microorganisms 
are present in the periodontal pocket (Southard and Godowski, 1998) with a greater number 
of Gram-negative and anaerobic bacteria (Wayne et al., 2001; Jain et al., 2008). Causative 
pathogens include: Porphyromonas gingivalis (P. gingivalis), Tannerella forsythensis (T. 
forsythensis), Treponema denticola (T. denticola), Actinobacillus actinomycetemcomitans (A. 
actinomycetemcomitans) and are accompanied by the release of bacterial leukotoxins, 
collenagenases, fibrionlysins and other proteases (Pihlstrom et al., 2005).  The use of 
antimicrobial medication in periodontal therapy is due to the microbial aetiology of 
inflammatory PD (Research, Science and Therapeutic Committee of the American Academy 
of Periodontology, 2004). 
Following local tissue destruction phospholipids present in the cell membrane, through the 
enzymatic action of phospholipase, lead to the formation of arachidonic acid (Heasman, 
1988). Furthermore, arachidonic acid is metabolised into prostaglandins, prostacyclin and 
Pellicle/Cuticle
(Bacteria free) 
Calculus/tartar 
Gingivitis 
Vincent Disease 
(Pyorrhoea) 
Periodontal 
pocket formation 
Periodontitis 
Plaque 
thromoboxane via the cyclooxygenase pathway or leukotrienes via the lipoxygenase 
pathway, as illustrated in Figure 1.3. The cyclooxygenase enzyme (COX) is present in two is 
forms as COX-1, antithromogenic and cytoprotective, and COX-2, inducing the production of 
prostaglandins (Vardar et al., 2003). Gingival tissue concentration of prostaglandin (PG) E2 
and leukotriene B4 are increased in PD with alveolar bone destruction (Requirand et al., 
2000). Therefore, a potential mechanism for blocking PD progression may depend on use of 
non-steroidal anti-inflammatory drugs (NSAIDs), through regulation of arachidonic acid 
metabolites alveolar bone resorption may be suppressed (Salvi and Lang, 2005). 
 
Figure 1.3: Simplified schematic of arachidonic acid metabolism indicating NSAIDs inhibiting 
phospholipase A2 
 
1.2. Rationale for the Study 
Delivery of therapeutic agents to the periodontium can be achieved through local or systemic 
administration. The success of the treatment is largely dependent on the environments in 
which the agent is administered, the mode of administration, the length of time that the 
therapeutic agent remains in the periodontal pocket and the type of therapeutic agent 
administered (Addy and Fugit, 1989; Goodson, 1994). There are three possible 
environments to administer therapeutic agents which deliver the drug to the periodontium, 
namely the supragingival or subgingival regions or systemically (Goodson, 1994).  Local drug 
delivery includes drugs that are administered to the supragingival and subgingival 
environments. Systemic drugs are administered via the oral route, absorbed in the 
gastrointestinal tract and enter the systemic circulation, where the drugs are distributed 
Local tissue 
detruction Phospholipids Arachidonic  acid 
Cyclooxygenase 
Thromboxane
Prostagladins
Prostacylin
5-lipoxygensase
Leukotrines
5-HETE
Other 
lipoxygenase s
Phospholipase 
A2
Inhibited by NSAIDs
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throughout the body. The supragingival environment refers to saliva, supragingival plaque, 
tongue, tonsils and oral mucosa, where therapeutic agents are normally administered as 
mouthwashes. The subgingival environment includes the gingival fluid and periodontal soft 
tissue (Goodson, 1994) with several drug therapies being developed for placement in the 
periodontal pockets, usually releasing the therapeutic agents over an extended period of 
time. Ryan (2005) summarised systemically delivered antimicrobial agents as well as 
supragingival and subgingival antimicrobial formulations, comparing the ability of the 
antimicrobial agent to penetrate deep within the periodontal pocket as well as the 
concentration of drug and duration of treatment (Table 1.1) 
 Table 1.1: Administration of antimicrobial agents to the periodontal pocket via four modes of 
application (Ryan, 2005) 
Objective Mouthrinse 
or toothpaste 
Local 
irrigation 
Systemic 
delivery 
Controlled 
delivery 
Reach pocket depth of 4mm Poor Good Good Excellent 
Adequate concentration Poor Good Fair Excellent 
Adequate duration  Poor Poor Fair Good 
Systemic drug delivery has traditionally been the preferred route of drug administration and 
refers to orally administered drugs. This popular route is used for systemic delivery of 
antimicrobials and anti-inflammatory agents for the treatment of PD. The systemic route of 
delivery is easy and convenient to use as well as ensuring even distribution of the drug to 
multiple sites of infection (Research, Science and Therapeutic Committee of the American 
Academy of Periodontology, 2004).  Disadvantages of systemic drug delivery include 
reduced patient compliance (Goodson, 1994; Loesche, 1998) and increased risk of adverse 
drug reactions (Soskolne, 1997; Research, Science and Therapeutic Committee of the 
American Academy of Periodontology, 2004) as well as leading to the emergence of 
resistant strains (Goodson, 1994). Peak concentrations of typical systemically administered 
antimicrobials are 3µg/mL in the gingival fluid and blood, however levels of between 1-
16µg/mL are necessary to inhibit the growth of microorganisms (Goodson, 1994).  
Site-specific drug delivery leads to administration of drugs via mucosal linings, namely nasal, 
rectal, vaginal, ocular and oral. The advantages of delivery through these transmucosal 
routes are that the dosage by-passes first pass metabolism in the liver, avoids presystemic 
elimination and directly delivers the drug to the systemic circulation (Shojaei, 1998; 
Hearnden et al., 2011). The aim of local drug delivery in PD is to achieve higher 
concentrations of therapeutic agents within the periodontal pocket over a predetermined 
period of time.   
 
Addy and Fugit (1989) differentiated the local drug delivery to the oral cavity according to the 
vehicle used in the delivery devices based on the expected time which the therapeutic agent 
would remain in the mouth as follows: 
a) Short-term (seconds to minutes): examples are toothpastes, mouthwashes and 
irrigations. 
b) Medium-term (hours): examples are gels and ointments. 
c) Long-term (days to weeks): examples are degradable and non-degradable sustained 
delivery devices.  
Short to medium term delivery vehicles are used mainly in supragingival plaque control and 
in the prevention of gingivitis (Addy, 1994). Pitcher et al. (1980) noted that mouth rinsing did 
not penetrate periodontal pockets sufficiently, therefore limiting its use in subgingival 
applications.  
 
Figure 1.4: Periodontal pocket: site of implantation of sustained drug delivery devices 
(Adapted from Gupta, 2008)  
Sustained drug delivery devices can be further subdivided into degradable and non-
degradable devices. The device generally consists of a matrix within which the drug is evenly 
distributed. In non-degradable devices, the drug diffuses from an insoluble non-degradable 
polymer which needs to be removed after treatment is completed, while degradable devices 
release the drug via diffusion and matrix erosion and therefore do not need to be removed 
from the periodontal pocket (Medlicott et al., 1994). Higher levels of drug in gingival fluid 
leading to improved clinical parameters evident with intra-pocket delivery systems (Jain et 
al., 2008) for even distribution of drug throughout the periodontal pocket (Soskolne, 1997). 
Site-specific drug delivery selectively target the diseased site with superior treatment results 
(Research, Science and Therapeutic Committee of the American Academy of 
Periodontology, 2001). Furthermore, degradable devices have the added advantage of 
improved patient compliance as there is no need to remove the device from the periodontal 
pocket (Medlicott et al., 1994).   
Periodontal pocket 
Site for administration of 
controlled release formulations 
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Currently there are no locally-acting products on the South African market to treat PD. If a 
product such as this is required, special permission has to be obtained from the Medicines 
Control Council (MCC) of South Africa to import the product from abroad (Medicines and 
Related Substances Act, 1965). If the device were to be used routinely, the product would 
need to be registered with the MCC as a medicine. The use of existing locally delivered 
products is costly (Venezia and Shapira, 2003). Furthermore, the difficulty of importing these 
products together with the importation costs are primary reasons why local devices are not 
generally used for the treatment of PD in South Africa. Hence, the development of a drug 
delivery system within South Africa is necessary.  
1.3. Aims and Objectives 
The aim of this study was to design, formulate and evaluate a novel polymeric fibre device 
(PFD) to deliver an antimicrobial and anti-inflammatory drug over a prolonged period of time 
that could be used for the treatment of PD. The PFD device is placed in the periodontal 
pocket for site-specific delivery of ciprofloxacin (model antimicrobial agent) and diclofenac 
sodium (model anti-inflammatory agent). To achieve this aim, the following objectives were 
outlined: 
1. To formulate a PFD loaded with an anti-inflammatory and antimicrobial agent.  
2. To evaluate the physicochemical and physicomechanical properties of the PFD.  
3. To assess the drug release behaviour of the model drugs from the PFD.  
4. To employ a 3-factor Box-Benkhen statistical design to analyse the ideal 
experimental variables established in preliminary investigations and to determine the 
optimum parameters to synthesise the PFD. 
5. To develop an ultra performance liquid chromatography method for the co-detection 
of the anti-inflammatory and antimicrobial agents. 
6. To develop a quantitative method to analyse the antimicrobial efficacy of the 
optimised PFD. 
7.  To evaluate the in vitro antimicrobial efficacy of the optimised PFD. 
1.4. Novelty of the Study 
Local drug delivery systems aim to deliver drug to the site of action. The affected site in PD is 
the periodontal pocket, which provides an ideal environment for the administration of a drug 
delivery device.  Numerous drug delivery systems, such as chips, gels, fibres, microparticles 
and strips have been formulated and tested but only a handful of these systems are now 
commercially available abroad and none of which are easily obtainable in South Africa. 
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Although numerous local delivery systems have been developed for the treatment of PD, this 
system is novel in the fact that: 
• The PFD is a biodegradable system, intended to be placed around the tooth for even 
distribution of drugs within the periodontal pocket simultaneously delivering 
ciprofloxacin, a fluoroquinolone antibiotic, and diclofenac sodium, a nonsteroidal anti-
inflammatory agent. 
• An innovative method of crosslinking a co-blended polymeric plasticised matrix was 
employed in formulating the fibres.  
• The first co-blended crosslinked glycerol and alginate PFD intended for treatment of 
PD.  
• According to the literature surveyed, this study is one of the first investigations in 
formulating a local delivery device in South Africa and the first fibre developed locally 
intended for the treatment of periodontal disease.  
1.5. Overview of the Dissertation 
The content of each chapter in this dissertation is based on the aforementioned aims and 
objectives. A schematic, Figure 1.5, reviews the content of each chapter.  
A concise review of PD followed by descriptions of the rationale and novelty of the study is 
given in Chapter 1. The literature reviewed in this chapter focuses on systemic versus local 
drug delivery within the periodontal pocket. The aims and objectives of the study are outlined 
in this chapter.  
Existing chemotherapeutic approaches to the treatment of PD are reviewed in Chapter 2, 
investigating systemic and local delivery of anti-inflammatory and antimicrobial agents. The 
chapter examines the design of the drug delivery devices and the polymers used in 
controlled delivery of a drug to the periodontal pocket.  
Chapter 3 reviews existing fibre formulations that have been prepared for controlled delivery 
of antimicrobial agents to the periodontal pocket, as well as preliminary studies in developing 
a suitable polymeric fibre. The effect of formulation components, identifying formulation 
variables and choosing a suitable antimicrobial agent are described in this chapter. 
A 3-factor Box-Behnken experimental design was used for analysis and optimisation of the 
PFD in Chapter 4. The responses used as the basis for the assessment and design of the 
proposed fibres were; Young’s modulus, ultimate strain and mean dissolution time over 10 
days for the release of ciprofloxacin and diclofenac sodium. Two optimised formulations were 
determined and tested; following which one was selected for further analysis. 
9 
 
Chapter 5 analyses the physicochemical and physiocomechanical properties of the 
optimised PFD where both ciprofloxacin and diclofenac sodium were simultaneously loaded 
in one formulation.  An ultra performance liquid chromatography method was developed to 
determine concurrent drug entrapment and release of ciprofloxacin and diclofenac sodium 
from the fibre. The assessment of hydration behaviour, textural properties and vibrational 
transitions of drug-loaded and drug-free fibres are described in this chapter. Lastly the static 
lattice atomistic simulations, using molecular mechanics energy relationships, elucidated the 
effect of formulation components and model drugs on the tensile properties of the fibre.   
The antimicrobial activity analysis of optimised ciprofloxacin- and diclofenac sodium-loaded 
PFD is contained in Chapter 6. Qualitative and quantitative results were obtained employing 
agar diffusion assays and minimum inhibitory concentration assays respectively.  
Chapter 7, the final chapter in the dissertation, contains the conclusion and future 
recommendations of the study. 
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Figure 1.5: Schematic of the content contained in each chapter of the dissertation 
 
 
Chapter 7
Chapter 6
Chapter 5
Chapter 4
Chapter 3
Chapter 2
Chapter 1
Identify disease 
condition and 
rationale for the 
study 
Review literature 
Local delivery of 
drugs 
Preliminary 
design 
Experimental 
design 
Analysis of 
optimised design  
Antimicrobial 
analysis of 
optimised design 
Conclusion and 
recmmendations
Sytemic delivery 
of drugs 
Identified formulation components: 
polymer, crosslinking salt, plasticiser and 
model drug. Establish upper and lower 
levels of design variables.  
A 3-factor Box-Behnken design generated 
15 experimental design formulations. 
Analysis of these formulations yielded an 
optimised design for further analysis.  
Ciprofloxacin and diclofenac sodium were 
simultaneously incorporated in the optimised 
design and the physicomechanical and 
physicochemical properties of the fibres 
were assessed.   
The antimicrobial activity of the drug 
loaded optimised fibres were assessed 
against a two Gram-positive and one 
Gram-negative periodontal pathogen.  
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CHAPTER 2 
ANTI-INFLAMMATORY AND ANTIMICROBIAL CHEMOTHERAPEUTIC APPROACHES 
TO THE TREATMENT OF PERIODONTAL DISEASE 
2.1. Anatomy and Physiology of the Periodontum 
The Latin translation of the word periodontum is “around the tooth” and includes the gingiva 
and attachment apparatus. Identifying the functions and structures of the periodontum is 
essential to understanding the diseases affecting these structures (Bartold, 2006). A basic 
anatomical sketch of the periodontum is shown in Figure 2.1.  
 
 
 
 
 
Figure 2.1: Anatomical structure of a healthy and diseased tooth and periodontum (Adapted 
from American Academy of Periodontology, 2011) 
The gingiva is a covering that protects components of the periodontum primarily against 
mechanical insults such as chewing and tooth brushing. It can be anatomically subdivided 
into the free gingiva, attached gingiva and interdental gingiva or papilla. Covering the gingiva 
is a layer of stratified squamous epithelium which regularly undergoes keratinisation leading 
to a high degree of cell turnover. The attachment apparatus can be divided into the 
periodontal ligament, cementum and alveolar bone. Their primary function is that of support 
and securing the teeth (Hassell, 1993). Vessels of the periosteum, periodontal ligament and 
alveolar bone supply blood to the gingiva. The rich blood supply and high permeability of the 
oral mucosa leads to its popularity as a route of administration for both systemic and local 
drug delivery (Shojaei, 1998). 
Healthy tooth 
and gum  
Diseased 
 tooth and gum  
Gingival tissues   
Alveolar bone   
Tooth consisting of 
enamel dentin and pulp  
Plaque   
Tartar 
Periodontal pocket 
Reduced bone level 
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The oral mucosa has been a popular route of drug administration for a variety of systemic 
and local applications. The advantages and disadvantages of this route of drug 
administration for the purpose of treating PD are summarised in Table 2.1.  
Table 2.1: Advantages and disadvantages associated with oral mucosal delivery relating to 
the treatment of PD (Adapted from Hearnden et al., 2011; Sankar et al., 2011) 
Advantages Disadvantages 
Accessible Permeability of oral mucosa  
Highly hydrated environment for drug dissolution  Mastication and speech may dislodge device 
Possible sustained delivery  Taste requires important consideration  
Potential reduction in systemic side effects Enzymes present  
Less drug is incorporated within the device as 
targeted drug delivery reduces wastage 
Small surface area available for absorption of 
drug  
Avoids first pass metabolism  Risk of choking / swallowing device 
Rich blood supply Saliva may wash drug away 
Clinical measures for the detection of periodontitis are gingival bleeding; bone loss 
(assessed through radiographs); probing depth of the pocket and Clinical Attachment Loss 
(CAL) (Research, Science and Therapeutic Committee of the American Academy of 
Periodontology, 2005). PD and CAL can be defined as the distance from the gingival margin 
and cementoenamel junction respectively, to the base of the crevice. Probing depth is rapidly 
measured and provides a good assessment of PD. In comparison, CAL estimates the 
damage to the periodontum, but is more difficult to measure (Research, Science and 
Therapeutic Committee of the American Academy of Periodontology, 2003). 
2.2. Risk Factors 
Identification of risk factors in patients is useful in determining their predisposition to 
developing certain conditions. Extensive research has been conducted into factors that may 
increase the possibility of developing PD. Review papers that summarised epidemiological 
studies were analysed to identify the key risk factors. Brief descriptions of the risk factors 
identified from these studies are given in Table 2.2.   
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Table 2.2: Risk factors associated with PD 
Risk Factor Relationship with (PD) Review Article 
Plaque and 
Oral hygiene 
• Causative relationship between plaque accumulated 
from poor oral hygiene and gingivitis.   
• Weak correlation between reduction in plaque 
accumulation and PD.  
*RST American Academy 
of Periodontology, 1996 
Microbiota • Gram-negative bacteria present at diseased sites: A. 
actinomycetemcomitans, T. forsynthesis, P. gingivalis, 
Prevotella intermedia, Fusobacterium nucleatum, 
Camphylobacter rectus, T. denticola.  
*RST American Academy 
of Periodontology, 1996 
Smoking • Smoking increases risk of developing PD. 
• PD more severe in smokers compared to non smokers.  
*RST American Academy 
of Periodontology, 1996 
Diet • Increased risk PD associated with severe vitamin C 
deficiency and malnutrition.  
Petersen and Ogawa, 
2005 
Pihlstrom et al., 2005 
Diabetes 
mellitus 
• Higher prevalence in patients with diabetes mellitus.  
• More severe periodontal infections compared to non-
diabetics.  
• Increased risk associated with poorly controlled 
diabetics. 
*RST American Academy 
of Periodontology, 1996 
Petersen and Ogawa, 
2005 
Pihlstrom et al., 2005 
HIV/AIDS • More severe and unusual forms of PD with AIDS. 
• CD4+ counts less than 200 cells per microliter often 
associated with the presence of necrotizing ulcerative 
periodontitis.  
*RST American Academy 
of Periodontology, 1996 
Pihlstrom et al., 2005 
*RST – Research, Science and Therapeutic Committee  
The majority of the studies from which the data in Table 2.2 was obtained were conducted on 
patients in the USA. Studies completed in South Africa and other parts of Africa provide 
pertinent information regarding the prevalence of and potential risk factors predisposing parts 
of the population to PD. These studies relate to socio-economic variables (Gugushe, 1998; 
Naidoo et al., 2001), diabetes (Peck et al., 2006; Matu et al., 2009) and HIV infection 
(Arendorf and Holmes 2000; Holmes and Stephen, 2002; Robinson, 2002; Ranganathan and 
Hemalatha, 2006) as risk factors affecting the South African population.     
A high prevalence of gingivitis and periodontitis was reported in African patients associated 
with poor nutrition and inadequate oral hygiene (Ranganathan and Hemalatha, 2006). A 
national health survey conducted in 1998 confirmed that oral diseases affect a large number 
of South Africans in older population groups, especially those considered non-urban Africans 
and people with little education (Naidoo et al., 2001). Gugushe (1998) studied the effect of 
race, education level and income on the prevalence of PD in the adult South African 
population and deduced that socio-economic variables appear to influence the frequency 
distribution of PD.  
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Worldwide studies have identified diabetes as a substantial risk factor associated with PD. 
Matu et al. (2009) confirmed that diabetics in a group of coloured and black communities in 
South Africa had a higher prevalence of PD than non-diabetics in the control group. A study 
conducted in a rural area in South Africa on type II diabetics found that PD was common 
(42%) in patients who had poorly controlled diabetes (Peck et al., 2006). An estimated 2 
million South Africans are living with diabetes (Butler, 2009), thus identifying diabetes as a 
serious risk factor in PD. 
Oral lesions associated with HIV vary in developing countries compared to developed 
countries (Holmes and Stephen, 2002; Ranganathan and Hemalatha, 2006). PD in HIV 
infection is significant as “they may alert the presence of HIV infection or the progression of 
the disease and they may have relevance to dentists for service planning and the treatment 
of individual patients” (Robinson, 2002). There is a higher prevalence of HIV-associated PD 
in developing countries compared to developed countries (Arendorf and Holmes, 2000). In 
2010, the number of South Africans living with HIV was estimated at 5.24 million (Statistics 
South Africa, 2010), therefore this is likely to be a significant factor affecting in the presence 
of PD in the South African population. 
2.3. Current Treatment of Periodontal Disease  
Mirth (1987) stated that “…accessibility of the oral cavity, the tolerance of the individuals to a 
variety of intra-oral appliances, and the known benefits of therapeutic agents in the 
prevention and treatment of oral disease, combined with the ability of compact controlled-
release therapeutic systems to deliver medicinal agents at a predictable rate for extended 
periods, make the development of therapeutic systems for oral disease a logical outcome.” 
This statement explains the initiative to develop a controlled release formulation for the 
treatment of PD. Several approaches to the treatment of PD exist. The choice of treatment is 
dependent on the type of PD present and the therapeutic objective of treatments as well as 
determining anatomical variations present and extent of attachment loss (Research, Science 
and Therapeutic Committee of the American Academy of Periodontology, 1997). Treatment 
of PD can be broadly categorised into, surgical and non-surgical treatments. The focus of 
this chapter is limited to nonsurgical treatments relating to pharmacological interventions.  
The goal when treating PD is eradication of microorganisms followed by regeneration of 
structures destroyed by the disease (Research, Science and Therapeutic Committee of the 
American Academy of Periodontology, 2001). Scaling and root planing (SRP) forms the crux 
of periodontal therapy involving the removal of calculus and plaque (Pihlstrom et al., 2005; 
Ryan, 2005). SRP combined with home care can lead to positive outcomes, but this may be 
hard to achieve (Chapple, 2009). Multiple clinical trials have proved SRP leads to a reduction 
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in microbial load, reductions in bleeding time upon probing and gain in attachment levels. 
However, this time-consuming process inevitably leaves behind microorganisms leading to 
recolonisation (Ryan, 2005).  Pharmacological therapy is often used in combination with SRP 
delivering one or more chemotherapeutic agents.  These may be delivered either 
systemically or locally within the periodontal pocket.  Antimicrobial and anti-inflammatory 
agents have shown to be beneficial in the treatment of PD. These two broad categories of 
pharmacological agents used in the treatment of PD is discussed with the focus on their 
mechanism of action, particular drugs used, form in which the drug is delivered, and their 
efficacy in the treatment of PD.  
2.3.1. Anti-inflammatory agents 
Anti-inflammatory agents are classified in two broad categories based on their inhibition of 
the COX isoforms. COX-1 selective agents and COX-2 selective agents inhibit 
cyclooxygenase enzyme 1 and 2 respectively. Non-steroidal anti-inflammatory drugs 
(NSAIDs) non-selectively inhibit COX-1 and COX-2 enzymes, with various NSAIDs 
displaying different affinities for these enzymes. 
NSAIDs have been investigated for their potential role in PD treatment. Jeffcoat et al. (1988) 
investigated the effect of flurbiprofen (50mg) administered twice daily for two months. Their 
investigation concluded that a significant decrease in bone loss was evident in the group 
receiving flurbiprofen compared to the placebo group. Vardar et al. (2003) compared oral 
administration of a relatively selective COX-2 inhibitor (nimesulide) and a non-selective COX-
1 and COX-2 inhibitor (naproxen) on the gingival tissue levels of PG E2 and PG F2α. 
Nimesulide inhibited PG F2α sufficiently, however insignificant inhibition of PG E2 was evident 
while naproxen inhibited PG E2 significantly. Offenbacher et al. (1989) reported elevated 
levels of PG reaching a maximum at 6 months in animal models resulting in the adoption of 
the principle of using anti-inflammatory agents over an extended period of time for the 
treatment of PD. Although NSAIDs demonstrate inhibition of COX-1 and COX-2 enzymes, 
their systemic side effects may limit their long term application in PD leading to the use of 
COX-2 selective agents. Non-selective inhibition of the COX enzyme leads to interference of 
the production of PG E2 and PG I2 which stimulate the production of a cytoprotective 
mucous, without which leads to damage of the gastric mucosa (Salvi and Lang, 2005).  
An over expression of COX-2 mRNA and protein levels are elevated in chronic periodontitis 
compared to healthy subjects (Zhang et al., 2003). This suggests a possible target for 
pharmacological treatment. In a double-blind study where 60mg Loxoprofen, a selective 
COX-2 inhibitor, in conjunction with SRP was administered to the experimental group, while 
the control group received SRP in conjunction with a placebo over the 28-day period (Pinho 
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Mde et al., 2008). Both groups had successful reduction of inflammation and promoted 
pocket size reduction on day 28 of the study. The experimental group receiving loxoprofen 
demonstrated a slight benefit compared to the placebo group. Although COX-2 selective anti-
inflammatories do not affect the gastrointestinal system, certain COX-2 selective anti-
inflammatories have been associated with cardiovascular risks (Mukherjee et al., 2001). 
Another chemotherapeutic agent targeting the immune response pathway is low doses of 
doxycycline (20mg per capsule), commercially branded as Periostat®. The FDA approved the 
subantimicrobial dose of doxycycline, which is not sufficient to inhibit the growth of 
periodontal bacteria, however it reduces production of collagenase, the enzyme responsible 
for the destruction of gingival tissues. Thomas et al. (1998) conducted a 9-month study, 
researching the long-term subantimicrobial doses of doxycycline and confirmed that the 
administration of Periostat® was not associated with the emergence of tetracycline-resistant 
bacteria.   Golub et al. (2001) studied the effect of subantimicrobial doses of doxycycline on 
collagenase activity and attachment loss in adult periodontitis conducting a three-part, 
placebo-controlled, double-blind, parallel group study. After completion of the 36-week study 
reduction of collagenase activity and improved levels of periodontal attachment were evident.  
The emergence of targeted drug delivery systems lead to the development of a local drug 
delivery devices which are placed within the periodontal pocket loaded with an anti-
inflammatory agent. Numerous devices, summarised in Table 2.3, have been formulated with 
various anti-inflammatories in an assortment of polymeric systems. The majority of these 
studies were limited to in vitro results only, however, clinical data is necessary in determining 
the success of locally delivering anti-inflammatories to the periodontal pocket.  
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Table 2.3: Local drug delivery devices containing anti-inflammatory agents  
Polymer matrix Archetype Model drug 
incorporated 
Data available Reference 
Atelocollagen  Film  Meloxicam  In vitro  Cetin et al., 2005 
Cellulose acetate Film Indomethacin / 
meloxicam 
In vitro  Cetin et al., 2004 
2-ethylhexyl 
acrylate, 2-
hydroxyethyl 
methacrylate & 
methacrylic acid 
Film  Ketorolac  In vitro  Wong and 
Nguyen, 1998 
Poly(L-lactide) 
(PLA) 
Membrane 
cast on 
poly(glycolide) 
mesh 
Flurbiprofen  In vitro  Park et al., 1997 
Poly(anhydride 
ester) 
Membranes Salicylic acid In vivo (animals) Erdmann and 
Uhrich, 2000 
Systemic and local administration on a rat model of selective inhibitors of COX-1 and COX-2 
agents were investigated to determine the role played by COX isoforms (Queiroz-Junior et 
al., 2009). Indomethacin, celecoxib, SC 236 {4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-
pyrazol-1-yl]benzenesulfonamide} and SC 560 [5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-
trifluoromethyl pyrazole] were the anti-inflammatory agents used, injected by subcutaneous 
bolus injection when dosed systemically or injected into the gingival tissue at the buccal side 
when administered locally. The results of the study revealed the use of both selective and 
non-selective COX inhibitors reduce the signs of the disease in periodontal tissues as well as 
confirming that administration, either locally or systemically, of COX inhibitors would be 
effective. It was further shown that treatment with local administration of NSAIDs would 
reduce systemic side effects associated with these drugs.  
Cetin et al. (2004) loaded cellulose acetate films with anti-inflammatory agent’s indomethacin 
or meloxicam to study their in vitro release behaviour. Indomethacin released the quickest, at 
a rate of 0.022mg/hr, for the first 8 hours then dropping to 0.01mg/hr between 24 and 118 
hours. A total of 70% of the entrapped drug was release over the time of the study. In 
comparison, meloxicam-loaded films released a total of 30% of drug over 118 hours at an 
initial rate of 0.8mg/hr for the first 8 hours then reducing substantially to 0.4mg/hr between 24 
and 118 hours. The study was the first of its kind investigating the sustained release rate of 
an anti-inflammatory agent over extended period of time from a cellulose acetate film.  
Park et al. (1997) proposed the development of a polymeric membrane consisting of a 
poly(glycolide) mesh which a poly(L-lactide) solution is spun onto. These membranes were to 
be placed subgingivally as part of guided tissue regeneration treatment.  Flurbiprofen or 
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tetracycline was loaded into the membranes and were chosen for their effect on alveolar 
bone loss through inhibiting arachidonic acid metabolism and their anti-collagenolytic activity 
respectively. In vitro drug release profiles revealed constant release of either drug over 7 
days; however tetracycline membranes initially demonstrated burst release. Drug release 
was dependent on hydrophobicity of the entrapped drug as well as the porosity of the 
membranes. The in vitro studies demonstrated the potential of the biodegradable membrane 
as a tool in improving guided regeneration techniques.  
2.3.2. Antimicrobial agents 
Eradication of pathogens from the periodontal cavity is the goal of antimicrobial treatment 
(Goodson, 1994). Antimicrobials may be delivered locally within the periodontal pocket or 
administered systemically. 
Systemic antibiotic therapy is not routinely recommended for patients diagnosed with 
gingivitis or periodontitis, but rather restricted to patients who continue to lose attachment 
while receiving SRP (Research, Science and Therapeutic Committee of the American 
Academy of Periodontology, 2004). Table 2.4 summarises the antibiotics commonly used in 
the treatment of PD including their mechanism of action as well as their activity against 
periodontal pathogens.  
A study conducted by Haffajee et al. (1995) compared clinical and microbiological outcomes 
in four groups each receiving a systemically administered agent namely, Augmentin®, 
tetracycline, ibuprofen and a placebo for 30 days. The data revealed that on average all 
groups achieved an overall gain in periodontal attachment. However, the Augmentin® and 
tetracycline group at 10 months showed more periodontal attachment compared to the 
ibuprofen and placebo groups. Furthermore, a reduction in periodontal pathogens 10 months 
post therapy was evident especially in the antibiotic groups yet no pathogen was completely 
eradicated.     
Resistance of pathogens to antimicrobials is a rising problem. Ardila et al. (2010) studied the 
susceptibility of Aggregatibacter actinomycetemcomitans and P. gingivalis to systemically 
delivered antimicrobials; clindamycin, metronidazole, amoxicillin and moxifloxacin and 
amoxicillin/clavulanic acid. The results revealed that both pathogens demonstrated 
resistance to amoxicillin, clindamycin and metronidazole while all isolates of these two 
pathogens were susceptible to amoxicillin/clavulanic acid and moxifloxacin.  
Numerous studies which have focused on the development of local drug delivery of 
antimicrobials to the supragingival and subgingival regions are summarised in Table 2.5. 
Antimicrobial agents contained within local devices is recommended for use as an adjunct to 
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SRP in chronic periodontitis with a pocket depth greater than or equal to 5mm that has not 
responded to conventional therapies with inflammation still present (Research, Science and 
Therapeutic Committee of the American Academy of Periodontology, 2006). The four 
products which are mostly widely used and commericially available in either the USA or UK 
are expanded upon following Table 2.4.  
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Table 2.4: Mechanism of action of antimicrobial agents frequently used in the treatment of PD including sensitivity of periodontal 
pathogens to specific antimicrobials  
 Mechanism of action Example of antimicrobial 
used in PD 
Notable activity against certain periodontal pathogens References 
C
e
l
l
 
w
a
l
l
 Penicillins   
Inhibit peptidoglycan synthesis Amoxicillin and 
Clavulanate  
A. actinomycetemcomitans and P. gingivalis 
 
 
Ardila et al., 
2010 
P
r
o
t
e
i
n
 
s
y
n
t
h
e
s
i
s
 
Lincosamides     
Interfere with initiation complexes and 
translocation reactions on the 50S 
ribosomal subunit   
Clindamycin  Spirochetes, motile rods, Prevotella intermedia, P. gingivalis, 
Selenomonas spp., Campylobacter rectus 
Sauvêtre et al., 
1993 
Macrolides     
Reversibly binding to the 50S 
ribosomal subunit 
Azithromycin, 
 
 
 
Clarithromycin 
Spirochetes 
Gram-negative anaerobes especially Fusobacterium spp., 
Bacteroides spp., Wolinella spp. , A. actinomycetemcomitans, 
Selenomonas spp., Mitsuokella multiacida 
Gram-positive anaerobes  including Actinomyces spp. , 
Propionibacterium spp. , Lactobacillus spp., Bifidobacterium 
dentium 
Sefton et al., 
1996 
Williams et al., 
1992 
Williams et al., 
1992 
Tetracyclines     
Reversibly bind to the 30S ribosomal 
subunit 
Doxycycline 
 
 
Tetracycline 
A. actinomycetemcomitans and P. gingivalis  
Serratia marcescens, Enterobacter cloacae, some strains of 
Enterobacter sakazakii, Acinetobacter baumannii 
Fusobacterium nucleatum, P. gingivali, Prevotella intermedia, 
Eikenella corrodens, Campylobacter rectus, A. 
actinomycetemcomitans  
Lavda et al., 
2004 
Barbosa et al., 
2001 
Lowenguth and 
Greenstein, 
1995 
D
N
A
 
Fluoroquinolones     
Inhibit one or more of a group of 
enzymes called topoisomerases that 
are essential for bacterial DNA 
replication and transcription; inhibit 
DNA gyrase 
Ciprofloxacin  A. actinomycetemcomitans 
Pseudomonas aeruginosa, Serratia marcescens, Klebsiella 
oxytoca, Enterobacter cloacae, Enterobacter sakazakii, 
Kluyvera cryocrescens, Acinebacter baumanni 
Conway et al. 
2000; Lavda et 
al. 2004 
Barbosa et al., 
2001 
Nitroimidazole     
Interfere with nucleic acid synthesis 
resulting in the loss in DNA structure, 
strand breakage and impaired DNA 
function. 
Metronidazole  Strong activity against Gram-negative anaerobes particularly 
spirochetes, Selenomonas spp., motile robs and Prevotella 
intermedia 
Loesche et al. 
1992 
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Table 2.5: Local drug delivery devices containing antimicrobial agents 
Polymer matrix Archetype Model drug  
incorporated 
Data available Reference 
Formulations containing one polymer: 
Atelocollagen  Film  Tetracycline  In vivo (humans)  Minabe et al., 1989 
Cellulose acetate Fibre Tetracycline In vivo (humans) Goodson et al., 
1979 
Chitosan Film  Ciprofloxacin In vitro  Ahmed et al., 2009 
 Microspheres Tetracycline  In vitro Govender et al., 
2005 
Ethylcellulose  Film  Minocycline  In vivo (humans) Elkayam et al., 1988 
 Film  Ornidazole  In vitro Ramachandra et al., 
2011 
Ethyl vinyl acetate  Fibre Tetracycline In vivo (humans) 
Commercially 
available product 
Actisite® 
Goodson et al., 
1991 
Hydroxypropyl 
cellulose 
Strip Tetracycline  In vivo (humans)  Noguchi et al., 1984 
 Strip Doxycycline  In vivo (humans)  Taner et al., 1994 
Hydoxypropyl 
methylcellulose 
Ointment Minocycline In vivo (humans) Nakagawa et al., 
1991 
 Strip Doxycycline  In vivo (humans) Taner et al., 1994 
Methylcellulose  Strip Doxycycline  In vivo (humans)  Taner et al., 1994 
Poly(ε-caprolactone) 
(PCL) 
Film Minocycline In vitro Kyun et al., 1990 
Fibres Gentamycin  In vitro  Chang et al., 2008 
Nanofibres Metronidazole  In vitro  Zamani et al., 2010 
Poly-co-glycolic acid 
(PLGA) 
Strip Tetracycline / 
metronidazole 
In vivo (humans)  Deasy et al., 1989 
Film  Amoxicillin & 
metronidazole 
In vitro Ahuja et al., 2006 
Strip Tetracycline  In vivo (humans)  Maze et al., 1995 
Film  Tetracycline  In vivo (humans)  Agarwal et al., 1993 
Gel Tetracycline In vivo (humans)  Maze et al., 1996 
Microparticles  Tetracycline  In vitro  Esposito et al., 1997 
Microparticles  Minocycline  In vivo (humans) 
commercially available 
Arestin® 
Van Dyke et al., 
2002 
Paquette, 2002 
Film  Metronidazole In vivo (humans)  Golomb et al., 1984 
Film  Tetracycline  In vitro  Agarwal et al., 1993 
Polyethylmetha 
acrylate (acrylic) 
Strip  Tetracycline / 
metronidazole   
In vivo (humans)  Addy et al., 1988 
Addy and 
Langeroudi, 1984 
Polyhydroxybutyric 
acid  
Strip Tetracycline / 
metronidazole 
In vivo (humans)  Deasy et al., 1989 
PLA Membrane cast 
on 
Poly(glycolide) 
mesh 
Tetracycline  In vitro  Park et al., 1997 
Poly(ortho esters) Semi-solid  Tetracycline  In vivo (humans)  Roskos et al., 1995 
Schwach-Abdellaoui 
et al., 2002 
 
 
 
 
 
 
22 
 
Polymer matrix Archetype Model drug  
incorporated 
Data available Reference 
Formulations consisting of two or more polymers: 
Chitosan & PCL Film  Metronidazole In vivo (humans) El-Kamel et al., 
2007 
Ethyl cellulose  & 
Polyethylene glycol 
Film  
Patch 
Tetracycline 
Tetrcycline / 
Carvacrol  
In vitro  
In vitro 
Azoury et al., 1998 
Obaidat et al., 2011 
Eudragit L® & 
Eudragit S® 
 
Film  Clindamycin  In vivo (animals)  Higashi et al., 1991 
Glycerol monooleate 
& sesame oil 
 
Gel Metronidazole In vivo (humans) 
commercially available 
- Elyzol® 
Noyan et al., 1997 
Hydroxyethyl 
cellulose & 
polycarbophil 
Gel Metronidazole In vitro Jones et al., 1997 
Hydroxyethyl 
cellulose & 
polyvinylpyrrolidone 
Gel  Tetracycline In vitro  Jones et al., 1996 
Hydroxypropyl 
cellulose & carbomer 
940  
Tablet Metronidazole In vitro Perioli et al., 2004 
Hydroxypropyl 
cellulose, 
hydroxyethyl 
cellulose, Eudragit 
RL-100 & 
ethylcellulose  
Strip Sparfloxacin In vitro  Muchalambe et al., 
2010 
Hydroxypropyl 
cellulose & 
methacrylic acid 
Strip Ofloxacin  In vivo (humans)  Higashi  et al., 1990 
Hydroxypropyl 
methylcellulose & 
sodium alginate  
Gel Doxycycline  In vitro  Obaidat et al., 2010 
Polyhydroxybutyric 
acid & PLA 
Compact Tetracycline In vivo (humans) Collins et al., 1989 
PLGA & 
methoxypoly(ethylen
eglycol) / diblock 
copolymer [poly(D,L-
lactic acid)-block-
methoxypolyethylene
glycol)] 
Film  Tetrcycline 
hydrochloride  
In vitro  Owen et al., 2010 
Poly(DL-lactide) & N-
methyl 2-pyrrolidone 
Gel  Doxycycline  In vivo (humans  
Commercially 
available - Atridox® 
Polson et al., 1997 
PLGA & PCL Microparticles Doxycycline In vivo (humans)  Mundargi et al., 
2007 
Polyvinyl alcohol  & 
carboxymethyl 
chitosan 
Film  Ornidazole In vivo (animals)  Wang et al., 2007 
Poly(vinyl methyl 
ether-co-maleic 
anhydride) & 
poly(ethylene oxide) 
Film  Metronidazole In vitro  Li and Lee, 2010 
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The first locally acting drug delivery device to be FDA approved comprised of tetracycline 
hydrochloride embedded in an ethylene vinyl acetate fibre, marketed as Actisite® (Actisite 
Pharmaceuticals Inc., North Andover, Massachusetts). The fibre, 23cm long and a of 0.5cm 
diameter, is placed within the periodontal pocket and removed after 10 days.  Tonetti et al. 
(1990) reported a zero-order release of tetracycline over a 10-day period and the device 
maintained a constant average concentration of 1590µg/mL in periodontal pockets. In one 
study locally delivered tetracycline produced similar clinical outcomes to 
amoxicillin/clavulanic acid delivered systemically after SRP treatment over the 9-month 
observation period (Purucker et al., 2001).  
Atridox®, manufactured by Tolmar Inc. (Fort Collins, Colorado) contains 42.5mg of 
doxycycline hyclate within a liquid polymeric system comprising of poly(DL-lactide) & N-methyl 
2-pyrrolidone. The product is packaged as a two-syringe mixing system, that once 
administered it flows to the bottom of the periodontal pocket and solidifies, releasing 
doxycycline over a 7-day period. Research conducted in two multi-centre studies with 411 
patients in each group with severe periodontitis, found doxycycline delivered from Atridox 
was equally effective as SRP over a 9 month period. Salvi et al. (2002) designed a single-
blind, randomised, parallel-designed clinical trial comparing Atridox®, Elyzol® and PerioChip®. 
The outcome of the trial was a recommendation that Atridox® to be used in conjunction with 
SRP in periodontal pockets with a residual depth of at least 6mm.  
Microparticulate minocycline system, Arestin® (OraPharma Inc., Warminister, Pensylvania), 
comprises of PLGA based microspheres which are injected directly into the periodontal 
pocket. Arestin® releases minocycline at a constant rate of 340µg/mL in crevicular fluid over 
a 14-day period (Williams et al., 2001). In vivo studies confirmed that minocycline in 
conjunction with SRP is more effective in reducing pocket depth than SRP alone (Williams et 
al., 2001; van Dyke et al., 2002, Paquette, 2002).  
Colgate Elyzol® 25%w/w Dental Gel (Colgate-Palmolive (UK) Limited, Surrey, UK) delivers 
metronidazole directly into the gingival crevice. The glycerol monooleate and sesame oil 
matrix has a low melting point that increases in viscosity within the periodontal pocket. After 
one application of the gel, metronidazole levels for 24 hours are maintained above the 
minimum inhibitory concentration required to inhibit growth of 50% (MIC50) of the susceptible 
pathogens (Stoltze, 1992). Griffiths et al. (2000) conducted a blind, randomised split-mouth 
designed study revealing that metronidazole in combination with SRP is superior to SRP 
alone in the treatment of chronic adult periodontitis over a 9-month period.  
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2.3.3. Antiseptic agents 
The role of chlorhexidine in PD, a cationic biguanide bactericidal antiseptic, has been 
extensively studied. This positively charged molecule attaches to the negatively charged 
bacterial cell wall and disrupts the osmotic balance. Its antibacterial spectrum includes Gram-
positive bacteria, yeasts and fungi while it is less active against Gram-negative bacteria (Puig 
Silla et al., 2008). As chlorhexidine was the first antimicrobial shown to inhibit plaque 
formation and prevention of gingivitis when a 0.2% mouthrinse was used daily, it provided a 
benchmark against which other antiplaque agents are compared (Addy, 1986).   Still today 
chlorhexidine mouthwashes are frequently used in the prevention and treatment of gingivitis 
(Barnett, 2003; van Zyl and van Heerden, 2010). However, subgingival plaque is not 
significantly disrupted when chlorhexidine is applied supragingivally (Radford et al., 1992), 
therefore limiting its use in PD (van Zyl and van Heerden, 2010). Cosyn et al. (2006) 
completed a randomised, controlled, single-blind, parallel study in which the chlorhexidine 
was applied as a varnish following SRP in 12 patients with chronic periodontitis. The pilot 
study revealed a reduction in pocket depths (between 0.7 - 1.37mm) and a gain in clinical 
attachment proving its potential in PD treatment.  
Chlorhexidine is a popular drug of choice loaded into a device for implantation in the 
periodontal pocket (Table 2.6). It was incorporated into a crosslinked hydrolysed gelatin and 
glutaraldehyde film containing 2.5mg of drug and is commercially available as Periochip® 
(Dexcel Pharma Technologies Ltd., Jerusalem, Israel). The film releases 40% drug within 24 
hours and the remainder over 7-10 days (Divya and Nandakumar, 2006). Studies revealed 
that Periochip® used in conjunction with SRP significantly improves clinical parameters of 
periodontitis (Killoy, 1999; Heasman et al., 2001). When compared to other commercially 
available products Atridox® and Elyzol®, Periochip® performed moderately (Salvi et al., 2002). 
This study further reported an increase in pocket probing depth 4 months after application, 
which may be attributed to the wafer dimensions.  
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Table 2.6: Local drug delivery devices loaded with chlorhexidine 
Polymer matrix Archetype Model drug 
incorporated  
Data available Reference 
Cellulose acetate Film  Chlorhexidine  In vitro  Cetin et al., 2004 
Chitosan  Film/gel Chlorhexidine  In vitro  Đkinci et al., 2002 
Chip Chlorhexidine In vivo 
(humans) 
Jothi et al., 2009 
Ethyl cellulose Film  Chlorhexidine In vitro  Friedman and 
Golomb, 1982 
Ethylene vinyl 
acetate copolymer 
Film  Chlorhexidine  In vitro  Tallury et al., 2007 
Film  Chlorhexidine  In vitro Arnold et al., 2008 
Gelatin  Film Chlorhexidine  In vitro Steinberg et al., 
1990 
Film  Chlorhexidine  In vivo 
Commercially 
available as 
Periochip ®  
Heasman et al., 
2001 
Hydroxyethyl 
methacrylate & 
polyethyleneglycol 
dimethacrylate 
Gel plus 
nanocomposites 
Chlorhexidine In vitro Bako et al., 2008 
Hydroxypropyl 
cellulose 
Strip Chlorhexidine In vivo 
(humans)  
Noguchi et al., 
1984 
Polyethylmetha 
acrylate (acrylic) 
Strip   Chlorhexidine  In vivo 
(humans)  
Addy et al., 1988 
Addy and 
Langeroudi, 1984 
PLGA Microspheres 
compressed 
into a chip 
Chlorhexidine  In vitro  Yue et al., 2004 
Polyurethane  Film Chorhexidine  In vitro Huynh et al., 2010 
Urethane 
dimethacrylate & 
triethyene 
dimethacrylate 
Disks  Chlorhexidine  In vitro  Anusavice et al., 
2006 
2.3.4. Combination therapies: Anti-inflammatory and antimicrobials agents 
PD forms a complex set of diseases that are difficult to treat (Goodson, 1994). Hence, the 
rationale for the concomitant administration of an antimicrobial and an anti-inflammatory 
agent. This therapeutic approach, where controlled release of antimicrobials combined with 
anti-inflammatory agents, would control the periodontal disease and stimulate bone 
regeneration (Soskolne, 1997). The antimicrobial and anti-inflammatory agents would target 
the bacteria and inflammatory mediators simultaneously within the pocket.  
To date only a few formulations (Table 2.7) simultaneously deliver an antimicrobial and anti-
inflammatory agent. As yet no clinical data is available, although the in vitro results 
demonstrate promising potential in treating PD.  
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Table 2.7: Local drug delivery devices containing two or more drugs 
Polymer matrix Archetype Model drug incorporated  Data 
available 
Reference 
Chitosan Film Ciprofloxacin & diclofenac In vitro Ahmed et al., 
2009 
Poly[1,6-bis(o-
carboxyphenoxy)
hexanoate] 
Disk  Salicyclic acid & 
clindamycin / chlorhexidine 
/ minocycline 
In vitro Johnson and 
Uhrich 2009 
Ahmed et al. (2009) developed a chitosan-based ciprofloxacin and diclofenac film 
crosslinked with gluteraldehyde, which simultaneously delivers these two chemotherapeutic 
agents. The flexible films demonstrated in vitro drug release data with an initial burst release 
followed by controlled release over 7 days for the uncrosslinked film and 21 days for the 
crosslinked film. The films inhibited the growth of Streptococcus mutans in vitro. These 
results demonstrate the potential of the device in PD treatment.   
A further in vitro study incorporating an antimicrobial agent and anti-inflammatory agent was 
conducted by Johnson and Uhrich (2009). An antimicrobial agent, chlorhexidine, clindamycin 
or minocycline, was incorporated into a salicylic acid-based polyanhydride-ester polymer 
blend. The resultant discs were in vitro evaluated and demonstrated no change in salicylic 
acid release when incorporated with the antimicrobial agents. Zero-order release of salicylic 
acid was achieved following a 15 hour lag period until reaching a plateau. The release 
profiles of the antimicrobials reflected the hydrophobicity of the drug influenced by its pKa. 
These discs demonstrated potential as a local device releasing the therapeutic agents for a 
minimum of three days.  
2.3.5. Alternative chemotherapeutic therapies 
Bisphosphonates inhibit bone resorption and show potential as host modulating therapies in 
the treatment of PD (Kirkwood et al., 2007). In a randomised clinical trial patients received 
one of two bisphosphonates or a placebo. The bisphosphonates groups demonstrated 
significantly improved clinical attachment levels, probing depth and bleeding on probing 
when compared to the placebo group at the 6- and 12-month intervals (Lane et al., 2005). A 
controlled release formulation with alendronate sodium in PLGA microspheres tested in vitro, 
had a high drug-loading efficacy and demonstrated potential in dental applications (Nafea et 
al., 2007). Avascular bone necrosis, a side effect of bisphosphonates, may limit its dental 
applications (Robinson, 2004).  
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2.4. Design of Controlled Release Formulations for the Treatment of Periodontal 
Diseases 
Since the 1970’s scientists have been developing prolonged delivery devices for placement 
within the periodontal pocket for the treatment of PD. Numerous antimicrobials and anti-
inflammatory drugs have been incorporated within a polymeric matrix which is secured within 
the periodontal pocket and the model drug is released over a extended period of time. The 
design of the devices can be broadly classified as fibres, films, gels or multiparticulate 
systems (Figure 2.1).  
 
 
 
 
 
 
 
 
Figure 1.2: Representations of local drug delivery devices in the form of (a) a fibre (Adapted 
from Spiller, 2000), (b) a chip (Adapted from Hutter, 2008), (c) microparticles (Adapted from 
Harrington, 2011) and (d) a gel (Adapted from Tolmar Inc., 2008-2010) 
 
 
 
 
 
 
 
Fibre 
Chip/
Film 
Microparticles 
Gel 
(a) (b) 
(c) 
(d) 
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2.4.1. Fibres 
The first fibre for delivery of an antimicrobial agent was developed by Goodson et al., (1979), 
where a hollow cellulose acetate fibre was filled with tetracycline, releasing 95% of the 
entrapped drug within 2 hours. Rapid release of the drug from a hollow fibre limited its clinical 
application. Subsequent development in fibre technology lead to the FDA approval of 
ethylene vinyl acetate fibre loaded with 12.3mg of tetracycline. This monolithic fibre releases 
tetracycline over 10 days. Fibres may either be place circumferentially into the pocket (Jain 
et al., 2008) or overlapping on itself until the pocket is filled (Donley, 1997) as illustrated in 
Figure 2.1a. The fibre is then secured in place with a cyanoacylate adhesive. Difficulties in 
fibre placement and necessity to remove the non-degradable device have been identified as 
disadvantages of Actisite®. 
2.4.2. Film/Chip 
Films have been used more extensively as a possible device in the development of a local 
drug delivery system for the treatment of PD, as evident in the number of films which have 
been prepared and tested as decribed in Tables 2.3 and 2.5-2.7. Films may vary in thickness 
and size for optimal placement in the periodontal pocket. In recent years, films intended for 
application in PD use biodegradable and bioadhesive polymers. As a result the films do not 
have to be removed once treatment is complete and no longer require the additional 
adhesives to remain in the pocket; an example of such a film is Periochip®. A disadvantage if 
using a film is the difficulty securing the device in place with the normal flushing of the 
periodontal pocket (Jones et al., 1996). It is hypothesised that another drawback of using a 
film compared to other devices is that the device is not evenly distributed in the pocket and 
the drug released is concentrated at the site of application.  
2.4.3. Multiparticulate systems 
Multiparticulates refer to both micro- and nanoparticulates which may be in the form of 
spheres, tubules, capsules, fibres or rods. These formulations optimise the theories of 
micrometrics, by using smaller particulates to alter the pharmacokinetic profiles of the 
polymeric matrices.  Several studies have used the microparticles in the development of 
extended release formulations for the treatment of PD. Such formulations uses particle size 
technology to optimise drug delivery, either administered on its own (Gopinath et al., 2009), 
compressed into a film or strips (Yue et al., 2004) or suspended within a formulation such as 
a gel or paste (Mundargi et al., 2007). Particles on the nanoscale affect the physicochemical 
and physicomechanical properties of the material such as melting point, electrical properties 
and optical properties (Kong et al., 2006). However, few studies thus far have employed the 
use of nanoparticles as a potential carrier of therapeutic agents to the periodontal pocket 
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(Piñόn-Segundo et al., 2005; Moulari et al., 2006; Shahverdi et al., 2007; Satishkumar and 
Vertegel, 2008). Yet this relatively new technology demonstrates promising benefits for 
reaching deep within the periodontal pockets below the gum line, which is not possible with 
other devices. Nanoparticles are further formulated with biocompatible, biodegradable and 
bioadhesive polymers which add to their attractiveness as a delivery device. A problem noted 
by Piñόn-Segundo et al. (2005) was that due to the increased surface area of the 
nanoparticles available for dissolution, drug release was faster than expected. 
2.4.4. Gels 
Several gels have been formulated as possible treatments for PD. Gels have a semi-solid 
consistency and therefore have the advantages of even distribution throughout the 
periodontal pocket. The gel comes into direct contact with the bottom of pockets and has 
faster drug release rates. A gel cannot be removed from the pocket following administration 
and for this reason biodegradable and biocompatible polymers are used, ensuring less 
irritation and allergic reactions. Together with bioadhesive polymers the gel is secured in the 
pocket. The key disadvantage of such systems is maintaining the formulation over an 
extended period of time within the pocket and the possibility of drug “dumping”.  A novel 
approach to overcome this problem was used in Atridox®, where the two part gel system 
solidifies within the periodontal. Solidification of the gel system in periodontal pocket results 
in controlled doxycycline levels over 46.73µg/mL in the ginigival crevicular fluid for 10 days 
(Kim et al., 2004). To sustain higher drug levels over longer time frames multiparticulates, 
such as micro- and nanopaticles, may be suspended within the gel altering the drug release 
profile of the system. 
2.5. Polymers Used in the Formulation of Controlled Release Formulations for the 
Treatment of Periodontal Diseases 
Controlled release formulations consist of one or more drugs incorporated in a matrix of 
polymeric materials. Drug release from a controlled delivery device occurs through erosion, 
diffusion, osmosis and disintegration mechanisms and is dependent on three factors; drug 
solubility, polymer used and the drug loading (Tangri and Khurana, 2011). The chosen 
polymer incorporated has a pivotal effect on the release characteristics of the device. 
Controlled drug delivery devices can be classified as reservoir devices, where the device is 
removed and drug release is controlled by diffusion through a membrane, or as matrix 
devices, where the device degrades over time within the periodontal pocket releasing drug 
via diffusion or erosion (Banker and Rhodes, 2002). Although it is easier to control the time 
which the pocket is exposed to the therapeutic agent when using a non-degradable device, 
they have largely been replaced by biodegradable devices. This is because degradable 
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devices are more compatible and evoke less of an immune response as well as having 
improved patient compliance when compared to non-degradable ones (Vyas et al., 2000). 
Recently, the use of mucoadhesive polymers in the formulation of local delivery devices for 
the treatment of PD has increased. Incorporation of mucoadhesive polymers allows direct 
contact with the adsorbing membranes involving ionic interactions between the polymer and 
the mucous membrane (Bernkop-Schnϋrch, 2005). Polymers which have been commonly 
used in the formulation of local delivery devices intended for the treatment of PD are listed in 
Table 2.8. 
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 Table 2.8: Polymers frequently used in the formulation of drug delivery devices placed within the periodontal pocket 
Polymer  
 
Non-
degradable 
Biodegradable Bioadhesive Sustained 
release 
Other Reference 
Cellulose derivatives: 
Cellulose acetate 
 
Ethyl cellulose 
Hydroxyethyl cellulose 
Hydroxypropyl cellulose 
Hydroxypropyl methylcellulose 
 
 
 
• 
 
• 
 
 
• 
• 
• 
 
 
 
 
• 
 
• 
 
 
 
• 
• 
 
• 
  
Goodson et al., 1979;  
Cetin et al., 2004 
Golomb et al., 1984 
Jones et al., 1996 
Noguchi et al., 1988 
Perioli et al., 2007 
Chitosan  
Carboxymethyl chitosan 
 • 
• 
• 
• 
 Antimicrobial  Đkinci et al., 2002 
Wang et al., 2007 
Ethyl vinyl acetate •   •  Goodson et al., 1983 
Gelatin   •  Crosslinked  Cetin et al., 2005 
Hydroxyethyl methacrylate  •    Bako et al., 2008 
Polyacrylic derivatives: 
Carbopol 971 
Carbomer 940 
Polycarbophil 
  
• 
• 
• 
 
• 
• 
• 
   
Perioli et al., 2004;  
Perioli et al., 2007 
Poly(anhydride esters)  •  • pH responsive release Erdmann and Uhrich, 2000 
PCL  •  •  Chang et al., 2008 
PLGA  •  •  Agarwal et al., 1993 
Polyethylene glycol  •    Golumb et al., 1984 
Polyethyleneglycol dimethacylate   •    Bako et al., 2008 
Polyhydroxybutyric acid  •   •  Collins et al., 1989 
PLA  •  •  Park et al., 1997 
Poly(ortho ester) 
 • •  pH sensitive release Roskos et al., 1995 
Polyvinyl alcohol    •  • High tensile strength Wang et al., 2007 
Polyvinylpyrrolidone   •   Jones et al., 1996 
 32 
 
2.6. Concluding Remarks 
PD is a known problem among the South African population and is compounded by the high 
prevalence of diabetes and HIV. These chronic conditions require patients to take medication 
on a daily basis. Therefore, a local drug delivery system controlling drug release to the 
periodontal pocket would be ideal in treating these patients for PD in comparison to 
systemically delivered therapies. This is because it would not require the additional self-
administered treatment and would reduce non-compliance.To date no such devices are 
routinely used to treat patients with PD in South Africa. The direct delivery of the drug to the 
affected area, the possible improved patient compliance and the large percentage of South 
Africans affected by PD, consequently provide the motivation for this study. 
The review of literature found that antimicrobials and anti-inflammatories play a role in the 
treatment of PD, both having been administered systemically and locally. Prescribing 
systemic therapeutic agents remains a popular route of drug administration, however 
research internationally has been focused on the development of devices for the local 
delivery of drugs in the treatment of PD. Several devices formulated have failed to meet their 
full potential in the clinical phase of research and development (Schwan-Abdellaoui et al., 
2000) resulting in only a few devices being available commercially abroad. There is still a 
need to develop intra-pocket periodontal systems that are biodegradable, adhere to the 
tooth’s surface and penetrate deep within the periodontal pockets (Jain et al., 2008). Only a 
few studies have incorporated both antimicrobial and anti-inflammatory agents and there is 
no clinical data to date. It is perhaps possible that this dual therapeutic approach is the way 
forward. The challenge that faces researchers is to design a formulation that delivers the 
therapeutic agent at a predetermined rate and over an extended period of time as well as 
being easy and convenient to use.  
In comparison to the fibres already developed for treatment of PD, the PFD formulated in this 
study, simultaneously delivers an antimicrobial and anti-inflammatory agent to the 
periodontal pocket. The device is biodegradable and biocompatible, therefore, would not 
need to be removed. A further advantage of the PFD is that the fibre, comprising of a specific 
polymer and plasticiser combination, is resilient yet malleable for easy placement within the 
periodontal pocket.  
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CHAPTER 3 
PRELIMINARY DESIGN OF A DRUG-LOADED POLYMERIC FIBRE DEVICE 
3.1. Introduction 
The review of formulations in Chapter 2, led to investigation into fibres as a delivery device 
for chemotherapeutic agents within the periodontal pocket. This chapter evaluates the fibres 
formulated specifically for the treatment of PD and attempts to design a formulation 
demonstrating potential as a device controlling the release of model drugs in the periodontal 
pocket. Few fibres have been formulated for the treatment of PD. Table 3.1 compares non-
degradable fibres, composed of cellulose acetate and ethyl vinyl acetate, to biodegradable 
fibres prepared from PCL.  Goodson et al. (1979) first published their results from loading 
tetracycline into cellulose acetate dialysis tubing (Table 3.1a). Once the hollow tube (outer 
diameter 250µm, inner diameter 200µm) was filled with tetracycline powder it was gently 
pressed into the periodontal pocket. The study showed that a dose reduction of over 1000 
fold was achieved compared to systemic administration of the same drug. This was the first 
antimicrobial-loaded device formulated for the treatment of PD and provided a platform form 
which further fibre formulations could be developed.  
Goodson et al. (1983) formulated a monolithic fibre where biocompatible polymers; 
polyethylene, polypropylene, PCL, polyurethane and cellulose acetate propionate, all 
released the drug in vitro within a day. However, ethylene vinyl acetate provided controlled 
delivery for up to 9 days (Table 3.1b). The ethylene vinyl acetate fibre demonstrated 
promising results in vivo maintaining constant tetracycline levels (1590µg/mL) over 10 days. 
The commercialisation of this tetracycline-loaded ethylene vinyl acetate fibre resulted in the 
product known as Actisite®. Although an improved clinical response is seen in these fibres 
administered in conjunction with SRP compared to SRP alone (Heijl et al., 1991, Newman et 
al., 1994), problems with the device have been identified. Fibre placement within the pocket 
is time consuming and requires trained personnel. Ethylene vinyl acetate fibres, a 
nondegradable device, need to be removed after treatment necessitating a further visit to the 
therapist. Furthermore, the fibres need to be secured within the pocket using cyanoacylate 
glue. These problems limit the use and acceptability of tetracycline-loaded ethylene vinyl 
acetate fibres (Soskolne, 1997; Vyas et al., 2000; Jain et al., 2008).      
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Table 3.1: Comparison of fibres formulated for the treatment of PD 
Image Characteristic Dimensions Reference 
 
Hollow tube 
Polymer: cellulose acetate 
Model drug: Tetracycline 
Drug release: 95% drug in 2 
hours (in vivo humans) 
Inner diameter: 200µm. 
Outer diameter: 250µm 
Tube: 25µm thick 
Goodson et al., 1979 
 
Monolithic fibre 
Polymer: ethylene vinyl acetate 
Model drug: tetracycline  
Drug release: constant drug 
levels in pocket over 10 days (in 
vivo humans) 
Diameter: 500µm Tonetti et al., 1990 
 
Gravity spun fibre 
Polymer : PCL 
Model drug: Gentamicin  
Drug release: 10-50 days (in vitro) 
Diameter range: 149-221µm Chang et al., 2008 
 
Nanofibres 
Polymer: PCL 
Model drug: Metronidazole 
Drug release: 19 days (in vitro)  
 
 
Diameter range: 313nm-999nm Zamani et al., 2010 
(a) 
(d) 
(c) 
(b) 
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Biodegradable fibre devices developed are gravity and electro spun which form a graft 
matrix-like structure which is placed within the periodontal pocket (Table 3.1c and d 
respectively). Thin fibres are formed resulting in an increased surface area for the diffusion of 
drug. PCL was the polymer incorporated in fibre formulations releasing gentamicin in vitro 
over 50 days from a nonhomogenised suspension  of gravity spun fibres (Chang et al., 2008) 
and  metronidazole over 19 days from electrospun nanofibres (Zamani et al., 2010). These 
novel approaches to fibre production produce a device which can more adequately be 
compared to a film than a fibre.  
 
Figure 3.1: Classification of polymeric fibre matrices  
Chapter 1 and Chapter 2 explained the rationale for local drug delivery of chemotherapeutic 
agents in the periodontal pocket as well as elucidating the use of antimicrobial and anti-
inflammatory agents used in the treatment of PD. This chapter describes the design of a 
flexible and strong polymeric fibre intended to be placed within the periodontal pocket 
delivering the model drug over 10 days.   
Alginate, which has been used extensively in wound care management, was crosslinked with 
a suitable cation forming the polymeric backbone of the fibre. Initially only ciprofloxacin was 
incorporated as a model antimicrobial drug for preliminary studies. Diclofenac sodium, the 
model anti-inflammatory agent, was incorporated in subsequent investigations. Alginate, a 
well known biocompatible polymer used extensively in the food and pharmaceutical industry, 
is a natural polysaccharide isolated from brown seaweed. The chemical structure of the 
“building blocks” of alginate are (1,4) linked α-L-guluronate and  β-D mannuronate, will be 
referred to as the G and M monomers (Figure 3.2a and b correspondingly). These monomers 
Examples
Matrix diffusion / 
erosion
Classification of 
polymeric matrix  
Matrix Polymeric material 
Matrix based 
delivery devices
Non-degradable 
Ethylene vinyl 
acetate fibers
(Goodson et al., 
1983)
Biodegradable
PCL fibers  
(Chang et al.,  
2008)
Reserviour based 
delivery devices
Non-degradable
Cellulose acetate 
fibers 
(Goodson et al., 
1979)
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are joined together to form blocks and may arrange themselves in one of the following 
patterns (GM), (GG) and (MM). Arrangements of these monomers within these blocks 
determine the mechanical stability with increased G monomers resulting in high mechanical 
strength while higher M monomers lead to increased flexibility (Smidsrød and Skjǻk-Bræk, 
1990).      
 
 
Figure 3.2: Monomers of alginate (a) (1,4) α-L-guluronate (G monomer) and (b) (1,4) β-D 
mannuronate  (M monomer) 
Multivalent cations bind to the carboxylic groups on the G monomers on two adjacent chains 
crosslinking the solution into a gel network (Augst et al., 2006). Haug and Smidrøds (1965) 
experimentally determined that the concentration of cations needed to induce gelation and 
precipitation of sodium alginate prepared from the Laminaria digitata and Laminaria 
hyperborean species in increasing order were: 
Ba > Pb > Cu > Sr > Cd > Ca > Zn > Ni > Co > Mn,Fe > Mg 
The “egg-box model” was developed by Grant et al. (1973) which describes the alignment of 
the polymeric chains into a two-dimensional model in the presence of cations resembling the 
shape of a corrugated egg box. This model, Figure 3.3, represents the alignment of the 
polymeric units forming a crosslinked structure resulting in a gelation of the solution. For the 
proposed fibre formulation barium chloride was selected as a suitable cation. Bajpai and 
Sharma (2004) determined that barium chloride is more stable in a medium of varying pH 
compared to calcium chloride and the large barium ion present in the polygluconate blocks 
maintained the integrity of the crosslinked beads investigated.   Gels crosslinked with barium 
cations have a higher Young’s modulus than the calcium crosslinked gels attributed to a 
higher crosslinker density (Jejurikar et al., 2011), further justifying the incorporation of barium 
as the crosslinking cation.  
(a) (b) (b) (a) 
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Figure 3.3: Alignment of alginate monomers upon addition of barium (Ba2+) ions forming an 
“egg-box” structure which relaxes once again in the presence of sodium (Na+) ions (Adapted 
from Qin, 2008) 
3.2. Materials 
Sodium alginate (Protanal LF 10/60) was purchased from FMC Biopolymer, Philadelphia, 
USA. Ciprofloxacin and metronidazole were sourced from Sigma-Aldrich, Steinheim, 
Germany. Barium chloride 2-hydrate was procured from Saarchem, Pty(Ltd), Unilab, 
Wadeville, South Africa. Glycerol (Mw=92.1g/mol) was purchased from Rochelle Chemicals, 
Johannesburg, South Africa. Dialysis tubing cellulose membrane, average flat width of 
33mm, was acquired from Sigma-Aldrich, Steinheim, Germany. The antimicrobial 
susceptibility test disks (ciprofloxacin 1µg and metronidazole 50µg per disk) and Tryptone 
Soya Agar (TSA) were obtained from Oxoid, Hamphire and Hants, UK, respectively. Stock 
cultures of microorganisms were obtained from the National Health Laboratory Service. 
Buffering components; potassium dihydrogen orthophosphate, sodium hydroxide pellets and 
hydrochloric acid were correspondingly obtained from, Ace (Johannesburg), Merck 
(Wadeville) and Rochelle (Johannesburg).  
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3.3. Methods 
3.3.1. Formulation of fibres 
Initially alginate based polymeric fibres were prepared by adding a 3%w/v alginate solution to 
5%w/v barium chloride solution,  using a 10mL syringe fitted with an 18G needle, by applying 
constant pressure to the plunger. The formulation cured for 24 hours allowing the fibres to 
sufficiently crosslink. The resultant fibres were washed with deionised water and air dried for 
48 hours at ambient conditions (25˚C). Additional components such as plasticisers and 
model drugs, depicted in Figure 3.4, were incorporated into the fibre formulation.  
 
Figure 3.4: Schematic representation of preparation of the fibres 
3.3.2. Characterisation of morphological transitions 
Approximately 1cm fibres were secured on carbon tape, attached to sample holders and 
sputter coated (Spi-Module Sputter Coater, Apollo Scientific, Pennsylvania, USA) with gold 
for 90 seconds. Samples were then mounted in a scanning electron microscope (SEM) 
(Phenom Microscope, FEI Company, Hillsboro, Oregon, USA). The images produced 
compared the effects of formulation components on the morphological structure of the fibre.  
 
 
 
Deionised water 
with model drug 
dispersed 
Alginate 
added 
Plasticiser 
added 
Addition of coblended 
polymer solution to 
barium chloride 
Cure (24 hours)  Dry (48 hours) 
Apply constant pressure  
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3.3.3. Addition of  suitable plasticiser 
Fibres were prepared using the same method as in Section 3.3.1., however a 4%w/v alginate 
solution crosslinked in a 2%w/v barium chloride solution. Plasticiser (7-10mL) was added to 
the polymer solution prior to crosslinking. Plasticisers, triethanolamine or glycerol, were 
added to alginate solution to form a homogenous mixture.  Table 3.2 indicates the plasticiser 
used and its concentration in each formulation.  
Table 3.2: Fibre formulations incorporating either triethanolamine or glycerol at varying 
concentrations  
Formulation Plasticiser Plasticiser concentration 
A (control) None - 
B Triethanolamine 7mL 
C Triethanolamine 10mL 
D Glycerol 7mL 
E Glycerol 10mL 
A TA.XTplus Texture Analyzer (Stable Micro Systems, England) was used for analysis of 
fibres. The tensile grip was calibrated at a 60mm distance from the sample stage. A fibre was 
secured to both the lower and upper custom made tensile grips, schematically represented in 
Figure 3.5. Table 3.3 below states the settings used in each test. 
  
Figure 3.5: Elasticity analysis of fibres (a) schematic representation of fibres breaking when 
the maximum force is exceeded and (b) a fibre attached to a custom made clamp and upper 
gripper of the TA.XTplus Texture Analyzer 
 
 
 
 
 
(a) (b) 
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Table 3.3: TA.XTplus Texture Analyzer settings for elastic analysis of fibres 
Settings Elasticity 
Mode Measure force in tension 
Option Return to start 
Pre-test speed 1.0mm/s 
Test speed 3.0mm/s 
Post-test speed 10.0mm/s 
Distance 100mm 
Trigger type Auto – 15g 
Data acquisition 400pps 
3.3.4. Preparation of antimicrobial-loaded fibres and determination of drug 
entrapment efficiency   
Ciprofloxacin and metronidazole were identified as possible antimicrobial agents to be 
incorporated within the crosslinked polymeric fibre. The fibres were prepared as described in 
Section 3.3.1. However, the antimicrobial drug (200mg), either ciprofloxacin or 
metronidazole, was dispersed in distilled water prior to the addition of alginate. Drug 
entrapment was determined through analysis of the drug remaining in the crosslinking 
solution once the fibres were removed. The amount of drug in the crosslinking solution was 
determined by ultraviolet spectroscopy (Specord 40, Analytik Jena, AG, Germany) at 
λmax=278nm for ciprofloxacin or λmax=275nm for metronidazole. Calibration curves were 
constructed in drug-free crosslinking solution individually for metronidazole and ciprofloxacin. 
All experiments were carried out in triplicate and then compared with standard calibration 
curves generated in crosslinking solution for each fibre. This quantity was deducted from the 
total amount of drug initially included for the formulation of the fibre. The difference between 
the two amounts is the quantity entrapped in the fibres as outlined in Equations 3.1 and 3.2.  
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3.3.5. Determination of the antimicrobial activity of antimicrobial-loaded fibres 
Agar plates were prepared with 100µL of culture and 20mL of molten TSA poured into sterile 
petri dishes and swirled to evenly distribute either Escherichia coli (E. coli) or Enterococcus 
faecalis (E. faecalis) cultures. E. Faecalis and E.coli are examples of Gram-positive and 
Gram-negative facultative anaerobes respectively, which have been found present in 
periodontitis (Colombo et al., 2002).  Using a sterile pair of forceps, samples of fibres were 
transferred onto the solidified agar. Ciprofloxacin- or metronidazole-loaded fibres tested 
simultaneously with the drug-free fibres, which served as the control (Figure 3.6a).  Control 
plates were prepared, using commercially available antibiotic-loaded disks (ciprofloxacin 1µg 
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and metronidazole 50µg) and were place on the solidified molten agar, which had been 
inoculated with the test pathogens. All the plates were placed in the fridge for 1 hour, 
allowing the drug to diffuse from the fibre or disc, after which they were incubated at 37˚C for 
24 hours. Post incubation, plates were examined to determine the antimicrobial activity of the 
fibres through visualising the zone of inhibition. This is the area surrounding the fibre that is 
free from microbial growth, represented by the yellow area in Figure 3.6b.  
(a) Prior incubation (b) Post incubation 
  
Figure 3.6: A diagrammatic sketch representative of agar diffusion plates with drug-loaded 
(DL) fibres tested alongside drug-free (DF) fibres (a) prior to incubation and (b) post 
incubation with the zone of inhibition represented by the yellow area  
 
3.3.6. Determination of drug release from fibres 
Dissolution studies were conducted in 0.2M phosphate buffer solution (PBS) at pH 4 and 6.8. 
PBS pH 4 and pH 6.8 were prepared according to the United States Pharmacopeia 23 (USP) 
(1995) recommendations. Simulated pockets were designed using cellulose membrane 
dialysis tubes, 3.3cm in diameter and 5cm in length. Ciprofloxacin-loaded fibres were 
weighed and placed within a simulated pocket. Either end was secured with a non-
degradable nylon based thread. The simulated pocket was placed in 20mL PBS in a 50mL 
glass jar and left in a shaking incubator (50 rpm) (Orbital Shaker Incubator, LM-530, Lasec 
Scientific Equipment, Johannesburg, South Africa) for 10 days. A 2mL filtered (0.22µm 
syringe filter) dissolution sample was withdrawn at specific time intervals (0, 1, 2, 4, 6, 8 and 
10 days) over the test period and sink conditions were maintained by replacing the withdrawn 
volume with PBS. The amount of drug released was determined by ultraviolet (UV) 
spectroscopy (Specord 40, Analytik Jena, AG, Germany) at λmax=278nm for ciprofloxacin. 
The results were analysed using WinASPECT® Spectroanalytical Software (Analytik Jena 
AG, Jena). All experiments were carried out in triplicate. 
DF DF DL DL 
Zone of  
inhibition  
Molten TSA 
inoculated with 
test pathogen  
Glass petri 
dish 
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3.3.7. Characterisation of nanoTensile properties  
Mechanical properties of drug-free fibres were tested using creep-, tensile- and dynamic-
loads. Tensile tests require prior determination of the cross-sectional area, length and test 
parameters. Cross-sectional area of the drug-free fibres was determined using 
stereomicroscope (Olympus SZX –ILLD2-200, Olympus Corporation, Tokyo, Japan). 
Samples for each were positioned using a custom-made clamp, exposing the cross-sectional 
area of the fibre. The tip of the fibre was coloured black using a permanent marker for 
adequate visualisation of the area. The area was calculated using the AnalySIS Olympus 
Soft Imaging Solutions version 5.1. The length was measured with digital callipers. The 
tensile analysis of drug-free fibres was determined using the nanoTensileTM 5000 (Hysitron 
Inc., Minneapolis, USA) (NT). Samples were mounted on metal brackets as outlined in 
Figure 3.7.  
 
 
 
 
 
 
 
    
Cardboard template Attach metal 
brackets to 
cardboard template 
using tape 
Secure fibre to 
metal plate using 
tape 
Glue the fibre to 
metal plate using a 
suitable adhesive 
Remove excess 
cardboard template 
Figure 3.7: Schematic representation of fibres mounted on metal brackets secured on a 
cardboard template 
The suitable test settings were chosen for either creep, tensile or dynamic-load analysis. 
Once the adhesive had dried, the samples were mounted on the upper gripper of the NT 
head and automatically weighed. The metal bracket was secured in place with tightening of 
the lower gripper and aligned. The cardboard segments between the two lines on either side 
of the template were then cut. Once the fibre had fractured or reached the time limit, the 
sample was removed from the upper and lower gripper. Plots generated were used to 
analyse the strength and flexibility of the fibre. The NT Head transducer constants were 
loaded as outlined in Table 3.4. 
 
 43 
 
Table 3.4: Standard NT transducer settings 
X, Y and Z NT Head transducer constants Setting 
X Force FP Gain 100 
X Force FP Filter (Hz) 300 
Y Force FP Gain  100 
Y Force FP Filter (Hz) 300 
Z Displacement FP Gain  100 
Z Displacement FP Filter (Hz) 300 
Z Force FP Gain  100 
Z Force FP Filter (Hz) 300 
3.3.7.1. Creep-load analysis 
Creep-load analysis of fibres held either the load-limit or displacement-limit constant. For this 
study the load-limit was set at 2000mN and 2100mN for analysis of fibres. The applied stress 
is kept constant over the duration of the test. The test was conducted over 10 minutes or until 
the fibre fractured. The maximum strain, displacement and force were recorded either at the 
point of fracture or after 10 minutes if the fibre was still intact.   
3.3.7.2. Dynamic-load analysis 
Dynamic-load test exposes the fibre to a minimum and maximum load or displacement at a 
set frequency. The minimum and maximum load was set at 1000mN and 1500mN 
correspondingly, while the frequency was held at 0.01Hz. 
3.3.7.3. Tensile-load analysis 
The tensile-load may be controlled via by the displacement, load or strain rate through 
adjustment of the test velocity, load rate or strain rate respectively. The rate of velocity was 
regulated at 20µm/sec with a displacement-limit of 150mm and a load-limit of 1N. The data 
was analysed using the NT analysis software and revealed information pertaining to yield 
stress, ultimate strength, ultimate strain and toughness as well as calculating the Young’s 
modulus for the fibres tested. 
3.3.8. Effect of formulation components on formation of fibres 
The effect of formulation components, polymer, crosslinking salt and plasticiser 
concentration, on fibre formation were observed. One factor at time was altered while the 
remainder factors kept constant.  Fibres were prepared as outlined in 3.3.1 and observations 
regarding fibre formation were noted.  
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3.4. Results and Discussion 
3.4.1. Fibre formulation 
Fibres formed as the polymer solution made contact with the cations present in the 
crosslinking solution. The polymeric solution in the presence of barium ions forms a gel in the 
shape of a fibre due to the constant pressure applied to the plunger of the syringe.  The 
alginate polymer used has a guluronic acid and mannuronic acid concentration of between 
65-75% and 25-35% respectively. Analysis of the crosslinked fibres morphology (Figure 3.8) 
confirms that monolithic fibres were formed of a consistent shape and size (diameter range 
393-458nm) with ridges evident on the surface of the fibres.  
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Figure 3.8: SEM images of 3%w/v alginate fibres crosslinked in 5%w/v barium chloride 
solution (a)-(d) illustrating the varying diameters (393-458µm) 
 
 
 
 
 
 
 
 
 
 
 
 
(a) (b) 
(c) (d) 
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3.4.2.  Effect of plasticiser on elasticity of  the fibre 
The fibres formed without plasticiser (formulation A in Figure 3.9 and Table 3.5) break at 
lower breaking forces and extend less than their plasticised counter parts (formulations B-E 
in Figure 3.9 and Table 3.5) The incorporation of a plasticiser in the crosslinked alginate 
matrix improves the strength as well as the flexibility of the fibres. The volume and type of 
plasticiser added affected the tensile properties of fibres. When 10mL of plasticiser was 
incorporated (formulation C and E in Figure 3.9 and Table 3.5) weaker fibres were produced 
that fractured at lower forces and stretched less compared to formulation where 7mL of 
glycerol or triethanolamine (formulation B and D in Figure 3.9 and Table 3.5) was 
incorporated.  Fibres where glycerol was added as a plasticiser (formulation D and E in 
Figure 3.9 and Table 3.5) were stronger and more flexible than the fibres where 
triethanolamine (formulations B and C in Figure 3.9 and Table 3.5) was added. From this 
study, glycerol was selected as the plasticiser for incorporation in alginate based monolithic 
fibres.  
 
Figure 3.9: Typical force (g) vs. time (sec) for fibre formulations – A, – B, – C, – D and  – E  
 
Table 3.5: Comparison of breaking force and extension distance of fibres incorporating 
triethanolamine or glycerol as a plasticiser (N=5) 
Formulation Breaking force (g) Extension distance (mm) 
A 294.3±53.45 3.51±0.35 
B 287.97±20.64 5.74±1.41 
C 238.03±127.58 4.74±2.27 
D 540.47±54.01 19.24±5.82 
E 356.43±28.27 8.50±3.06 
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3.4.3. Drug entrapment efficiency of antimicrobial-loaded fibres 
The calibration curves, Figure 3.10a and b, for ciprofloxacin and metronidazole respectively 
were conducted in crosslinking solution and used to determine the quantity of drug that was 
entrapped within the fibre.  
 
 
Figure 3.10: Calibration in crosslinking solution for (a) ciprofloxacin and (b) metronidazole 
The amount of ciprofloxacin and metronidazole entrapped within the fibres was 80.06%±0.06 
and 19.52%±0.27 respectively. Metronidazole readily diffuses from the fibre into the 
crosslinking solution resulting in only a small quantity of drug being entrapped within the 
fibre, compared to ciprofloxacin. The SEM images reveal that a similar shape and structure 
of the fibres (Figure 3.11) is maintained following the addition of glycerol and either 
ciprofloxacin or metronidazole as model antimicrobial agents compared to drug-free 
crosslinked alginate fibres (Figure 3.8). The diameter increases slightly to 510.1µm for 
ciprofloxacin-loaded (Figure 3.11a) and 594.8µm metronidazole-loaded (Figure 3.11b) fibres. 
 
 
 
(a) 
y = 113.3 x 
R2 = 0.992 
y = 9.820 x 
R2 = 0.999 
(a) 
(b) 
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Figure 3.11: SEM images of (a) ciprofloxacin-loaded (diameter 510.1µm) and (b) 
metronidazole-loaded (diameter 594.8µm) and (c) drug-free (diameter 424.3µm) fibres 
 
 
 
(b) 
(c) 
(a) 
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3.4.4. Antimicrobial assays for ciprofloxacin- and metronidazole-loaded fibres 
Ciprofloxacin-loaded fibres demonstrated activity against both pathogens indicated by a clear 
zone of inhibition (Figure 3.12a and b). Similarly the ciprofloxacin-loaded disc was active 
against both pathogens (Figure 3.12e and f).  Metronidazole-loaded fibres showed no activity 
against either E. coli or E. faecalis (Figure 3.12c and d). Likewise the metronidazole-loaded 
disc showed no activity against either pathogen (Figure 3.12e and f). No zone of inhibition 
surrounded the drug-free fibres (Figure 3.12a-d), which served as a further control, 
confirming that the polymeric fibre has no inherent antimicrobial activity against these 
pathogens.  
The resistance of E.coli and E. faecalis to metronidazole exhibited in the drug-loaded fibres 
is similar to the literature results found.  A study conducted by Onderdonk et al. (1979) 
confirmed that metronidazole did not demonstrate activity against E. coli in both animal 
models used and in vitro cultures tested. Investigation of E. faecalis activity against 
metronidazole revealed that E. faecalis demonstrates not only resistance to metronidazole, 
but inactivates the activity of the antibiotic against Bacteroides fragilis (Nagy and Földes, 
1991). Ciprofloxacin is a bactericidal antibiotic with a wide spectrum of activity against Gram-
positive and Gram-negative pathogens and demonstrated activity against both pathogens 
when loaded within the polymeric fibre.  
Testing the fibres against causative pathogens was not possible as these periodontal 
pathogens were not available. Therefore, the model antimicrobial to be incorporated in the 
fibres needed to demonstrate activity against E. coli and E. faecalis. This study confirms that 
metronidazole is not active against these two pathogens and therefore should not be used as 
the model antimicrobial drug for further investigation.  
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 Figure 3.12: Antimicrobial activity represented by the zone inhibition (ZI) of ciprofloxacin-
loaded (CL) and metronidazole-loaded (ML) fibres compared to controls; drug-free fibres 
(DF) and antimicrobial disks, against E. coli and E. faecalis 
 
 
 
 
Ciprofloxacin 1µg 
Metronidazole 50µg Metronidazole 50µg 
Ciprofloxacin 1µg 
DF CL 
DF ML DF 
DF CL 
ML 
(a) 
(e) 
(b) 
(c) (d) 
(f) 
ZI 
ZI 
ZI ZI 
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3.4.5. Dissolution studies  
Standard USP (1995) apparatus and tests for dissolution would not adequately mimic the 
periodontal pocket environment where the fibres would be placed. To date there is no set 
dissolution methodology which mimics the periodontal pocket. This is illustrated in Table 3.6 
which describe ten in vitro studies conducted on various local drug delivery devices for 
placement in the periodontal pocket.  In each study the volume and pH of the dissolution 
medium where the device was placed as well as in the degree of agitation the device was 
exposed to while in the dissolution apparatus was different.  
It has been reported that the pH of a single periodontal pocket ranges from 2 to 9 (Galgut, 
2001). This creates distinctly different chemical environments and given that alginate 
displays pH responsive behaviour (Takka et al., 1994; Al-musa et al., 1999; Pillay and 
Fassihi, 1999), dissolution tests were conducted in PBS pH 4 and 6.8. In an attempt to create 
a pocket-like environment fibres were placed in the dialysing tube as described in a study 
conducted by Mundargi et al. (2007). The dialysing tube was tied at either end with nylon 
thread to prevent the escape of the fibre and then submerged in PBS. The dialysing tube 
used freely allows the passage of compounds with a molecular weight less than 12 
000g/mol. Ciprofloxacin with a molecular weight of 331.35g/mol would easily pass through 
the membrane.  
Table 3.6: Comparison of in vitro dissolution test apparatus for drug delivery systems 
intended for placement in the periodontal pocket 
Archetype Dissolution medium pH Degree of agitation Reference 
Film 10mL PBS 7.4 Rotating (15 rpm) Park et al., 1997 
Wafer 1mL distilled water or 
human serum 
*NS Rotating (250 rpm) Bromberg et al., 2000 
Chip 1mL distilled water 
(using Eppendorf 
tubes) 
6-6.5 Rotating Yue et al., 2004 
Hydrogels 35mL distilled water *NS Stirred with magnetic 
stirrer 
Bako et al., 2008 
Microspheres 50mL PBS (placed in 
dialysis tube) 
7.4 Rotating (50 rpm) Mundargi et al., 2007 
Film 100mL of PBS / citrate 
buffer 
3.5 and 7.4 Rotating Wang et al., 2007 
Ointment 20mL PBS 
(thermostated flow-
through erosion cell) 
7.4 Flow rate 10mLhr-1 Roskos et al., 1995 
Film 1mL PBS 6.6 Static Ahmed et al., 2009 
Disk 10mL PBS 7.4 Rotating (65 rpm) Johnson and Uhrich, 
2009 
Nanofibres 10mL PBS 7.4 *NS Zamani et al., 2010 
*NS – not stated  
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Dissolution samples were tested in PBS at both pH 4 and pH 6.8; therefore calibration curves 
were constructed at both pH’s. Calibration curves (Figure 3.13) were used to determine the 
amount of ciprofloxacin which had been released at each time point.  
  
Figure 3.13: Calibration curve ciprofloxacin (λ278nm) in PBS (a) pH 4 and (b) pH 6.8  
 
The dissolution results confirmed the controlled release of ciprofloxacin from crosslinked 
alginate fibres with or without plasticiser at both pH 4 and 6.8 (Figure 3.14). A burst release 
of ciprofloxacin is seen in PBS pH 4 releasing 39.43% and 46.74% from alginate crosslinked 
fibres and plasticised alginate crosslinked fibres respectively in the first 24 hours. Alginate 
crosslinked fibres in PBS 6.8 release ciprofloxacin at a more controlled rate, releasing 
16.31% in the first day, however, over 10 days more than half the drug remains entrapped 
within the fibre. Ciprofloxacin released from plasticised alginate crosslinked fibres in PBS pH 
6.8 resembles a zero-order release pattern, with an average of 71.28% of drug released over 
the test period.  
The results of the dissolution confirmed that glycerol had a noteworthy effect on 
ciprofloxacin’s release. In both PBS pH 4 and pH 6.8 ciprofloxacin released faster from the 
plasticised fibres when compared to the non-plasticised formulations. Studies conducted on 
formulations where a plasticiser was added confirmed that zero-order delivery may be 
achieved when incorporating a suitable plasticiser (Pongjanyakul and Puttipipatkhachorn, 
2007) as well as the presence of a plasticiser affects the permeability of the matrix (Qussi 
and Suess, 2006).    
Changes in the morphological structure of the fibres were assessed in SEM images of fibres 
following the 10-day dissolution test in PBS pH 4 and 6.8 (Figure 3.15). Examination of the 
fibres in PBS pH 4 showed that the shape of the fibre remains intact following dissolution 
y = 120.3 
R2 = 0.999 
y = 112.6 
R2 = 0.999 
(a) (b) 
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(Figure 3.15a-d). Therefore, drug must have diffused from the matrix into the surrounding 
fluid. Relaxation and swelling of the polymeric matrix is evident in Figure 3.15e-h 
representing samples which underwent dissolution at pH 6.8. Furthermore, the flakes or 
pieces attached to the surface of the fibres are indicative of surface erosion. This analysis 
confirms that drug release in PBS pH 6.8 occurs as a result of swelling and erosion leading 
to disruption of the polymeric matrix. Tønnesssen and Karlsen (2002) describe the release of 
drug from calcium chloride crosslinked alginate as a “swelling–dissolution–erosion process” 
thereby modulating drug release. However, a crosslinked alginate forms an insoluble matrix 
in an acidic medium releasing the drug via diffusion mechanisms.   
 
Figure 3.14: Fractional release of ciprofloxacin from crosslinked alginate fibres with and 
without plasticiser at pH 4 and pH 6.8  
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Fibre without plasticiser Fibres with plasticiser 
Drug-free (control) Ciprofloxacin-loaded Drug-free (control) Ciprofloxacin-loaded 
    
    
    
Figure 3.15: SEM images of fibres dried following a 10-day dissolution in PBS pH 4 and pH 6.8
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3.4.6. Tensile analysis 
The crosslinked plasticised alginate fibres were designed for placement within the 
periodontal pocket either around the tooth or overlapping on itself filling the pocket. As 
mentioned in Chapter 2 fibre placement is difficult, therefore necessitating tensile analysis to 
determine the fibres robustness.  A suitable method to determine the tensile strength and 
flexibility of the fibres was determined through creep-, tensile- and dynamic-load analysis. 
The system used allows for precision testing of small-scale materials with an adjustable X-Y-
Z axis and is free from external disturbances (Solomon, 2009). 
Stereomicrographs (Figure 3.16) illustrated that although the fibres appear to be cylindrical in 
shape they have an irregular cross-sectional area. The average cross-sectional area was 
calculated at 0.338±0.028mm2.  
The preliminary fibres were assessed using creep-, tensile- and dynamic-loads. Typical 
strain and displacement profiles for fibres in Figure 3.17 allow for comparison of these three 
tests.  The different load settings were compared to develop a suitable method which would 
quantify the strength and flexibility fibres and allow for easy comparison of different 
formulations when an experimental design would be employed.  
 
 
Figure 3.16: Stereomicrographs depicting the cross-sectional area of crosslinked alginate 
plasticised fibres (a) 0.377mm2 and (b) 0.354mm2  
 
 
 
 
 
 
 
(a) (b) 
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Strain profiles  Displacement profiles  
 
 
 
 
 
 
Figure 3.17: Typical strain and force vs. displacement curves for creep-, dynamic- and 
tensile-load analysis of fibre
(a) 
(f) (e) 
(d) (c) 
(b) 
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3.4.6.1. Creep-load analysis 
In the creep-load analysis the force was held at a constant value measuring the length the 
fibre would stretch to as shown in the typical strain and displacement profiles in Figure 3.17a 
and b. The results for fibres were assessed at 2000 and 2100mN are contained in Table 3.7. 
When fibres were held at a constant-load of 2000mN, two of the 5 fibres samples did not 
break over the 10 minute testing period. The maximum force which the test reached varied 
from 2268-2658mN with samples stretching between 4.03-10.76mm in length. In 
comparison, only one sample remained intact after 10 minutes when the load limit was 
increased to 2100mN, while the maximum force and displacement were similar at 2379-
2656mN and 7.00-10.80mm respectively. The large variation within the five samples tested 
at both 2000mN and 2100mN, limits the usefulness of creep-load analysis for the 
comparison of data.  
Table 3.7: Creep-load analysis of fibres at constant load limit of 2000 and 2100mN with the 
applied stress at 5.92MPa and 6.21MPa respectively (N=5) 
Load limit 
(mN) 
Time till 
fracture (sec) 
Strain 
(MPa) 
Maximum 
Displacement (mm) 
Maximum 
force (mN) 
2000 >600 0.29 6.01 2405 
38.5 0.42 9.00 2495 
159.0 0.31 6.36 2268 
37 0.62 10.76 2658 
>600 0.19 4.03 2328 
2100 34 0.60 10.08 2379 
32 0.48 7.00 2522 
>600 0.37 7.85 2460 
41 0.85 7.91 2584 
33 0.55 9.83 2656 
3.4.6.2. Dynamic-load analysis 
Dynamic-load testing varied the load the fibre was exposed to and resulted in fluctuating 
strain and displacement profiles shown in Figure 3.17e and f. The results for dynamic-load 
analysis, included in Table 3.8, represented a fibre exposed to fluctuating loads between 
1000 and 1500mN at 0.01Hz. Two of the samples did not fracture over the 5 minute test 
period. The number of cycles to fracture varied significantly from 0.34-3.00. The maximum 
strain was fairly constant (0.12-0.16MPa) for four of the samples test. Dynamic-load analysis 
revealed little information regarding the strength and flexibility of the fibres. Results between 
samples varied substantially. Furthermore, difficulties in setting of parameters led to wastage 
of samples. 
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Table 3.8: Dynamic-load analysis of fibres with oscillating load between 1000mN and 
1500mN and the mean stress of 7.4MPa (N=5) 
 Number of cycles till fracture Time to fracture (sec) Maximum strain 
1 3.00 >300 0.16 
2 0.46 46 0.68 
3 0.34 30.5 0.15 
4 1.28 123 0.12 
5 3.00 >300 0.15 
3.4.6.3. Tensile-load analysis 
Tensile-load analysis of the fibres requires prior knowledge of standard engineering stress 
and strain terms. Figure 3.18 visually describes some of the terms used in analysing the 
tensile properties of the fibre. The fibre begins to deform as a force is applied, first 
undergoing elastic or reversible deformation, until a yield value is reached. Following which 
plastic or irreversible deformation occurs at higher stresses applied, finally leading to 
fracturing of the sample. The schematic (Figure 3.18) is similar in shape to the typical stress 
versus strain profile in Figure 3.17c.  
Analysis of the tensile-load test calculates the Young’s modulus, ultimate strength and strain, 
yield stress and toughness of the fibres (Table 3.9). Determination of the Young’s modulus 
reveals information regarding the stiffness of the fibre and is defined as the ratio of stress 
over strain (Equation 3.5). The yield stress represents the value at which the fibre would 
plastically deform. Deformation beyond this point would lead to permanent non-reversible 
deformation. Ultimate strength represents the highest stress point measured. Flexibility of the 
fibres were analysed through determination of the ultimate strain. The fibres undergoes 
plastic deformation and the strain at which the fibre fractures is the ultimate strain value 
recorded.  Toughness characterises the resistance of the fibre to fracture when stressed is 
applied and is calculated using the area under the curve.  
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Figure 3.18: Schematic sketch of stress vs. strain profile (Adapted from Cooke et al., 1996) 
 
Table 3.9: Tensile-load analysis (N=5) of fibres at a constant velocity rate of 20µmsec-1 
 Young’s 
modulus  (MPa) 
Yield stress 
(MPa) 
Ultimate 
strain 
Ultimate 
strength 
(MPa) 
Toughness 
(Jcm-3) 
1 218.85 3.99 5.91 0.15 0.76 
2 258.50 4.75 7.07 0.12 0.65 
3 280.63 5.28 6.80 0.08 0.45 
4 251.87 3.38 4.44 0.053 0.14 
5 270.70 5.51 7.79 0.087 0.52 
Ave: 256.11± 23.59 4.58±0.89 6.40±1.29 0.098±0.04 0.50±0.24 
The tensile-load analysis software uses engineering stress and strain equations specified in 
Equations 3.3 and 3.4 respectively. Equation 3.3 represents the determination of stress (N) 
where the force [F] measured in Newton’s represents the instantaneous load applied and [A0] 
measures the cross-sectional area prior to deformation. The strain, Equation 3.4 compares 
the change in deformation of the fibre to the original fibre, [li] and [l0] representing the final 
and original length of the fibres, respectively. The Young’s modulus is ratio of tensile stress 
(σ) to tensile strain (ε) as represented in Equation 3.5.  
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Determination of Young’s modulus, yield stress, ultimate strength, ultimate strain and 
toughness allows for easy comparison of the extensibility and strength of the fibres. 
Therefore, tensile-load tests were used for further tensile analysis of the experimental design 
and optimised formulations.    
3.4.7. Effect of formulation components on the formation of fibres 
Fibres were prepared with varying concentrations of alginate, barium chloride and glycerol to 
determine the upper and lower limits which the Design of Experiments would be based upon. 
The polymer, crosslinking salt and plasticiser concentrations were identified as principle 
parameters in the forming of fibres. The upper and lower limits for each formulation 
component were determined (Table 3.10). Adequate fibres formed when the alginate and 
barium chloride was at a concentration between 1-4%w/v and 0.5-10%w/v respectively and 
incorporating 5-25mL of glycerol.  
Table 3.10: Effect of formulation components alginate, barium chloride and glycerol on 
observed fibre formation  
Alginate 
( %w/v) 
Barium chloride 
(%w/v) 
Glycerol 
(ml/25mL polymer solution) 
Remark 
0.25-0.5 2.00 7 Fibres formed web 
1.00-3.00 Adequate fibres formed 
4.00 Very viscous polymer solution  
>4.00 Solution too viscous 
2.00 0.125-0.25 7 Fibres formed clumps 
0.50-10.00 Adequate fibres formed 
>10.00 No difference in fibre 
formation 
2.00 2.00 <5 Too brittle 
5-25 Adequate fibres formed 
>25 Flat shape 
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3.5. Concluding Remarks 
This chapter aimed to design a PFD which could potentially be used in the treatment of PD. 
The monolithic fibre formulated was assessed according to drug entrapment, antimicrobial 
activity, drug release and tensile strength. The tests aided in choosing a suitable plasticiser 
and antimicrobial for incorporation within the fibre as well as setting the upper and lower 
limits of the formulation components for the experimental design.   
Brittle fibres were formed when alginate was crosslinked in a barium chloride solution. 
Investigations revealed that glycerol was a suitable plasticiser, which would increase the 
strength and flexibility of the crosslinked fibres. Tensile analysis of preliminary fibres 
investigated the creep-, tensile- and dynamic-loads. Creep- and dynamic-load tests provided 
limited quantitative information regarding the tensile properties of the fibres. The results were 
difficult mean in order to characterise the formulation. The variable parameter settings meant 
that the test needed adjustment for each sample tested. In comparison, tensile-load analysis 
provided valuable information which was used in the quantitative comparison of the 
experimental design formulations. 
Qualitative antimicrobial analysis and determination of the drug entrapment indicated that 
ciprofloxacin was active against both E. coli and E. faecalis as well as having a notably 
higher drug entrapment within the PFD. This provided the motivation for incorporation of 
ciprofloxacin as the model antimicrobial. 
Controlled drug release was evident in crosslinked alginate formulations, with or without 
plasticiser, tested at pH 4 and 6.8. Drug release of ciprofloxacin from fibres was pH 
responsive, which correlated with the literature surveyed. Upon examination of SEM images 
with dissolution data, drug release at pH 4 occurs as a result of drug diffusing through the 
polymeric matrix, however, at pH 6.8, disruption of the fibre structure leads to drug release 
as a consequence of the swelling and erosion of the matrix. Ciprofloxacin is released faster 
from fibres following incorporation of glycerol. Promising dissolution results were obtained 
from PFD, with zero-order release at pH 6.8 from the plasticised alginate fibres.  
Polymer, crosslinking salt and plasticiser concentrations were identified as the noteworthy 
factors affecting fibre formulation. The upper and lower limits were determined as 2-4%w/v, 
0.5-10%w/v and 5-25mL for alginate, barium and glycerol respectively. These formed the 
bases of the experimental design which was elaborated upon in Chapter 4.    
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CHAPTER 4 
FABRICATION AND OPTIMISATION OF A POLYMERIC FIBRE DEVICE 
4.1.  Introduction 
Pharmaceutical technology has progressed from traditionally changing one variable at a time 
to a systemic approach, utilising a Design of Experiments (DoE) demonstrating the following 
advantages (Singh et al., 2004; Singh et al., 2005): 
• Reduced number of experiments. 
• Problem tracing and rectification. 
• Identifying drug / polymer interactions. 
• Simulate product performance using model equations. 
• Evaluate processes leading to improved product development and scale-up 
production.  
In a multifactor approach the variables are changed together rather than one at a time. This 
provides pertinent information regarding the magnitude and nature of interactions between 
variables as well as obtaining a measure of experimental error. Box and Behnken (1960) 
devised a statistical based experimental design where multiple variables may be changed 
simultaneously.  A stepwise approach delineated in Figure 4.1 can be employed in the 
optimisation of pharmaceutical formulations. Numerous extended release products intended 
for intraoral application have used a DoE approach to optimise the formulation employing a 
32 full factorial design (Bukka et al., 2010; Narendra et al., 2005; Wong et al., 1998).  A 3-
Factor Box-Behnken Design, which generates 15 experimental design formulations with 3 
centre points as sketched in Figure 4.2, was the design upon which the PFD for this study 
was built.  
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Figure 4.1: Schematic outline of the DoE process (Adapted from Singh et al., 2004) 
 
 
 
 
Figure 4.2: A combined cube with three interlocking 32 factorial design (Adapted from 
Ferreira et al., 2007) 
 
 
 
1
• Formulated objectives of the study . 
• Plan experiment.
2
• Selection of factors .
• Establish a relationship between formulation and selected factors.
3
• Implementaion of a DoE.
• Identify factors, factor levels and responses. 
4
• Experimental design formulations are prepared according to DoE and evaluated using the 
identified responses.
5
• Application of a suitable mathematical model for analysis of data and optimal formulations 
generated
6 • Validation of DoE.
7
• Scale-up production. 
X2 
X3 
X1 
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The schematic, Figure 4.1, suggests a process specific approach to the DoE in the 
formulation of pharmaceutical products (Singh et al., 2004). As outlined, steps 1-6 are 
necessary in the optimisation of the PFD. Thus far, the formulation process and variables 
have been identified. Preliminary studies described in Chapter 3 investigated possible 
variables such as formulation components, component concentrations and formulation 
processes. Polymer, crosslinking salt and plasticiser concentrations where isolated as 
variables possibly possessing a notable effect on the overall mechanism of operation of the 
fibres. It was anticipated that optimisation of the PFD would enhance drug release over 10 
days and ensure that the mechanical properties of the fibre met the intended criteria for easy 
placement within the periodontal pocket. Hence, proposed responses to be measured, 
focused on the in vitro drug release profiles and mechanical properties of the co-blended 
polymeric fibre. 
4.2. Materials  
Materials used were obtained as outlined in Chapter 3 Section 3.2. Diclofenac sodium was 
obtained from Sigma-Aldrich, St Louis, Missourri.  
4.3. Methods 
4.3.1. Formulation preparation using a 3-Factor Box-Behnken Design 
The experimental design fibre formulations were prepared by varying the polymer, 
crosslinking salt and plasticiser concentration. The upper and lower limits, as indicated in 
Table 4.1, formed the factors upon which the design was built.   
Table 4.1: Upper and lower limits of the independent variables; polymer, crosslinking salt 
and plasticiser concentration 
Independent Factors Lower level Upper level 
Polymer concentration (X1):   
Sodium Alginate (%w/v) 2 4 
Crosslinking salt concentration (X2):   
Barium Chloride 2-hydrate (%w/v) 0.5 10 
Plasticiser concentration (X3):   
Glycerol (mL/25mLpolymer solution) 5 25  
A Box-Behnken design, generated by Minitab® V14 (Minitab®, USA), was employed to 
statistically optimise the fibre formulation. A 3-factor design provided 15 experimental 
formulations varying the sodium alginate (ALG), glycerol (GLY) and barium chloride 2-
hydrate (BaCl) concentrations as shown in Table 4.2. 
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Table 4.2: The 3-factor Box-Behnken Design generated for optimisation of the fibres 
Experimental design  ALG BaCl GLY 
formulation (%w/v) (%w/v) (mL/25mL) 
1 2.00 10.00 15.00 
2 4.00 5.25 25.00 
3 2.00 5.25 25.00 
4 3.00 5.25 15.00 
5 3.00 10.00 5.00 
6 4.00 10.00 15.00 
7 2.00 5.25 5.00 
8 3.00 5.25 15.00 
9 3.00 0.50 5.00 
10 4.00 0.50 15.00 
11 3.00 0.50 25.00 
12 3.00 5.25 15.00 
13 3.00 10.00 25.00 
14 2.00 0.50 15 
15 4.00 5.25 5.00 
4.3.2. Preparation of PFD 
Polymeric based monolithic fibres were prepared using various combinations of alginate (2-
4%w/v), barium chloride (0.5-10%w/v) and glycerol (5-25mL) according to the 15 experimental 
design formulations generated in the 3-factor Box-Behnken design. The fibres were prepared 
as in Chapter 3 Section 3.3.1 with each formulation prepared in triplicate; drug-free, 
diclofenac sodium-loaded (500mg) and ciprofloxacin-loaded (200mg) fibres. For drug-loaded 
formulations the model drug was dispersed in distilled water prior to the addition of alginate.  
4.3.3. Determination of drug entrapment efficiency  
Drug entrapment was determined through analysis of the drug remaining in the crosslinking 
solution once the fibres were removed, as described in Chapter 3 Section 3.3.4. The 
entrapment was calculated separately for diclofenac sodium and ciprofloxacin for each of the 
15 experimental designs formulations. The amount of drug in the crosslinking solution was 
determined by UV at λmax=278nm for ciprofloxacin or λmax=276nm for diclofenac sodium.  
4.3.4. In vitro drug release studies 
The dissolution apparatus and methodology was the same as described in Chapter 3 Section 
3.3.6. Drug release of ciprofloxacin- and diclofenac-loaded fibres were tested individually for 
each of the experimental design formulations.  
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A pharmacokinetic model-independent approach was used to compare the dissolution data 
in PBS pH 6.8. The mean dissolution time (MDT) over 10 days was calculated as in Equation 
4.1.  
/0   ∑  
2
2∞
"
$34                                                                                                   Equation 4.1 
Mt is the fraction of dose released in time ti = (ti – ti-1) / 2 and M∞ corresponds to the loading 
dose. 
4.3.5. Tensile strength analysis  
Mechanical properties of drug-free fibres were tested for each of the experimental designs 
and were assessed according to their tensile strength. Samples were prepared and loaded 
as outlined in Chapter 3 Section 3.3.7. The experimental design formulations were analysed 
using the tensile-load setting described in Chapter 3 Section 3.3.7.3.  
4.3.6. Optimisation of design 
 The experimental design generated polynomial equations which were solved for the 
optimised formulation taking into consideration the output response variables for MDT, 
ultimate strain and Young’s modulus. The predetermined constraints facilitated the 
generation of an ideal formulation. The design was assessed according to the degree of 
correlation between experimental and predicted data. 
4.4. Results and Discussion 
4.4.1. Preparation of the experimental design formulations 
The first group of 15 formulations were prepared without drug. The second and third groups 
were prepared with ciprofloxacin and diclofenac sodium respectively.  Drug entrapment and 
release behaviour studies were performed on the on ciprofloxacin- and diclofenc-loaded 
fibres while tensile strength analysis was conducted on drug-free fibres.  
4.4.2. Drug entrapment of experimental design formulations 
Calibration curves were determined for diclofenac sodium and ciprofloxacin in the drug-free 
crosslinking solution for each of the 15 experimental design formulations. Typical examples 
of a calibration curves are represented in Figure 4.3 and 4.4 for the experimental designs of 
formulation 3 for ciprofloxacin (λ278nm) and diclofenac sodium (λ276nm) respectively. Similar 
calibration curves were constructed for the remaining 15 experimental design formulations, 
however these were not included for the sake of brevity.   
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Figure 4.3: Calibration curve ciprofloxacin (λ278nm) in curing solution prepared in formulating 
experimental design formulation 3  
 
 
 
 
 
Figure 4.4: Calibration curve diclofenac sodium at (λ276nm) in curing solution in formulating 
experimental design formulation 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
y = 107.5 x 
R2 = 0.999 
y = 27.25 x 
R2 = 0.999 
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The average ciprofloxacin and diclofenac entrapment including standard deviations for each 
experimental design formulation are summarised in Figure 4.5. Drug entrapment for all 
formulations exceeded 60% both for ciprofloxacin and diclofenac sodium.  
 
Figure 4.5: Vertical bar chart representing the percentage of ciprofloxacin and diclofenac 
sodium entrapped in the 15 experimental design formulations (N=3) 
4.4.3. In vitro drug release 
Drug release of ciprofloxacin and diclofenac sodium from the experimental design 
formulations were tested individually at pH 4 and 6.8. Dissolution results are shown in Figure 
4.6-4.9. Each figure includes dissolution results for an experimental design formulation 
releasing ciprofloxacin and diclofenac in PBS at pH 4 and 6.8. One of the key parameters 
controlling drug absorption is solubility (Amidon et al., 1995). The results obtained in the 
dissolution profiles reflect the solubility of ciprofloxacin and diclofenac in the respective 
dissolution media.  
Diclofenac sodium is a weak acidic drug (pKa = 4.0) and is poorly soluble in acidic 
conditions. Therefore dissolution tests are normally conducted in media with a pH greater 
than 6.5 (Palomo et al., 1999). The poor solubility is verified in the fractional drug release 
profiles at pH 4 in Figures 4.6-4.9. However, the rate and amount of diclofenac sodium 
released in PBS pH 6.8 was far greater. Pillay and Fassihi (1999) noted that diclofenac 
release from alginate beads crosslinked with calcium at pH 6.6 is dependent on drug 
solubility as well as matrix swelling and relaxation. 
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Reddy et al. (2011) calculated the intrinsic solubility constant for ciprofloxacin in 0.1N HCl as 
6.55mg/cm2min compared to 0.02mg/cm2min in PBS pH 6.8. The increased solubility in 
acidic solutions was attributed to protonation of the piperazine ring. Ciprofloxacin is released 
faster and to a greater extent from fibres submerged in PBS pH 4 compared to PBS pH 6.8, 
demonstrated in Figures 4.6-4.9. However, the difference in release profiles is not as severe 
as diclofenac sodium released in PBS pH 4 and 6.8 
Similar trends to the fractional release curves in Chapter 3 Section 3.3.5 are evident. Drug 
release from a crosslinked alginate matrix in an acidic medium is dependent on the drug 
diffusing from the matrix into the dissolution medium. Diclofenac sodium, poorly soluble in 
acidic solutions, is hardly released in PBS pH 4 compared to ciprofloxacin, which is highly 
soluble in acidic solutions. Both ciprofloxacin and diclofenac sodium are released in PBS pH 
6.8, due to swelling and erosion of the crosslinked alginate fibre.  
Drug release is an important factor that needs to be optimised in the DoE. As diclofenac was 
poorly released in PBS pH 4, it was decided that dissolution results in PBS pH 6.8 for both 
diclofenac sodium and ciprofloxacin would be used in the optimisation of the fibres. For 
accurate comparison of formulations the MDT over 10 days was calculated. A reduction in 
MDT indicates that the matrix retards drug release.  
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Figure 4.6: Drug release profiles for experimental design formulations 1 – 4 (a – d) (N=3) 
 
 
 
 
(a) (b) 
(d) (c) 
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Figure 4.7: Drug release profiles for experimental design formulations 5 – 8 (a – d) (N=3) 
 
(a) (b) 
(c) (d) 
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Figure 4.8: Drug release profiles for experimental design formulations 9 – 12 (a – d) (N=3) 
 
 
 
 
 
 
(a) (b) 
(c) (d) 
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Figure 4.9: Drug release profiles for experimental design formulations 13 – 15 (a – c) (N=3) 
 
 
 
(a) 
(b) 
(c) 
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Fibres were optimised using fractional drug release results for ciprofloxacin and diclofenac at 
pH 6.8. The MDT over 10 days for ciprofloxacin and diclofenac sodium released in PBS pH 
6.8 was calculated as in Equation 4.3. Analysis of the main effects plots and interaction plots 
established a relationship between the formulation components and the drug release 
behaviour exhibited by the experimental designs (Figure 4.10 and 4.11). Calculation of the 
MDT indicated the effect of the polymer on the drug release rate from the formulation (Kuksal 
et al., 2006).  
High alginate (4%w/v) and lower barium chloride (0.5%w/v) concentrations had a noteworthy 
effect on respectively increasing and decreasing the MDT10 days for diclofenac release (Figure 
4.10a). In comparison the plasticiser had a notable influence on the MDT10 days for 
ciprofloxacin release (Figure 4.11a), the MDT value increases with an increasing volume of 
glycerol added to the formulation.  
Examination of the interaction plots, Figure 4.10b and 4.11b, determined the combined 
effects of two variables on MDT. Low polymer and crosslinking salt levels had the greatest 
effect on decreasing the MDT10 days for diclofenac release (Figure 4.10b). The highest 
MDT10days for diclofenac release was noted when a 4%w/v alginate solution was crosslinked in 
a 10 %w/v barium chloride solution or when combined with minimum amount of glycerol (5mL) 
(Figure 4.10b). High levels of glycerol combined with a 4%w/v alginate solution increased the 
MDT10 days for ciprofloxacin substantially (Figure 4.11b).  
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Figure 4.10: Factor plots, (a) main effects plot and (b) interaction plots, depicting the 
correlation between MDT10 days for the release of diclofenac sodium and design variables 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) 
(b) 
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Figure 4.11: Factor plots, (a) main effects plot and (b) interaction plots, depicting the 
correlation between MDT10 days for the release of ciprofloxacin and design variables  
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
(a) 
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4.4.4. Tensile analysis 
Tensile analysis is an important parameter in optimisation of fibres as it affects the 
manufacturing processes used for fibre production and placement of the fibre within the 
periodontal pocket. The periodontal pocket is a narrow sulcus which is formed as free gingiva 
moves away from the tooth surface, which is approximately 3mm deep in healthy gums and 
increases to 6mm in the presence of PD (Nield-Gehrig, 2007). This relatively small area 
poses challenges for placement of a device, therefore it is necessary to formulate a strong 
flexible fibre that is easily handled and placed within the pocket. Tensile analysis requires 
determination of the cross-sectional area of the fibres. The fibres appear cylindrical to the 
naked eye, however, examination of fibres using the stereomicroscope reveal an irregular 
shape. The cross-sectional area of the 15 experimental designs is contained in Table 4.3. 
Tensile-load analysis of the experimental design formulations allowed for comparison of the 
strength and flexibility of the formulations, which are compared in the vertical bar charts 
Figures 4.12-4.16. Young’s modulus, yield stress and ultimate strength results (Figure 4.12-
4.14) displayed a similar pattern and were a measure the tensile strength of the material. 
Concurrent analysis of these charts reveals that formulation 7 was the strongest formulation 
(Young’s modulus 1814±96.33MPa; ultimate strength 35.83±9.18MPa; yield stress 
25.37±3.57MPa) while formulation 3 is the weakest (Young’s modulus 28.47±4.94MPa; 
ultimate strength 1.18±0.23MPa; yield stress 0.73±0.16MPa). The extensibility of the fibres is 
described by the ultimate strain value (Figure 4.15) demonstrating a distinctly different 
distribution compared to Young’s modulus, ultimate strength and yield stress charts (Figure 
4.12-4.14). Formulation 7, demonstrating high tensile strength had the lowest ultimate strain 
(0.08±0.05). The most extensible formulation was formulation 10 with the highest ultimate 
strain value (0.61±0.11).  
The formulation components, plasticiser, crosslinker and polymer concentration are noted in 
literature to affect the tensile properties of the matrix. Kuo and Ma (2007) reported that 
crosslinker density and concentration as well as polymer concentration affected the 
mechanical properties the crosslinked alginate matrix. Crosslinked alginate matrices once 
formed are brittle, but incorporation of a plasticiser reduces the interaction between polymer 
chains resulting in a flexible structure (da Silva et al., 2009). Plasticised crosslinked alginate 
films result in reduced tensile strength while increased elongation of the matrix (Olivas and 
Barbosa-Cànovas, 2008; da Silva et al., 2009). To elucidate the extent to which the fibre 
matrix is influenced by the concentration of alginate, barium chloride 2-hydrate and glycerol, 
Young’s modulus and ultimate strain were identified as responses for optimisation.  
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Table 4.3: Cross-sectional area of the experimental design formulations (N=5) 
Experimental design formulation  Cross-sectional area (mm2) 
1 0.07±0.03 
2 0.20±0.05 
3 0.11±0.02 
4 0.14±0.03 
5 0.17±0.05 
6 0.21±0.07 
7 0.05±0.01 
8 0.14±0.03 
9 0.09±0.04 
10 0.12±0.02 
11 0.09±0.02 
12 0.14±0.03 
13 0.27±0.01 
14 0.05±0.01 
15 0.17±0.05 
 
 
 
Figure 4.12: Vertical bar chart of Young’s Modulus values for the 15 experimental design 
formulations (N=5) 
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Figure 4.13: Vertical bar chart of yield stress values for the 15 experimental design 
formulations (N=5) 
 
 
 
Figure 4.14: Vertical bar chart of ultimate strength values for the 15 experimental design 
formulations (N=5) 
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Figure 4.15: Vertical bar chart of ultimate strain values for the 15 experimental design 
formulations (N=5) 
 
 
 
Figure 4.16: Vertical bar chart of toughness values for the 15 experimental design 
formulations (N=5) 
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The Young’s modulus and ultimate strain values were assessed in optimisation of the 
experimental design formulations. Main effect plots related the formulation components, 
alginate, glycerol and barium chloride concentrations to the ultimate strain and Young’s 
modulus, represented in Figure 17a and 18a respectively. A linear relationship is observed 
between ultimate strain and alginate concentration (Figure 4.17a), increasing the polymer 
concentration therefore resulted in fibres that could withstand a higher strain. On the contrary 
as the amount of barium chloride increased, the ultimate strain decreased and resulted in 
rigid fibres (Figure 4.17a). Increasing the quantity of the plasticiser, glycerol, initially 
increased the strain, though raising the quantity above 15mL had little effect (Figure 4.17a). 
Young’s modulus values were higher at lower alginate and glycerol concentrations and 
higher barium chloride concentrations. The plasticiser, glycerol, has the greatest effect on the 
Young’s modulus (Figure 4.18a). The mean Young’s modulus value is greatest, 
approximately 800MPa, when the lowest quantity of glycerol is added. This value plummets 
to below 200MPa as the quantity of glycerol added increases to 15mL.  
The interaction between two formulation components and either ultimate strain or Young’s 
modulus are apparent in Figure 17b and 18b correspondingly. Interactions between alginate 
and barium chloride as well as glycerol and alginate were significant with respect to ultimate 
strain values. Rigid fibres were formulated when the concentration barium chloride was high 
and the alginate concentration is low as well as when concentration of glycerol was low and 
the alginate concentration was high (Figure 4.17b). The most flexible fibres were formulated 
using a higher alginate concentrations combined with either lower barium chloride 
concentrations or higher quantities of glycerol (Figure 4.17b).  An interesting relationship was 
found to exist between the formulations components and the Young’s modulus values. The 
highest Young’s modulus value was attained when the lowest volume of glycerol was 
combined with a 2%w/v alginate solution (Figure 4.18b).  The interaction between crosslinking 
salt and plasticiser was noteworthy at higher concentrations of barium chloride with the 
lowest quantity of glycerol added (Figure 4.18b).  
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Figure 4.17: Factor plots, (a) main effects plot and (b) interaction plots, depicting the 
correlation between ultimate strain and design variables  
  
 
 
 
 
(b) 
(a) 
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Figure 4.18: Factor plots, (a) main effects plot and (b) interaction plots, depicting the 
correlation between Young’s modulus and design variables  
 
 
 
 
 
 
 
 
 
 
 
(b) 
(a) 
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4.4.5. Analysis of the Box-Behnken response surface design 
Data used for the optimisation of experimental design formulations related to drug release in 
PBS pH 6.8 as well as tensile analysis to determine the strength and flexibility of fibres, 
therefore the MDT over 10 days for ciprofloxacin and diclofenac were measured in addition 
to calculating the Young’s modulus and ultimate strain values. Experimental and predicted 
values for the responses are reviewed in Table 4.4.  
The residual plots (Figure 4.19) for MDT10 days for ciprofloxacin and diclofenac, Young’s 
modulus and ultimate strain were employed for analysis of the model. Analysis of the normal 
plot of the residuals shows normal distribution as all points are in close proximity to the 
straight line (Figure 4.19a-d). One outlying point is noted on the MDT10 days diclo curve (Figure 
4.19b). Even distribution on either side of the zero line is evident in the fitted residual versus 
fitted value plots (Figure 4.19e-f). A bell-shaped histogram indicates normal distribution of 
data (Figure 4.19k-l). Slightly irregular histograms are apparent for MDT10 days for both 
diclofenac and ciprofloxacin release (Figure 4.19i-j).  Regular fluctuation on either side of the 
centre line displayed in the residual versus observation order plots suggest the error terms 
are not correlated with one another (Figure 4.19m-p).  
The coefficient of determination assesses the extent that the model fits the data, the R2 for 
Young’s modulus, ultimate strain and MDT10days diclo were above 75%, however, the 
MDT10days cipro is significantly lower at 56.2%.  
The regression equations generated for MDT10 days for diclofenac and ciprofloxacin, Young’s 
modulus and ultimate strain are specified in Equations 4.2-4.5: 
MDT10daysdiclo=13.9262+(7.0651)[ALG]+2.6392[BaCl]+0.1087[GLY]+1.9542[ALG*ALG]+(0.1272)[BaCl*BaCl]+0.0008[GLY*GLY]+ 
(-0.1947)[ALG*BaCl]+(-0.0690)[ALG*GLY]+(0.0075)[BaCl*GLY] 
Equation 4.2 
MDT10dayscipro=23.2545+(7.4112)[ALG]+1.5069[BaCl]+(0.8573)[GLY]+1.1508[ALG*ALG]+(0.0502)[BaCl*BaCl]+0.0021[GLY*GLY]
+(-0.6100)[ALG*BaCl]+0.2615[ALG*GLY]+0.0673[BaCl*GLY]  
Equation 4.3 
Young’smodulus=4117.20+(1604.69)[ALG]+133.22[BaCl]+(196.17)[GLY]+145.24[ALG*ALG]+(4.71)[BaCl*BaCl]+2.73[GLY*GLY
]+4.33[ALG*BaCl]+34.64[ALG*GLY]+(-4.65)[BaCl*GLY] 
Equation 4.4 
Ultimatestrain=(0.058696)+0.082237[ALG]+0.008864[BaCl]+0.008711[GLY]+0.005000[ALG*ALG]+(0.000443)[BaCl*BaCl]+(0.0
00525)[GLY*GLY]+(0.009474)[ALG*BaCl]+0.002750[ALG*GLY]+0.000579[BaCl*GLY] 
Equation 4.5 
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 Figure 4.19: Summary of residual plots for MDT10 days for the release of diclofenac sodium and ciprofloxacin, Young’s modulus and ultimate strain 
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Table 4.4: Correlation between experimental and predicted values for Young’s modulus, ultimate strain and MDT10 days for the release of diclofenac 
sodium and ciprofloxacin 
 Young’s Modulus 
(MPa) 
Ultimate strain MDT 10 days Diclo MDT 10 days Cipro 
 
Formulation 
 
 
Experimental 
 
Predicted 
 
St residual 
 
Experimenta
l 
 
Predicte
d 
 
St residual 
 
Experimental 
 
Predicted 
 
St residual 
 
Experimental 
 
Predicted 
 
St residual 
1 290.95 481.06 -1.17 0.13 0.162 -0.65 15.66 16.02 -0.43 19.12 16.45 0.93 
2 81.32 439.56 -2.21 0.48 0.426 1.08 18.13 18.56 -0.51 26.71 20.61 2.12 
3 38.55 78.53 -0.25 0.26 0.164 1.93 15.75 14.73 1.23 15.75 14.96 0.28 
4 157.94 157.94 0.00 0.30 0.30 0.00 13.48 13.48 -1.66 11.52 12.98 -0.31 
5 823.31 991.44 1.04 0.18 0.094 1.73 17.23 17.30 -0.08 9.61 6.19 1.19 
6 298.52 170.38 0.79 0.29 0.28 0.2 20.46 19.37 1.32 8.45 11.08 -0.91 
7 1784.00 1425.77 2.21 0.08 0.134 -1.08 16.02 15.60 0.51 7.21 13.31 -2.12 
8 157.94 157.94 0.00 0.30 0.30 0.00 17.13 15.73 1.04 16.04 12.98 0.65 
9 267.71 99.58 1.04 0.24 0.326 -1.73 9.36 9.29 0.08 8.12 11.54 -1.19 
10 61.91 -128.202 1.17 0.55 0.518 0.65 15.81 15.46 0.43 12.68 15.34 -0.93 
11 62.51 292.60 -1.42 0.36 0.27 1.28 11.49 10.83 0.80 14.53 11.06 1.21 
12 157.94 157.94 0.00 0.30 0.30 0.00 16.57 15.73 0.62 11.39 12.98 -0.34 
13 145.75 -84.34 1.42 0.17 0.234 -1.28 13.68 14.35 0.80 15.99 19.46 -1.21 
14 136.6 264.74 -0.79 0.21 0.22 -0.20 7.31 8.40 -1.32 11.76 9.13 0.91 
15 401.9 361.11 0.25 0.19 0.29 -1.93 21.16 22.18 -1.23 7.71 8.51 -0.28 
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A p-value under 0.05, highlighted in Table 4.5, indicates a significant relationship between 
the factor and the response which is identified in Table 4.5. The relationships worth noting 
are the glycerol concentration (p=0.044) and its effect on the Young’s modulus as well as the 
effect of barium chloride concentration (p=0.14, BaCl; p=0.021 BaCl*BaCl) on MDT10 days of 
diclofenac.  
Table 4.5: Probability of the test (p-test) obtaining the measured responses, highlighted are 
the significant values (<0.05) 
Term   p-value 
 Young’s 
modulus 
Ultimate strain MDT 10 days 
diclofenac 
MDT 10 days 
ciprofloxacin 
Constant  0.073 0.920 0.193 0.502 
ALG 0.192 0.811 0.249 0.710 
BaCl 0.389 0.846 0.014 0.573 
GLY 0.044 0.715 0.783 0.539 
ALG*ALG 0.429 0.927 0.073 0.716 
BaCl*BaCl 0.557 0.855 0.021 0.721 
GLY*GLY 0.167 0.358 0.926 0.947 
ALG*BaCl 0.904 0.408 0.314 0.360 
ALG*GLY 0.080 0.605 0.442 0.405 
BaCl*GLY 0.232 0.605 0.686 0.317 
4.4.6. Response surface analysis 
Response surface methodology is defined by Myers et al. (2004) as “a collection of statistical 
and optimisation techniques used to optimise processes and product designs”. Response 
surface methods were employed to observe the relationship that exists between the three 
factors of polymer, plasticiser and crosslinking salt concentrations. MDT for ciprofloxacin and 
diclofenac (PBS, pH 6.8) over ten days, the strain the fibres could withstand without 
fracturing and Young’s modulus were the variables which the factors were analysed against. 
The surface plots, shown in Figures 4.20, 4.22 and 4.24, provide valuable information 
regarding the interaction between two factors and a response.   
4.4.6.1. Response surface analysis for MDT10 days of ciprofloxacin and diclofenac (PBS pH 
6.8) 
Analysis of the response surface plots provided information regarding interaction between 
two variables on the MDT for the release of either ciprofloxacin or diclofenac (Figure 4.20). 
Interaction between the polymer, crosslinking salt and plasticiser in the formation of a fibre 
was found to have a definite effect on the drug release from the matrix. The effect of drug 
solubility discussed in Section 4.4.3 influences the dissolution data. Further considerations 
are however necessary in the assessment of drug release. Alginate is pH responsive 
polymer, therefore the crosslinked alginate fibres initially swell and then erode when 
submerged in PBS pH 6.8.  
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The complexity of the relationship existing between the MDT10 days for the release of 
ciprofloaxin together with the alginate and barium chloride concentrations was depicted in 
Figure 4.20a.  To visualise this relationship more clearly a contour plot was assessed (Figure 
4.21). At low polymer and crosslinking salt concentrations the MDT was the lowest. However, 
the highest MDT was recorded when the 2%w/v alginate solution was crosslinked in a 10%w/v 
barium chloride solution as well as when a 4%w/v alginate solution was crosslinked in 0.5%w/v 
barium chloride solution. MDT10 days for the diclofenac release (Figure 4.20d) was maximised 
when a 4%w/v alginate solution was crosslinked in a barium chloride solution where the 
concentration exceeded 5%w/v. 
The inclusion of a plasticiser in the formulation was expected to disrupt the interaction 
between polymer and cations present in solution.  Addition of a plasticiser considerably 
increased MDT10 days for the release of ciprofloxacin as depicted Figure 4.20b and c. Glycerol 
had a less prominent effect on the diclofenac drug release (Figure 4.20e and f).  
Gelation, induced by the binding of the barium cations with the polymeric structure, ultimately 
had the greatest affect on MDT10 days for diclofenac release (p=0.014). MDT steadily 
increased with increasing concentrations of barium chloride (Figure 4.20d and f).  
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MDT 10 days ciprofloxacin 
 
 
 
 
 
MDT 10 days diclofenac 
 
 
 
 
 
Figure 4.20: Response surface plots relating MDT10 days for the release of ciprofloxacin to 
design variables (a) alginate (ALG) and barium chloride (BaCl), (b) alginate (ALG) and 
glycerol (GLY) and (c) barium chloride (BaCl) and glycerol (GLY) as well as comparing 
MDT10 days for the release of diclofenac to design variables (d) alginate (ALG) and barium 
chloride (BaCl), (e) alginate (ALG) and glycerol (GLY) and (f) barium chloride (BaCl) and 
glycerol (GLY) 
 
 
Figure 4.21: Contour plot depicting the relationship between MDT10 days for the release of 
ciprofloxacin and the concentration formulation variables, barium chloride (BaCl) and alginate 
(ALG). Hold value for glycerol 15mL 
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4.4.6.2. Response surface analysis for Young’s modulus and ultimate strain 
Barium crosslinked alginate fibres formed a rigid matrix that would not fit within the 
periodontal pocket without fracturing of the fibre. Addition of a plasticiser reduced the extent 
to which cations bind to form the crosslinked matrix and resulted in elastic fibres that were 
easily manipulated for placement in the periodontal pocket while retaining their form. To 
understand the relationship between the variables and reponses on the strength and 
flexibility of the fibre, surface and contour plots (Figure 4.22-4.25) were assessed.  
Glycerol had the most significant effect on the Young’s modulus (p=0.044). Following 
analysis of surface plots (Figure 4.22b and c) and contour plots (Figure 4.23a and b), the 
relationship between glycerol with the variables and Young’s modulus were further 
explained. After the subsequent addition of plasticiser, the fibres became elastic and 
deformed under the applied stress until finally fracturing. When more than 10mL of glycerol 
was added the fibres weakened as the Young’s modulus values noticeably dropped below 
200MPa.  
 
 
 
 
 
Figure 4.22: Response surface plots relating Young’s modulus to design variables (a) 
alginate (ALG) and barium chloride (BaCl), (b) alginate (ALG) and glycerol (GLY) and (c) 
barium chloride (BaCl) and glycerol (GLY) 
 
 
 
 
Figure 4.23: Contour plots depicting the relationship between Young’s modulus and design 
variables (a) barium chloride (BaCl) and glycerol (GLY) (hold value for alginate 3%w/v) and 
(b) glycerol (GLY) and alginate (ALG) (hold value for barium chloride 5.25%w/v) 
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The effect of the variables on the extensibility of the fibres is depicted in Figure 4.24 and 
4.25. The effect of increasing concentrations of cations present in solution had a negative 
result on strain and formed in a brittle matrix. This is evident in Figure 4.24a and b as a drop 
in strain values occurred with increased concentrations of barium chloride ions. To describe 
the relationship between glycerol and alginate on the strain the fibre endured the contour plot 
(Figure 4.25) was assessed. A rise in glycerol and alginate quantities caused an increase in 
the degree of deformation the matrix endured and higher ultimate strain values were reached 
before fracture. 
 
 
 
 
Figure 4.24: Response surface plots relating ultimate strain to design variables (a) alginate 
(ALG) and barium chloride (BaCl), (b) alginate (ALG) and glycerol (GLY) and (c) barium 
chloride (BaCl) and glycerol (GLY) 
 
 
Figure 4.25: Contour plot depicting the change in ultimate strain with varying glycerol (GLY) 
and alginate (ALG) concentrations. Hold value for barium chloride 5.25%w/v 
To establish a relationship between Young’s modulus, ultimate strain and formulation 
variables overlaid contour plots were generated. The Young’s modulus and ultimate strain 
ranges were set between 100-300MPa and 0.2-0.4 respectively. The opaque regions in 
Figure 4.26 represented the concentrations of the variables which according to data would 
produce formulations fitting within these parameters. In Figure 4.26 it is evident that the 
variables, Young’s modulus and ultimate strain are inter-related.  
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Figure 4.26: Overlaid plots establishing a relationship between Young’s modulus, ultimate 
strain and design variables: (a) barium chloride (BaCl) and glycerol (GLY) (hold value for 
alginate 2%w/v), (b) glycerol (GLY) and alginate (ALG) (hold value for barium chloride 
5.25%w/v) and (c) barium chloride (BaCl) and alginate (ALG) (hold value for glycerol 15mL) 
 
 
 
(b) 
(a) 
(c) 
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4.4.7. Response optimisation 
Fibre optimisation was conducted using the measured responses for MDT10 days for the 
release of ciprofloxacin and diclofenac as well as the Young’s modulus and ultimate strain. 
The aim was to show that the optimised levels of variables would result in strong yet flexible 
fibres releasing at the drug at the desired rate, resulting in favourable MDT for ciprofloxacin 
and diclofenac over 10 days. Optimisation plots, Figure 4.27 and 4.28 for two optimal 
formulations were developed with a composite desirability for formulation 1 of 91.00% and 
formulation 2 of 88.90%. 
 
 
 
Figure 4.27: Optimised plots for formulation 1 for the optimisation of the PFD 
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Figure 4.28: Optimised plots for formulation 2 for the optimisation the PFD 
Ideal formulations were prepared instituting the optimal setting. The experimental value was 
compared to the predicted value as shown in Table 4.6. The Young’s modulus, ultimate 
strain and MDT10 days for formulation 1 were similar to the expected values (R2 = 0.998) 
therefore the formulation was in near agreement to what was predicted. The only response in 
formulation 2 that correlated with the predicted value was ultimate strain, resulting in a less 
than perfect fit (R2 = 0.942). The analysis the MDT demonstrated greater deviation from 
predicted values compared to other variables. Therefore, a more sensitive and accurate 
method of detecting drug release was developed based on liquid chromatography principles 
(Chapter 5). 
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Table 4.6: Experimental and predicted values for optimised formulation 1 and 2  
Response Formulation 1 Formulation 2 
 Predicted 
Value 
Experimental 
Value 
Desirability 
(%) 
Predicted 
Value 
Experimental 
Value 
Desirability 
(%) 
Youngs modulus 
 
355.60MPa 314.04MPa 100.00 265.00MPa 81.92MPa 67.50 
Ultimate strain 
 
0.27 0.29 75.28 0.30 0.29 100.00 
MDT 10 days –
ciprofloxacin   
14.22 14.77 92.58 13.22 20.63 92.55 
MDT 10 days – 
diclofenac   
9.98 28.19 100.00 10.85 31.27 100.00 
4.5. Concluding Remarks 
Preliminary investigations identified the polymer, crosslinking salt and plasticiser 
concentration as factors upon which the overall physicochemical and physiomechanical 
behaviour of the fibre formulation was dependent upon. Upper and lower levels for each 
factor were determined experimentally and employed in the generation of a 3-factor Box-
Behnken Design. The DoE created 15 random formulations that were assessed using drug 
entrapment, in vitro drug release and tensile strength as the possible responses. Four 
responses were further identified for optimisation: MDT10 days of ciprofloxacin and diclofenac 
sodium, Young’s modulus and ultimate strain. The design was evaluated according to the 
extent to which it fitted the predicted responses using standardised residuals, p-values and 
coefficients of determination as well as residual and factor plots. Analysis revealed that the 
alginate and glycerol composition had a notable effect on mechanical properties of the matrix 
while the binding of barium ions to the polymer complex had a considerable result on drug 
release behaviour.  
Constrained settings for optimisation were ascertained and two optimised formulations were 
prepared and tested against optimisation responses. The experimental values for Young’s 
modulus and ultimate strain tests were similar to the predicted values. However, the drug 
release studies did not fit the model as well as predicted. The responses for formulation 1 
were in close agreement to the predicted values and formulation 1 was used in subsequent 
studies for further analysis. This confirmed that the Design of Experiment is a suitable means 
for optimising the PFD. 
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CHAPTER 5 
EVALUATION OF THE PHYSICOCHEMICAL AND PHYSICOMECHANICAL PROPERTIES 
OF AN OPTIMISED CIPROFLOXACIN- AND DICLOFENAC-LOADED POLYMERIC FIBRE 
DEVICE 
5.1. Introduction 
The challenge facing pharmaceutical research is to ensure that the in vitro activity of a 
product leads to sufficiently high concentrations of drug present at the site of action to ensure 
a therapeutic response (Tønnesen and Karlsen, 2002).  This in turn, has lead to the 
development of targeted drug delivery devices, yet many of these fail to meet the necessary 
requirements. During the 1990’s numerous antimicrobial-loaded devices for the treatment of 
PD were developed, however, most of these had limited success (Chapple, 2009). Therefore 
providing was the rationale for developing a device capable of simultaneously delivering two 
drugs, an antimicrobial and anti-inflammatory agent, over an extended period of time within 
the periodontal pocket.   
Local delivery systems placed within the periodontal pocket needs to meet specific criteria. 
The formulation should be both biocompatible and biodegradable delivering the 
chemotherapeutic agent(s) over the intended period of time. As well as being easily inserted 
within the periodontal pocket, remain in place for the duration of treatment and release 
sufficient drug to adequately meet the therapeutic levels required. These criteria necessitate 
specific chemical and mechanical in vitro analysis of the device. Drury et al. (2004) stated 
when reviewing alginate hydrogels that the “…knowledge of the mechanical and material 
properties of the hydrogels and the properties that govern and influence them is necessary to 
adequately design and effectively use these systems.” Likewise, it is necessary to assess the 
in vitro behaviour of the alginate based fibre in forecasting its success in vivo. The 
optimisation of the PFD described in Chapter 4 yielded a prototype fibre.  Further 
investigation predicted the usefulness of such a device in the treatment of PD.  
5.2. Materials 
Double deionised water was obtained from a Milli-Q system (Milli-Q, Millipore 
Johannesburg). UPLC grade acetonitrile and methanol were purchased from Romil Pure 
Chemistry, distributed by Microsep, Johannesburg. Formic acid (99%) was purchased from 
Merck, Wadeville. Sample vials (2mL pre-silt, PTFE/silicone septa, screw top) and the Aquity 
UPLC® Bridged Ethyl Hybrid (BEH) Shield RP18 column was procured from Waters, USA. All 
further chemicals were purchased from suppliers as outlined in previous chapters. 
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5.3. Methods 
 
5.3.1. Preparation of optimised fibres 
The optimised PFD described in Chapter 4 yielded a formula which employed set polymer, 
crosslinking salt and plasticiser combinations as indicated in Table 5.1. This formulation was 
prepared as (1) ciprofloxacin-loaded (200mg), (2) diclofenac sodium-loaded (500mg), (3) 
ciprofloxacin(200mg)/diclofenac sodium(500mg)-loaded fibres and (4) drug-free. The fibres 
were prepared as outlined in Chapter 3 Section 3.3.1. with the model drugs dispersed in 
water prior to addition of alginate.  
Table 5.1: Formulation components for optimised fibres prepared  
Formulation components Formulation number  
 1 2 3 4 
Alginate (%w/v) 3.14 3.14 3.14 3.14 
Glycerol (mL) 22.54 22.54 22.54 22.54 
Barium chloride 2-hydrate (%w/v) 10.00 10.00 10.00 10.00 
Ciprofloxacin (mg) 200 - 200 - 
Diclofenac sodium (mg)  - 500 500 - 
5.3.2. Characterisation of morphological transitions 
Samples were prepared and analysed as outlined in Chapter 3 Section 3.3.2.  
5.3.3. Development of a method for the co-detection of ciprofloxacin and diclofenac 
sodium 
Ciprofloxacin and diclofenac sodium absorb UV light within the same range, λmax=278nm and 
λmax=276 nm respectively. A method to simultaneously detect the model drugs was needed. 
An ultraperformance liquid chromatography (UPLC) method was developed using a Waters® 
Aquity Performance LC system (Waters, Milford, MA, USA) coupled with a photodiode array 
detector (PDA). The UPLC was fitted with an Aquity UPLC® Bridged Ethyl Hybrid (BEH) 
Shield RP18 column, with a pore size of 1.7µm. A gradient method with a run time of 3 
minutes, depicted in Table 5.2, was developed using acetonitrile and 0.1%v/v formic acid in 
double deionised water as the mobile phases. Ciprofloxacin and diclofenac samples were 
filtered, using 0.22µm syringe filter, into 2mL vials. The vials were placed in the UPLC 
sample holder. The injection volume was standardised at 2µL per injection.   
Table 5.2: Gradient method used in the separation of ciprofloxacin and diclofenac sodium 
indicating mobile phase concentrations and flow rate at various time periods over the 3 
minute run time 
Time (min) Flow rate (mL/min) 0.1 %v/v Formic acid solution Acetonitrile 
Initial  0.5 85% 15% 
1.00 0.5 20% 80% 
3.00 0.5 85% 15% 
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5.3.4. Determination of drug entrapment of optimised fibres  
Using the UPLC method developed, determining the quantity of the two model drugs 
entrapped within a fibre was possible. Model drugs, ciprofloxacin and diclofenac sodium, 
were dissolved in PBS pH 8 to generated standard calibration curves for subsequent 
determination of the drug entrapped in the optimised fibre. Serial injections (2µL) of varying 
concentrations of drug were injected and the area under the curve (AUC) was calculated for 
peaks at 0.8 and 1.6 minutes for ciprofloxacin and diclofenac sodium respectively. This was 
plotted against drug concentration and a calibration curve created.   
The addition of glycerol to crosslinked barium fibres generated a strong yet flexible matrix 
which presented difficulties in milling and dissolving the formulation, which is necessary to 
quantify the amount of drug entrapped. Approximately 25mg of fibres were submerged in 
100mL PBS pH 8 and stirred until the fibres had disintegrated. The samples were then 
filtered through a 0.22µm filter into a 2mL sample vial. A 2µL sample was injected and UV 
absorbance detected at λ=278nm. The area under the curve was calculated and compared 
to the calibration curve to determine the concentration of model drug entrapped within the 
fibres. 
5.3.5. Determination of drug release from optimised fibres  
Ciprofloxacin- and diclofenac-loaded fibres were assessed for the simultaneous release of 
these two drugs. The dissolution apparatus used was the same as described in Chapter 3 
Section 3.3.6. The drug release studies were conducted in triplicate. Samples were removed 
on days 0, 1, 2, 4, 6, 8 10 and frozen at -7˚C until analysis. Samples were thawed at room 
temperature and filtered using a 0.22µm syringe filter into a 2mL sample vial. Once all the 
samples were filtered and loaded, a sample set was run and the autosampler injected 2µL of 
each sample according to the specified method (Section 5.3.3). Each sample was tested in 
triplicate. Standard samples were run after the dissolution samples had been tested.  
For comparison standard samples contained a known quantity of ciprofloxacin and diclofenac 
sodium dissolved in a 50:50 solution of doubled deionised water and acetonitrile. Serial 
dilutions with varying concentrations of drugs were injected. The areas under the curve for 
the relevant peaks were calculated and plotted against concentration of drug to construct a 
calibration curve, against which the dissolution samples were compared.  
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5.3.6. Characterisation of textural properties  
Textural analysis on drug-loaded and drug-free fibres would elucidate the effect of the model 
drugs on the strength and flexibility of the ciprofloxacin-, diclofenac- and 
ciprofloxacin/diclofenac-loaded fibres to the drug-free formulation. The same method as 
described in Chapter 3 Section 3.3.7.3 was used.   
5.3.7. Characterisation of hydration dynamics behaviour 
Once fibres were submerged in PBS the matrices displayed diverse behaviour depending on 
the pH of the solution. To investigate the hydration behaviour of the optimised formulation, 
drug-free and drug-loaded fibres were separately assessed in 20mL of PBS pH 4 or pH 6.8 
and placed in a shaking incubator (Orbital Shaker Incubator, LM-530, Lasec Scientific 
Equipment, Johannesburg, South Africa) for 10 days. Samples were removed on day 0, 1, 2, 
4, 6, 8 and 10. Once removed the degree of swelling and erosion was determined through 
measuring the diameter of the fibre. The degree of hydration was calculated using the 
average diameter measured at three positions along the length of the fibre using digital 
calipers. The average diameter of the wet fibre was compared against the diameter of the dry 
fibre as a measure of the degree of hydration as represented in Equation 5.1.  
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5.3.8. Characterisation of vibrational transitions 
Chemical interactions between polymer, crosslinking salt, plasticiser and model drugs were 
investigated using Fourier Transform Infrared (FTIR) Spectroscopy using a 100FT-IR 
Spectrometer (PerkinElmer Inc., Waltham, Massachusetts, USA). The reference spectrum 
used was air. Samples tested included drug-free and drug-loaded polymeric fibres. Changes 
in vibrational absorption occur as new bonds are formed altering the infra red spectra which 
were qualitatively compared against one another. Formulation components and model drugs 
were run individually such that the sample spectra were compared to standard spectra.  
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5.3.9. Static lattice atomistic stimulations relating to Young’s modulus  
The effect of varying the plasticiser and crosslinking ion concentration on Young’s modulus 
and ultimate strain of the fibres and the performance of the ciprofloxacin- and/or diclofenac-
loaded optimised fibre was further elucidated and conceptualised using Molecular Mechanics 
Energy Relationships (MMER) by exploring the spatial disposition of energy minimised 
molecular structures. All modelling procedures and calculations, including energy 
minimisations in molecular mechanics, were performed using the HyperChemTM 8.0.8 
Molecular Modeling System (Hypercube Inc., Gainesville, Florida, USA) and ChemBio3D 
Ultra 11.0 (CambridgeSoft Corporation, Cambridge, UK) on an HP Pavilion dv5 Pentium 
Dual CPU T3200 workstation. The structures of alginate – Alginate10 (Alg10: ten 
oligosaccharide units for tensile analysis of preoptimised batches) and Alginate4 (Alg4: four 
oligosaccharide units for drug loaded optimised batch) were generated (1,4-linked β-D-
mannuronate:α-L-guluronate, 1:1) using sugar builder module on HyperChem 8.0.8. 
Structures of Glycerol (Gly), Ciprofloxacin (Cpr) and Diclofenac (Dcl) were built up with 
natural bond angles as defined in the Hyperchem software. The models were initially energy-
minimised using MM+ force field and the resulting structures were again energy-minimised 
using the Amber 3 (Assisted Model Building and Energy Refinements) force field. The 
conformer having the lowest energy was used to create the polymer-plasticiser, polymer-
crosslinker and polymer-drug complexes. A complex of one molecule with another was 
assembled by disposing the molecules in a parallel way, and the same procedure of energy-
minimisation was repeated to generate the final models: Alg-Gly, Alg-Ba2+, Alg-Gly-Ba2+, Cpr-
Dcl, Alg-Cpr, Alg-Dcl and Alg-Cpr-Dcl. Full geometry optimisation was carried out in vacuum 
employing the Polak–Ribiere conjugate gradient algorithm until an RMS gradient of 
0.001kcal/mol was reached. Force field options in the AMBER (with all hydrogen atoms 
explicitly included) and MM+ (extended to incorporate non-bonded cut-offs and restraints) 
methods were the HyperChem 8.0.8 defaults (Kumar et al., 2011). A molecular mechanics 
conformational searching procedure was employed to acquire the data employed in the 
statistical mechanics analysis, and to obtain differential binding energies of a Polak–Ribiere 
algorithm and to potentially permit application to polymer composite assemblies. MM+ is a 
HyperChem modification and extension of Norman Allinger's Molecular Mechanics program 
MM2 (Warhurst et al., 2003), whereas AMBER, is a package of computer programs for 
applying molecular mechanics, normal mode analysis, molecular dynamics and free energy 
calculations to simulate the structural and energetic properties of molecules (Pearlman et al., 
1995).  
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5.4. Results and Discussion  
5.4.1. Morphological and surface structure analysis  
Analysis of SEM images revealed the interaction between the model drugs and the polymeric 
fibre as depicted in Figure 5.1. A uniform cylindrical filamentous structure is evident in the 
drug-free formulation (Figure 5.1d). Images of fibres loaded with ciprofloxacin and diclofenac 
sodium (Figure 5.1a and b respectively) display a similar structure to the drug-free fibre. 
However, when these two drugs are simultaneously loaded into the fibre the structure is 
disrupted as represented in Figure 5.1c. The surface of ciprofloxacin and diclofenac sodium-
loaded fibre appears uneven and less aligned in structure compared to the other 
formulations.   
 
 
 
 
 
 
 
 
 
 
Figure 5.1: SEM images (a) ciprofloxacin-loaded fibre, (b) diclofenac sodium-loaded fibre, 
(c) ciprofloxacin/diclofenac-loaded fibre, (d) drug-free fibre 
 
 
 
(a) (b) 
(d) (c) 
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5.4.2. UPLC method development  for the co-detection of ciprofloxacin and 
diclofenac sodium 
The UPLC builds on the technology of high performance liquid chromatography (HPLC) 
analysing compounds with increased speed, sensitivity and resolution while drastically 
reducing run times and has significantly improved processes within drug delivery (Swartz, 
2005). Inclusion of ciprofloxacin and diclofenac within the same fibre necessitated the 
development of a chromatographic method for the co-detection of these two drugs from 
dissolution samples. The reverse phase chromatographic method analyses the chemical 
structures affinity for the non-polar stationary phase or the more polar mobile phase. Using a 
gradient method, the composition of the mobile phase was adjusted to ensure that both 
drugs produced narrow peaks without visible tailing and that these peaks were easily 
resolved from one another. 
The three dimensional analysis of the PDA spectrum from λ=220-400nm identified that 
ciprofloxacin was eluted before diclofenac sodium with retention times of 0.8 minutes and 1.7 
minutes respectively, depicted in Figure 5.2. Adequate separation of the two peaks as well 
as the maximum peak for both drugs was between 270-280nm, therefore the channel was 
set at λ=278nm for analysis.     
 
Figure 5.2: PDA spectrum for the detection of ciprofloxacin and diclofenac sodium at 
approximately 0.8 and 1.7 minutes respectively 
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5.4.3. Drug entrapment efficiency of fibres 
The USP (1995) states that both peak height and area can be related to analyte 
concentration, however, peak areas have been considered a more accurate method for 
quantification. Resolution between peaks was sufficient; consequently the peak areas were 
used to quantify the concentration of ciprofloxacin and diclofenac sodium in both standards 
and samples. 
Two calibrations curves for ciprofloxacin and diclofenac sodium, shown in Figure 5.3a and b 
respectively, were used to determine the drug entrapment within the optimised fibre, plotting 
the area under the curve (AUC) versus the concentration of either ciprofloxacin or diclofenac 
sodium. The incremental increases in absorbance and thus area, is noted in Figure 5.4, 
representing an increase in concentration of drug with each standard sample injected.     
 
 
Figure 5.3: Calibration curve in PBS pH 8 for (a) ciprofloxacin and (b) diclofenac sodium  
(a) Ciprofloxacin  
(b)  Diclofenac sodium  
y = 3.72 X 109 x 
R2 = 0.99 
y = 1.27 X 1010 x 
R2 = 0.999 
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Figure 5.4: Overlaid chromatograms representing the serial dilutions where the area under 
the curve at 0.8 minutes and 1.7 minutes was used in determining the calibration curves for 
ciprofloxacin and diclofenac sodium respectively 
It was uncertain if both drugs would remain entrapped within the fibre when combined 
simultaneously in the same formulation. Drug entrapment samples that were taken from 
drug-loaded fibres dissolved in PBS pH 8 confirmed that both ciprofloxacin and diclofenac 
were successfully retained within the formulation at 79.43% and 95.78% correspondingly.   
5.4.4. In vitro drug release behaviour 
For accurate analysis the analyte needs to be soluble in the mobile phases, hence for 
analysis of dissolution samples, standard samples of ciprofloxacin and diclofenac sodium 
were dissolved in water and acetonitrile at a ratio of 1:1, which was completely miscible with 
the mobile phases over the three minute run time. The AUC was calculated and plotted 
against drug concentration giving calibration curves for ciprofloxacin and diclofenac sodium 
in Figure 5.5a and b respectively.   
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Figure 5.5: Calibration curves in acetonitrile:water (50:50) for assessment of (a) ciprofloxacin 
and (b) diclofenac sodium release 
Drug release results of the optimised formulation revealed critical information regarding the 
successful formulation of the PFD. Drug interactions between ciprofloxacin and diclofenac 
affecting release kinetics as well as capacity of the fibre to retain these two drugs in sufficient 
concentrations were two major concerns of simultaneous drug entrapment. The fractional 
drug release over 10 days (Figure 5.6) confirmed that ciprofloxacin was consistently released 
over 10 days at both pHs tested. Diclofenac sodium was poorly released in PBS pH 4, but 
was steadily released in PBS pH 6.8 over the same time period. These results are visually 
represented in the stacked chromatograms representing drug release at each time point in 
PBS pH 4 and pH 6.8 correspondingly in Figures 5.7 and 5.8. The peak at approximately 1.7 
minutes, characterising diclofenac release, is absent in Figure 5.7, however, it is present in 
the chromatograms at each time interval from day 1 to day 10 in Figure 5.8. Comparatively 
peaks at approximately 0.8 minutes represent ciprofloxacin released at pH 4 and pH 6.8 and 
is present at each time interval tested.  
y = 7.05e9 x 
R2 = 0.998 
y = 2.99e9 x 
R2 = 0.998 
 (b) Diclofenac sodium  
(a) Ciprofloxacin  
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Drug release kinetics has been reported to depend on drug solubility, pH of dissolution 
medium and changes in the crystalline structure of the matrix upon hydration (Hodsdon et al., 
1995). Furthermore, Bajpai and Sharma (2004) stated that alginate in an acidic environment 
undergoes hydrolysis to for alginic acid leading to reduced mechanical strength and a degree 
of crosslinking. These explanations could account for the release of ciprofloxacin and 
diclofenac in PBS pH 4 and pH 6.8 with or without swelling of the polymeric matrix. 
Ciprofloxacin, a weak basic drug, was released to a greater extent in PBS pH 4 as it is more 
soluble in acidic media compared to PBS pH 6.8 where it is less soluble. However, it is 
suggested that the swelling and relaxation of the fibre accounted for the ciprofloxacin’s 
release in PBS pH 6.8.  In contrast diclofenac sodium, a weak acidic drug, released 80% of 
entrapped the entrapped drug in PBS pH 6.8. Exceptionally low levels of diclofenac were 
released in PBS pH 4, which can be hypothesised as being due to the drugs poor solubility in 
acidic media in conjunction with reduced swelling and relaxation of the PFD in PBS pH 4.  
 
Figure 5.6: Simultaneous fractional drug release of ciprofloxacin and diclofenac sodium from 
the optimised fibre formulation (N=3) 
 
 
107 
 
 
 
 
 
Figure 5.7: Stacked chromatograms of dissolution samples in PBS pH 4 on day (a) 1, (b) 2, 
(c) 4, (d) 6, (e) 8 and (f) 10 at λ=278nm 
(a) 
(b) 
(c) 
(d) 
(f) 
(e) 
Note consequential increase in AU, 
 implies increase in drug release  
Peaks representing 
ciprofloxacin release 
Peaks absent 
representing poor 
diclofenac sodium 
release at pH 4  
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Figure 5.7: Stacked chromatograms for dissolution samples in PBS pH 6.8 on day (a) 1, (b) 
2, (c) 4, (d) 6, (e) 8 and (f) 10 at λ=278nm 
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The MDT for ciprofloxacin and diclofenac sodium in PBS pH 4 and 6.8 is summarised in 
Table 5.3. In comparison to the MDT for optimised fibres with either ciprofloxacin or 
diclofenac sodium loaded within the fibre reported at the end of Chapter 4, a notable 
reduction in MDT 10 days for both drugs at both pH’s was noted. A reduction in MDT validated 
the proposition that the matrix retards the release of both the drugs.  This may too be 
attributed to the more sensitive method of quantifying drug release using UPLC compared to 
a UV.    
Table 5.3: MDT10 days for ciprofloxacin and diclofenac release in PBS pH 4 and pH 6.8 
Days MDT 10 days ciprofloxacin MDT 10 days diclofenac sodium 
 pH 4 pH 6.8 pH 4 pH 6.8 
0 0 0 0 0 
1 0.24 0.21 0 0.11 
2 0.91 0.74 0 0.62 
4 2.11 1.21 0.012 1.18 
6 4.14 1.64 0.002 2.87 
8 6.45 3.18 0.04 5.15 
10 9.31 4.29 0.15 7.28 
 
5.4.5. Textural analysis  
Jejurikar et al. (2011) examined tensile curves of alginate hydrogels and found a two-stage 
deformation profile. The steep first part of the curve represents an elastic response with 
some stretching until a yield value is reached after which plastic deformation occurs where 
disruption in crosslinking bonds and chain sliding occurs. Tensile analysis of drug-free and 
drug-loaded optimised fibres revealed profiles for further analysis, as depicted in Figure 5.9.  
 
Figure 5.9: Stress versus strain profiles for drug-free and drug-loaded fibres  
 
( - ) Drug-free fibre 
( - ) Ciprofloxacin-loaded fibre 
( - ) Diclofenac Na-loaded fibre 
( - ) Cipro/Diclo-loaded fibre 
110 
 
Two important tensile properties, strength and flexibility, are vital in the analysis of fibres for 
placement within the periodontal pocket. Firstly, fibres need to be tough enough enabling 
handling and processing without breakage. The tensile strength of the fibres were attributed 
to both the type and concentration of polymer and crosslinking salt incorporated.  Drury et al. 
(2004) investigated the tensile properties of alginate based hydrogels and deduced that 
higher G monomers enhance the tensile properties within the polymeric backbone. The high 
tensile strength may also be be attributed to barium’s large ionic radii, being responsible for 
the stronger crosslinked hydrogel formed compared to other divalent cations such as calcium 
(Jejurikar et al., 2011). Secondly, fibres require a particular degree of flexibility for 
manipulation during placement within the periodontal pocket. Glycerol was included in the 
formulation as a plasticiser for this reason.  Avella et al. (2007) researched the interaction 
between glycerol and alginate and deduced that the flexibility of the matrix attributed to the 
structure of the polysaccharide used, where higher molecular weight and higher amounts of 
G monomers present leads to entanglement of glycerol within the polymeric structure. 
Furthermore, their results revealed a significant drop in Young’s modulus values and stress 
at breakage, while an increase in the strain at breakage values, with decreasing sodium 
alginate and increasing glycerol concentrations.  
Following the experimental design, polymer, crosslinking salt and plasticiser concentrations 
were optimised and were held constant while comparing the interaction of the two drugs, 
ciprofloxacin and diclofenac sodium with fibre components. Drug-free fibres were compared 
to diclofenac-loaded, ciprofloxacin-loaded and ciprofloxacin/diclofenac-loaded fibres. A visual 
comparison of these formulations is seen in the stress vs. strain plots with the four curves 
superimposed on each other and in the force vs. displacement profiles, in Figure 5.9 and 
5.10 respectively. Drug-free fibres withstood the highest stress and strain before fracturing 
compared to drug-loaded fibres as reviewed in Table 5.4. Incorporation of either diclofenac 
sodium or ciprofloxacin within the fibres reduces the strength and flexibility of the formulation. 
Surprisingly as seen in the typical force versus displacement profiles (Figure 5.10b) when the 
two drugs were combined, the resultant drug-loaded fibre fractures at a higher stress value 
(1205mN) while still stretching 3.457 mm in length before fracturing. These observations are 
consistent with the higher Young’s modulus values (326.34±37.91MPa) calculated for the 
ciprofloxacin/diclofenac sodium loaded fibers and lower ultimate strain values (0.15±0.05). 
Both diclofenac-loaded and ciprofloxacin-fibres fractured at considerably lower forces with 
Young’s modulus values plummeting to 78.02 and 132.87MPa respectively.  
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Figure 5.10: Typical profiles detailing the relationship between force (mN) and displacement 
(mm) for (a) drug-free fibres, (b) ciprofloxacin/diclofenac-loaded fibres, (c) ciprofloxacin-
loaded fibres and (d) diclofenac-loaded fibres 
 
Table 5.4: Tensile analysis results comparing drug-free fibres to drug-loaded fibres (N=5) 
 Drug-free 
 fibres 
Ciprofloxacin-loaded 
fibres 
Diclofenac-loaded  
fibres 
Ciprofloxacin/diclofenac 
-loaded fibres 
Young’s modulus (MPa) 314.04±18.93 78.02±9.65 132.87±37.23 326.34±37.91 
Yield stress (MPa) 5.80±0.40 1.51±0.23 2.02±0.51 4.25±0.84 
Ultimate strength (MPa) 10.05±2.09 2.97±0.30 3.50±0.60 6.49±1.68 
Ultimate strain 0.29±0.12 0.83±1.11 0.26±0.10 0.15±0.05 
Toughness (Jcm-3) 2.39±1.25 0.74±0.07 0.71±0.18 0.93±0.49 
 
 
 
 
 
 
 
 
6.416 mm 
685 mN 
3.457 mm 
1205 mN 
652 mN 672 mN 
4.597 mm 6.616 mm 
(d) (c) 
(b) (a) 
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5.4.6. Swelling and erosion analysis 
Alginate interacts with divalent cations resulting in gelation or precipitation while a soluble 
salt complex is formed when monovalent cations interact with the polymer (Tønnesen and 
Karlsen, 2002). Crosslinker density, alginate concentration and alginate chemical 
composition have been identified as factors affecting swelling behaviour of crosslinked 
alginate hydrogels (Kuo and Ma, 2007). 
Alginate based polymeric fibres initially swelled in PBS pH 6.8 up to 300% in the first day, 
after which the matrix eroded steadily over the next few days. In comparison the fibre does 
not swell in PBS pH 4 but slowly erodes. Swelling of crosslinked alginate matrices in PBS is 
explained as a result of the divalent crosslinked ions being replaced by sodium ions present 
in solution,  resulting in repulsion of the  -COO- groups, chain relaxation and swelling (Bajpai 
and Sharma, 2004).  
The degree of hydration varied considerably in PBS at pH 6.8 between the drug loaded and 
drug-free samples as depicted in Figure 5.11. Ciprofloxacin/diclofenac-loaded fibres swelled 
to almost twice as much as drug-free fibres. This may perhaps be ascribed to the degree of 
crosslinking and porosity of the matrix interacting with the sodium ions present in solution. 
 
Figure 5.11: The hydration behaviour drug-free and ciprofloxacin/diclofenac-loaded PFD 
over 10 days in PBS pH4 and 6.8 (N=3) 
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5.4.7. Vibrational transition analysis 
Functional groups within molecules experience vibrational excitation and absorb infrared 
radiation corresponding to the vibrational energies. The absorption spectra are a blue print of 
the molecular structure and can therefore be used in the analysis of an unknown spectrum to 
reference spectrum (Coates, 2000). The unknown spectra analysed were drug-free and 
drug-loaded co-blended crosslinked alginate based fibres, illustrated in Figure 5.12. These 
spectra were compared against spectra of the individual components employed in the 
formulation of the fibres namely alginate, barium chloride 2-hydrate and glycerol as depicted 
in Figure 5.13.    
The analysis of the FTIR spectrum revealed broad peaks present in all fibres ranging from 
3260.70-3273.79cm-1, which characterises the presence of O-H groups. C-H stretching 
(2850-3000cm-1) was present in the glycerol spectra with two peaks visible at 2932.32cm-1 
and 2879.69cm-1. Similar peaks were present in all fibre formulations shifting towards slightly 
higher wavelengths. Two unknown peaks at 1635.68cm-1 and 1599.62cm-1 were present in 
the barium chloride spectra.  The crosslinking between alginate and barium chloride was 
observed by Lawrie et al. (2007) identifying the antisymmetric carbonyl vibration (1596cm-1) 
been most sensitive to addition of barium chloride ions. Similarly, in Figure 5.13, the peak 
present in the sodium alginate spectra at 1594.28cm-1 was absent or had shifted in the 
spectra in Figure 5.12.   A comparable peak at approximately 1640cm-1 was observed in all 
four fibre formulations which may reflect the unknown peak from the barium chloride spectra 
or a shift in the carbonyl vibration present in sodium alginate. Furthermore, a shift in the 
bands to higher or lower energies may have occurred due to sodium alginate crosslinking 
with divalent ions which is dependent on the M/G monomer ratio (Lawrie et al., 2007). Shifts 
in peaks at 1405.28cm-1 and 1024.82cm-1 in the sodium alginate spectrum to 1413.17-
1415.80cm-1 and 1036.27-1037.87cm-1 respectively, further reflected in the interaction 
between barium chloride and alginate. The shift in peak at 1030cm-1 was noted by Sakugawa 
et al. (2004) reflecting a change in M monomer concentration in the presence of calcium 
ions, confirming the shifts in peaks evident between 1024.82cm-1 and approximately 1037cm-
1
 as an interaction between the polymer and crosslinking salt.  
Incorporation of ciprofloxacin and diclofenac, individually or in combination within the fibre did 
not result in any significant changes in the spectra when compared to the drug-free fibres. If 
no chemical interactions between the polymer and drug are evident, the release will depend 
on the hydrophobicity of the drug diffusing through the gel pores (Augst et al., 2006).  
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Figure 5.12: FTIR spectrum representing (–) drug-free fibres, (–) ciprofloxacin-loaded fibres, (–) 
diclofenac sodium-loaded fibres and (–) ciprofloxacin/diclofenac-loaded fibres 
 
   Figure 5.13: FTIR spectrum of (–) alginate, (–) barium chloride 2-hydrate and (–) glycerol  
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5.4.8. Static lattice atomistic simulations  
Molecular mechanics energy relationship (MMER), a method for analytico-methematical 
representation of potential energy surfaces, was used to provide information about the 
contributions of valence terms, noncovalent Coulombic terms, and noncovalent van der 
Waals interactions in mechano-tensile properties and drug incorporation effect. The MMER 
model for potential energy factor in various molecular complexes can be written as: 
Emolecule/complex = V∑ = Vb + Vθ + Vφ + Vij + Vhb + Vel                                                    Equation 5.2 
where, V∑ is related to total steric energy for an optimised structure, Vb corresponds to bond 
stretching contributions
 
(reference values were assigned to all of a structure's bond lengths), 
Vθ denotes bond angle contributions (reference values were assigned to all of a structure's 
bond angles), Vφ represents torsional contribution arising from deviations from optimum 
dihedral angles, Vij incorporates van der Waals interactions due to non-bonded interatomic 
distances, Vhb symbolises hydrogen-bond energy function and Vel stands for electrostatic 
energy (Choonara et al., in press)  
In the present molecular modeling study, the global energy relationships for the various 
complexes derived after assisted model building and energy refinements were as follows: 
EALG-10 = 74.426V∑ = 5.204Vb + 32.485Vθ + 34.168Vφ + 30.709Vij - 28.142Ve                                 Equation 5.3 
EGLY-5 = 14.315V∑ = 0.230Vb + 1.345Vθ + 10.615Vφ + 2.185Vij - 0.065Vhb
 
                                   Equation 5.4 
EALG-GLY5 = 22.558V∑ = 5.698Vb + 32.688Vθ + 47.908Vφ + 17.697Vij - 1.454Vhb - 79.979Vel              Equation 5.5  
EALG-Ba2+10 = 38.839V∑ = 5.662Vb + 31.068Vθ + 40.489Vφ + 36.363Vij - 74.744Vel                         Equation 5.6 
EALG-GLY5-Ba2+10 = 14.917V∑ = 5.641Vb + 27.792Vθ + 38.072Vφ + 24.932Vij - 1.456Vhb -80.065Ve        Equation 5.7  
EALG-4 = -12.974V∑ = 2.562Vb + 22.378Vθ + 37.927Vφ + 16.696Vij - 4.584Vhb - 87.954Ve                   Equation 5.8  
ECPR = 118.194V∑ = 0.989Vb + 99.998Vθ + 9.149Vφ + 8.063Vij - 0.006Vhb                                      Equation 5.9 
EDCL = 7.483V∑ = 0.668Vb + 3.845Vθ + 0.814Vφ + 2.434Vij - 0.28Vh                                        Equation 5.10 
EALG-CPR = 84.568V∑ = 3.552Vb + 120.693Vθ + 47.076Vφ + 12.08Vij - 4.375Vhb - 94.559Vel            Equation 5.11 
EALG-DCL = -17.938V∑ = 3.107Vb + 27.608Vθ + 37.187Vφ + 5.907Vij - 3.903Vhb - 87.845Vel             Equation 5.12 
EALG-CPR/DCL = 422.162V∑ = 220.235Vb + 81.482Vθ + 23.052Vφ + 136.476Vij - 1.629Vhb -37.454Vel.  Equation 5.13 
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5.4.8.1. Formulation and crosslinking of plasticised-alginate fibres 
The present work focused on the fabrication of a polysaccharide (alginate) based macro-
fibrous system integrating a unique combination of plasticiser (glycerol) and crosslinker 
(divalent barium ions).  The energy changes brought about by crosslinking of plasticised 
alginate system and the resulting geometrical minimisations are depicted in Figure 5.14. In 
accordance with the sequence of steps in Chapter 3 Section 3.3.1, alginate solution was first 
plasticised with addition of glycerol and thereafter crosslinked in barium chloride solution in 
the form of fibres. Although the tensile analysis was conducted on crosslinked-plasticised 
fibre, the effect of addition of the individual component to the alginate during the initial stage 
of static simulations is elucidated upon. 
 
Figure 5.14: Visualisation of energy minimised geometrical preferences of a) alginate (10 
monosaccharide units); b) alginate-glycerol; c) alginate-Ba2+; and d) alginate-glycerol-Ba2+ 
showcasing the intra- and inter- molecular interactions in crosslinked-plasticised-alginate 
fibres after molecular simulations in vacuum. Glycerol molecules are rendered as tubes in 
yellow and barium ions are rendered spherically in violet. Colour codes for elements: C 
(cyan), O (red), N (blue), and H (white) 
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The incorporation of glycerol to alginate conceded the standards of polymer-plasticiser 
combination, both kinetically and thermodynamically. Kinetically, glycerol dissolved rapidly 
into the alginate solution and in the thermodynamic sense, the free energy of mixing or the 
change in total steric energy of complex was negative (-66.183kcal/mol; Eqns. 2-4; Table I), 
thereby forming a highly stable preferential molecular composite with intra- and inter-
molecular H-bonds ranging from 2.2052A° to 3.0464A° (avg. 2.4647A°). Furthermore, 
glycerol displayed strong interactions with the polysaccharide as displayed in Figure 5.14.  
Alginates are known to exhibit interactions with various divalent metal ions, such as calcium 
and barium, where they display concentration-dependent intra- and inter-molecular 
crosslinking and complexation of the polymer matrix (da Silva et al., 2009). It is evident from 
Table 5.5, Alg-Ca2+ was energetically stabilised by 35.587kcal/mol (Eqns. 2 and 5) as 
compared to alginate because of strong electrostatic interactions (∆E = -46.602kcal/mol) 
along with high torsional energy (∆E = 6.321kcal/mol) leading to the formation of a strained 
network structure - with smaller intramolecular H-bonds ranging from 2.208A° to 3.3595A° 
(avg. 2.2996A°) - due to calcium crosslinking thereby limiting the complete interaction as 
observed with the non-crosslinked structure (Figure 5.14). These results are in line with the 
earlier reported studies where the polyguluronates (alginate) displayed better strength and 
stereospecificity in binding to calcium through “Egg-box model” (Braccini and Pérez, 2001). 
The crosslinked-plasticised polymeric matrix, Alg-Gly-Ba2+, formed by ionic crosslinking and 
subsequent gelation of already plasticised alginate displayed a well organised structure with 
formation of several intra- and inter-molecular H-bonds (although at different positions as 
compared to bimolecular structures) having bond length ranging from 2.2051A° to 3.1906A° 
with (avg. 2.5486A°). The trimolecular complex is stabilised by 38.237kcal/mol which is in-
between the stabilisation energies of the corresponding bimolecular structures, Alg-Gly and 
Alg-Ba2+, demonstrating the conformational stability and compatibility of the three molecules 
in conjugation with each other. Interestingly and unexpectedly, all the energy values viz., 
bonding and non-bonding energies underwent stabilisation with all ∆E values in negative 
(Table 5.5), further confirming the thermodynamic and steric rationality of the selected 
plasticiser and crosslinker combination for alginate fibres. 
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Table 5.5: Calculated energy parameters (kcal/mol) of polymer-plasticiser, polymer-
crosslinker and crosslinked-plasticised polymer assemblies 
Name ∆Energiesa 
∆Totalb ∆Bondc ∆Angled ∆Dihedrale ∆Vdwf ∆H-bondg ∆Electroh 
Alg-Gly5 i -66.183 0.264 -1.142 3.125 -15.197 -1.389 -51.837 
Alg-Ba2+10 j -35.587 0.458 -1.417 6.321 5.654 0.000 -46.602 
Alg-Gly5-Ba2+10 k -38.237 -0.251 -4.621 -13.032 -13.616 -1.391 -5.321 
a
 ∆Ebinding = E(Host.Guest) - E(Host) - E(Guest) 
b Total steric energy for an optimised structure 
c Bond stretching contributions 
d
 Bond angle contributions 
e
 Torsional contribution 
f van der Waals interactions 
g Hydrogen-bond energy function 
h
 Electrostatic energy 
i Five glycerol molecules in conjugation with an alginate chain 
j Ten Barium ions in conjugation with an alginate chain 
k Five glycerol molecules and ten barium ions in conjugation with an alginate chain 
 
5.4.8.2. Tensile analysis of crosslinked-plasticised-alginate fibres 
Molecular mechanics simulations of polymer-plasticiser-crosslinker composite, wherein the 
energy changes calculated involved in the amalgamation of alginate, glycerol and barium 
cations, derived energy relationships based on molecular interactions and thus predicted the 
effect of formulation variables on Young modulus and ultimate strain of the composite 
material. Conceptually, the addition of a plasticiser may lead to lowering of rigidity of the 
polymer matrix thereby lowering the elastic modulus and increasing in ultimate strain as was 
evident from the experimental results and is in line with previous studies (Gil et al., 2006). 
Additionally, with the inclusion of chemical and physical cross-links, increases the Young 
modulus and hence decreases the ultimate strain of a crosslinked composite as predicted in 
the experimental results and similar studies (Griebel et al., 2005). It is therefore proposed 
that the mechanical properties of the alginate fibres may be predominantly dependent on the 
cohesive energy density (CED) of/between the polymer fragments based on the various 
intra- and inter-molecular interactions mainly in terms of non-bonded energy terms such as 
van der Waals forces (vdWf).  
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A typical relation between Young’s modulus (E) and CED was derived by Roberts et al. 
(1991) as follows: 
>  ?.
ABCD
E
                                                            Equation 5.14 
F  GH 
ABCD
E
                                                                                 Equation 5.15 
> 
A
IJ4KHLM
                                                                       Equation 5.16 
where, K is bulk modulus, Ecoh is energy of vaporization (J.mol-1), V is the molar volume 
(cm3.mol-1), δ is the solubility parameter, ν is Poisson’s ratio and x is a constant related to the 
cubic lattice of the molecule under investigation. 
From Equation 5.14-5.16, 
 N F                                                                       Equation 5.17 
The complexation of 10-monosaccharide units’ alginate chain with five glycerol molecules led 
to a decrease in vdWf by ~15kcal/mol (Table 5.5) which in turn may lead to a decrease in 
CED thereby decreasing the Young’s modulus. This seems obvious as a reduction in 
cohesion will help the adjacent polymer chains to stretch/slide over each other thereby 
increasing the elongation of the fibres. Apart from this, the water soluble plasticiser, glycerol, 
used in this investigation showed a high affinity to diffuse into and interact with the polymer 
molecules (as shown in Figure 5.14 and total energy stabilisation) by forming non-bonding 
interactions in terms of hydrogen bonding contribution, vdWf and electrostatic interaction (the 
∆E of all these energies is negative; Table 5.5) and hence lead to an increasing in polymer’s 
mobility. In this way, the brittle character of the polymer may decrease with an increase in 
plasticiser’s concentration (Gutiérrez-Rocca and McGinity, 1994). The increase in ultimate 
strain with the addition of a plasticiser can also be explained based on above data and 
discussion.  
Coming to the prediction of the effect of crosslinking on tensile properties of alginate fibers, 
there have not been many fully atomistic simulations of crosslinked polymers in which tensile 
properties have been calculated as a function of energy values of the complexed molecular 
structure. Although the total energy was stabilised by ~36kcal/mol in Alg-Ba2+, an increase of 
vdW energy by 5.654kcal/mol (Table I) was observed which may be responsible for the 
increase in the Young’s modulus due to an increase in CED with increase in barium ions 
concentration. Apart from dispersion forces, Alg-Ba2+10 was not stabilised by H-bonding and 
even the electrostatic were less stabilised, as compared to Alg-Gly5.  
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Griebel et al. (2005) suggested a logarithmic dependency of the Young’s modulus on the 
amount of cross-links and deduced the following relationship: 
OJ	M  P Q Rln J	M                                                                                            Equation 5.18 
where, P was a estimator to predict Young’s modulus, α was a constant and E0 was a 
parameter with units of GPa. Furthermore, in accordance with the Lennard-Jones energy 
potential, the elastic modulus is a measure of the rigidity of materials and is directly related to 
the energy of interaction between molecules and their distance of separation (Roberts et al., 
1991). The simulation results showed that ionic cross-links may cause disturbance at high 
crosslink densities resulting in distortion of bond lengths, angles, and torsions from their 
equilibrium values eventually causing strained and rigid-framework. Additionally, the buildup 
of cohesion between adjacent polymer chains (intermolecular crosslinking) may initiate a 
significant axial stress providing a reasonable explanation for the experimentally observed 
reinforcement and rigidification of the crosslinked formulations leading to decreased ultimate 
strain. 
The effect of variation of levels of plasticiser and crosslinker on the tensile properties of 
alginate fibres can be explained on similar lines. The CED in case of Alg-Gly5-Ba2+10 seems 
to be tilted more in favour of Alg-Gly5 with ∆Vdw of Alg-Gly5-Ba2+10 (~13kcl/mol) close to that 
of Alg-Gly5. An increase in crosslinking may significantly decrease the liquid (plasticiser) 
transport through the matrix (by regidification) and may even push out the already present 
glycerol (diffused within the matrix) thereby hindering the impact of plasticiser (by 
reinforcement). In the opposite way, an increase in plasticiser content may result in 
weakening of Ba2+ induced intermolecular attractions thereby increasing the polymer’s free 
volume causing an increase in their flexibility by allowing the polymer molecules to move 
more freely (Gutiérrez-Rocca and McGinity, 1994). Nevertheless, the effect of addition of 
Ba2+ on Alg-Gly5 was evident from the fact that all the energy values attained stabilisation 
with even stretching and torsional contributions playing their part in structural optimisation. 
This confirms that an optimised alginate fibre formulation having desired tensile properties 
can be attained by varying the concentrations of plasticiser and crosslinking agent. 
5.4.8.3. Tensile analysis of drug-loaded optimised crosslinked-plasticised-alginate fibres 
The mechanically optimised fibres were loaded with model drugs, diclofenac and 
ciprofloxacin. The addition of individual drugs significantly affected the tensile properties of 
alginate fibres with a steep decline in Young’s modulus. However, the alginate fibres 
regained the Young’s modulus’ original magnitude when both the drugs were incorporated 
simultaneously (and cumulatively) into the optimised formulation (Table 5.4). A molecular 
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mechanics assisted model building and energy refinements approach to establish the 
mechanism for the above interesting observations. 
The results obtained when loading fibres with either ciprofloxacin or diclofenac drug were in 
line with the previously reported work by Wu and McGinity (1999) where they used 
chlorpheniramine maleate and ibuprofen to influence the mechanical properties of polymeric 
films and proposed that these drugs acted as “non-traditional plasticisers” and hence caused 
a reduction in Young’s modulus. This effect is also evident from energy Equations 5.3-5.7 
and Table 5.6 that the incorporation of ciprofloxacin and diclofenac into alginate 
accompanied with ∆vdWf of 12.679kcal/mol and 13.223kcal/mol, respectively, thereby 
causing a decrease in CED between the monosaccharide residues. The drug molecules 
seem to lie between the monosaccharide units thereby connecting them providing the 
required flexibility for sliding over. This decrease in CED seems to be responsible for the 
decline of Young’s modulus on the same ground as explained previously with addition of 
glycerol. Furthermore, as for the addition of glycerol, addition of drugs individually to the 
polymer matrix resulted in stabilisation of total steric energy of the polymer-drug complex 
confirming the thermodynamic stability of the molecular system – a prerequisite for efficient 
plasticisation. 
Surprisingly but interestingly, the simultaneous incorporation of ciprofloxacin and diclofenac 
led to a highly increased vdWf and total steric energies (both positive in magnitude) along 
with highly stabilised bond angle and torsional contributions (both negative in magnitude) as 
calculated in Table 5.6. The geometrical conformation displayed in Figure 5.15 confirms the 
close interaction profile of this trimolecular complex system. The unexpected rise of Young’s 
modulus in the experimental results may be attributed to following: 
1. Incorporation of both the drugs simultaneously (200mg ciprofloxacin + 500mg 
diclofenac sodium) may have led to an increase in individual drug concentration above their 
saturation solubility in the adhesive layer of polymeric matrix. Additionally, from Equation 
5.15, CED is directly proportional to the solubility parameter. The solubility parameter (δ) 
may reach its maximum value after achieving saturation solubility which in turn may cause a 
very high increment in CED (CED N δ2) thereby leading to higher Young’s modulus than the 
individual drug’s incorporation (Roberts et al., 1991). 
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2. An increase in cumulative drug concentration may also lead to filling up of pores 
leading to a decrease in porosity of the polymer matrix. According to Spriggs’ equation 
(Spriggs,1961): 
  P ?UJVOM                                                                                     Equation 5.19 
where, E is the Young’s modulus, E0 is the Young’s modulus at zero porosity, P is the 
porosity and b is a constant in Spriggs’ equation. It is clear from the above exponential 
relationship that a decrease in porosity will lead to an increase in Young’s modulus as 
observed in the experimental results.  
3. These explanations however, do not fully define the reason for the increase in 
Young’s modulus as once the saturation solubility is reached, the precipitated drug crystals 
(superfluous) may cause filling of the existing cracks, notches, voids or crazing in the 
polymeric fibre being tested leading to a increase in rigidity and decrease in movability of the 
adjacent alginate chains finally leading to a increase in Young’s modulus (Gutiérrez-Rocca 
and McGinity, 1994). Additionally, increase in the crystallinity of a fibre structure may 
promote intermolecular forces, thus increasing the rigidity and brittleness of the film (Wu and 
McGinty, 1999). 
The above three reasons may be responsible for the regaining of the Young’s modulus value 
(from individual to simultaneous addition of drugs) thereby retaining the tensile properties of 
the initially optimised crosslinked-plasticised-alginate fibres by acting as “non-conventional 
biomedical tensile modifiers of polymeric fibres”. 
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Table 5.6: Calculated energy parameters (kcal/mol) of polymer-drug assemblies 
Name ∆Energiesa 
∆Totalb ∆Bondc ∆Angled ∆Dihedrale ∆Vdwf ∆H-bondg ∆Electroh 
Alg-Cpr i -20.652 0.001 -1.683 0 -12.679 0.215 -6.605 
Alg-Dcl j -12.447 -0.123 1.385 -1.554 -13.223 0.961 0.109 
Alg-Cpr-Dic k 309.459 216.016 -44.738 -24.838 109.283 3.2408 50.4996 
a
 ∆Ebinding = E(Host.Guest) - E(Host) - E(Guest) 
b Total steric energy for an optimised structure 
c Bond stretching contributions 
d
 Bond angle contributions 
e
 Torsional contribution 
f van der Waals interactions 
g Hydrogen-bond energy function 
h
 Electrostatic energy 
i Ciprofloxacin molecule in conjugation with an alginate chain 
j Diclofenac molecule in conjugation with an alginate chain 
k Ciprofloxacin and diclofenac molecules in conjugation with an alginate chain 
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Figure 5.15: Visualisation of energy minimised geometrical preferences of alginate (4 
monosaccharide units) with a) ciprofloxacin molecule; b) diclofenac molecule; and c) 
ciprofloxacin and diclofenac molecules, showcasing the intra- and inter- molecular 
interactions in drug-loaded crosslinked-plasticised-alginate fibres after molecular simulations 
in vacuum. Colour codes for elements: C (cyan), O (red), N (blue), and H (white) 
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5.5. Concluding Remarks 
Optimisation of the PFD in Chapter 4 provided a formulation which necessitated further 
evaluation to determine its appropriateness in the treatment of PD. In this chapter analysis of 
the optimised formulations physicomechanical and physicochemical parameters revealed 
information regarding the degree of crosslinking, the effect of the plasticiser and the 
interaction of formulation components affecting the strength, flexibility and drug release from 
the matrix. Literature has attributed these changes to the monomeric composition of polymer 
and the crosslinker ion present (Martinsen et al., 1987; Kuo and Ma, 2001; Tønnesen and 
Karlsen, 2002; Jejurikar et al., 2011) as well as the interactions with the plasticiser (Avella et 
al., 2007; Olivas et al., 2008). 
Evaluation of drug release using a UPLC proved to be a more sensitive method of detecting 
both diclofenac and ciprofloxacin release in PBS pH 4 and 6.8. Release of ciprofloxacin and 
diclofenac sodium was dependent on the solubility of the drug within dissolution media as 
well as swelling and relaxation of the polymeric matrix. Simulated molecular modelling 
elucidated the effect of formulation components, alginate, barium ions and glycerol, on the 
Young’s modulus. The tensile properties of the fibre when both ciprofloxacin and diclofenac 
were incorporated led to higher Young’s modulus than expected. Molecular modeling helped 
to explain this result, with hypothesised reasons relating to porosity and drug solubility 
saturation. Changes in vibrational energies characteristic of crosslinked alginate were 
observed in the IR spectra evident of the chemical changes occurring within the fibre 
affecting its structural characteristics. Addition of ciprofloxacin and diclofenac sodium 
seemed not to affect the chemical structure of the fibre. The fibre swelled considerably at pH 
6.8 over the first 24 hours, however, it eroded at a steady rate for the reminder of the 10 
days. In comparison, the fibre did not swell at pH 4 though it was consistently eroded over 
the same time period. Thus, the in vitro results of the fibre were promising, demonstrating the 
PFD’s potential in the treatment of PD.   
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CHAPTER 6 
IN VITRO ANTIMICROBIAL EVALUTION OF THE POLYMERIC FIBRE DEVICE  
6.1. Introduction  
An extensive range of microflora both anaerobic and aerobic, are present within the buccal 
cavity with over 500 species cultured from dental plaque (Pihlstrom et al., 2005). Periodontal 
pathogens are divided into categories based on the weight of evidence available as 
illustrated in Figure 6.1. Teles et al. (2006) stated “The best way to control these periodontal 
infections is to control the pathogenic species residing in these locations”, which forms the 
principle for the use of antimicrobials in the treatment of PD. Researchers in turn need to 
develop methods to assess the drug delivery device, confirming antimicrobial activity of the 
formulation against periodontal pathogens in vitro. 
Since 1929, antimicrobial susceptibility tests have been used to determine the antimicrobial 
effect of an agent/compound placed in a medium which is able support the growth of the 
microorganisms (Poupard, 1994).  Antimicrobial susceptibility tests may be employed in the 
development of new antimicrobial agents as well as investigating the efficacy of drug delivery 
device loaded with antimicrobial agents. Numerous screening tests have been used to 
determine the in vitro efficacy of locally placed devices against periodontal pathogens 
(Elkayam et al., 1988; Đkinci et al., 2002; Yue et al., 2004; Moulari et al., 2006). 
Elkayam et al. (1988) tested the in vitro antimicrobial effect of ethylcellulose films loaded with 
minocycline. Films were placed on blood agar plates which were inoculated with 
Staphylococcus aureus and incubated at 37˚C. The zone of inhibition was recorded on day 2, 
after which the film was transferred onto a freshly seeded agar plate. This process was 
repeated on day 4, 7 and 14. This screening test not only provided information regarding the 
antimicrobial activity of the sustained delivery device, but confirmed that the biological activity 
of the drug had been maintained once incorporated into a polymeric matrix.    
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Figure 6.1: Periodontal pathogens divided into categories based on prevalence of these 
pathogens in PD according to literature reviewed by American Academy Periodontology 
(2004) and Teles et al. (2006)  
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Using a similar method, Đkinci et al. (2002) investigated the antimicrobial activity of chitosan 
against P. gingivalis. Variations in the formulation such as molecular weight of chitosan, 
degree of deacetylation and incorporation of chlorhexidine were compared against one 
another detecting changes in antimicrobial activity by measuring the zones of inhibition. The 
microbial susceptibility tests assisted in the identification of the necessary components in the 
development of an optimal formulation measuring the zone of inhibitions on Schaedler agar, 
supplemented with hemin and vitamin K, and inoculated with P. gingivalis, isolated from 
subgingival plaque.  
Bacteriological studies may be utilised in determining whether in vitro dissolution release 
correlates to effective inhibition of periodontal pathogens as described by Yue et al. (2004). 
The study tested the antimicrobial activity of chlorhexidine-loaded microspheres, which were 
compressed into a chip, against P. gingivalis and B. forsynthus. The polymeric chip was 
placed on plates, which were inoculated with pathogens and the zone of inhibition was 
measured over 10 days.  
In vitro antimicrobial tests have further proved their usefulness as screening assays to 
determine the activity of new compounds or devices against a range of periodontal 
pathogens. The bactericidal activity of Harungana madagascariensis Lam. ex Poir. ethyl 
acetate leaf extract was compared to ethyl acetate extract-loaded nanoparticles (Moulari et 
al., 2006). The minimum bactericidal concentration was determined using the microtiter plate 
method, where bacterial strains were combined in a well with either the leaf extract or the 
extract was loaded in nanoparticles. Analysis of the data compared the antimicrobial activity 
of the leaf extract to the extract-loaded nanoparticles against the Actinomyces, 
Fusobacterium, Lactobacillus, Prevotella, Propionibacterium and Streptococcus species.  
The aforementioned studies highlight the importance of antimicrobial assays in the in vitro 
analysis of controlled delivery devices placed within the gum pocket for the treatment of PD. 
They served as the basis for incorporation of similar antimicrobial analysis in this study.  
Ciprofloxacin was chosen as the model antimicrobial drug for incorporation within the PFD. 
This fluoroquinolone antibiotic has been used both systemically and locally in the treatment 
of periodontal diseases. It is a broad spectrum bactericidal antibiotic, which targets bacterial 
DNA, specifically topoisomerase II enzyme.  Chin and Neu (1984) compared activity of 
ciprofloxacin to norfloxacin, cefotaxime, cephalexin, ceftazidime, moxolactam, amoxicillin and 
methacillin against a number of microorganisims. Their results confirmed ciprofloxacin 
inhibits both anaerobic and aerobic cocci and bacilli in relatively low concentrations 
(≤0.05µg/ml) as well as demonstrating consistently better activity compared to norfloxacin. 
Furthermore, ciprofloxacin inhibited gentamicin-, ameikacin-, cefotaxime-, and moxalactam-
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resistant members of the family Enterobacteriaceae and Pseudomonas aeruginosa and 
methicillin-resistant Staphylococcus aureus.   
An in vitro study conducted on bacteria invading the oral cavity investigated ciprofloxacin’s 
activity against causative pathogens (Wade, 1989). The antibiotic was dissolved in distilled 
water preparing a stock solution (0.2%w/v) and diluted in Wilkins-Chalgren agar, in 9cm petri 
dishes, at a final concentration of 128-0.25mg/L. Once the plates were inoculated with the 
appropriate microorganism they were incubated for 96 hours in an anaerobic chamber and 
the minimum inhibitory concentration (MIC) was determined. This study quantified 
ciprofloxacin’s activity against Actinomyces spp. (MIC range 0.5-128mg/L), Bacteriodes spp. 
(MIC range1-4mg/L), Eubacterium spp. (MIC range 1-2mg/L), Fusobacterium nucleatum 
(MIC range 2-4mg/L), Peptostreptococcus spp. (MIC range <0.25-16mg/L), P. gingivalis (MIC 
range 0.25-16 mg/L) and Selenomonas spp. (MIC range <0.25-0.5mg/L).   The MIC range 
and values against Actinomyces spp. confirm that in vitro ciprofloxacin is needed in higher 
concentrations to inhibit growth of this microorganism. However, in vivo ciprofloxacin 
demonstrates better activity against A. actinomycetemcomitans than expected. Easmon and 
Crane (1985) confirmed that ciprofloxacin is four to eight times more concentrated within 
human neutrophils compared to extracellular levels.   
Significantly higher levels of ciprofloxacin where found in polymorphonuclear leukocytes 
(PMNs) in vivo compared to intracellular fluid (Garraffo et al., 1991). This explains the higher 
levels of ciprofloxacin in gingival crevicular fluid compared serum levels (Tözϋm et al., 2004).  
PMNs, released as part of the primary host defense, are responsible for the phagocytosis of 
bacteria, however, A. actinomycetemcomitans seems to evade destruction via PMNs (Holm 
et al., 1993). Cacchillo and Walters (2002) investigated the effect of ciprofloxacin loaded 
PMNs on A. actinomycetemcomitans. Their study concluded that when high concentrations 
of bacteria to PMNs (90:1 and 30:1) is present ciprofloxacin loaded PMNs were more 
effective than the control PMNs or ciprofloxacin alone in killing A. actionmycetecomitans.   
The review of the literature confirmed that ciprofloxacin has been used effectively in the 
treatment of PD and is active against causative periodontal pathogens. To confirm and 
quantify the antibacterial activity of the optimised PFD, the fibres were analysed against 
Escherichia coli (E. coli) (ACC 8739) and Enterococcus faecalis (E. faecalis) (ATCC 29212), 
representative of anaerobic Gram-negative and Gram-positive microbe respectively, as well 
as Streptococcus mutans (S. Mutans) (NCTC 10919), a facultative Gram-positive anaerobe. 
In Chapter 3, it was mentioned that E. Faecalis and E.coli have been found present in PD. S. 
Mutans has been used on numerous occasions to test the antimicrobial activity of a device 
formulated for the treatment of PD (Ahmed et al., 2009; Muchalambe et al., 2010; 
Ramachandra et al., 2011). These microbes serve as model test pathogens which 
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determined if sufficient ciprofloxacin was entrapped and then subsequently released from the 
PFD to in inhibit microbial growth over 10 days. Both qualitative and quantitative data was 
attained through agar diffusion assays and minimum inhibitory concentration (MIC) assays 
respectively. Ethics was not required for this project as stipulated in appendix D.  
6.2. Materials  
NundronTM Surface MIC plates were purchased from Nunc, Denmark. Mueller Hinton (MH) 
agar was obtained from Oxoid, Hampshire.  Iodonitrotetrazolium chloride indicator dye was 
procured from Sigma-Aldrich, St Louis, Missourri, USA and plate seals were attained from 
AEC, Amersham. Stock culture (S. Mutans) as well as sheep’s blood were obtained from the 
National Health Laboratory Services. Other materials utilised were purchased from suppliers 
as described in previous chapters.  
6.3. Methods 
6.3.1. Preparation of fibres 
The optimised PFD was prepared using a fixed combination of alginate, barium chloride and 
glycerol as indicated in Table 6.1. Each formulation was prepared in triplicate; (1) 
ciprofloxacin-loaded (200mg) fibres, (2) ciprofloxacin/diclofenac sodium-loaded 
(200mg/500mg) fibres and (3) drug-free fibres. Fibres were prepared as outlined in Chapter 3 
Section 3.3.1 with model drugs added to distilled water followed by the addition of alginate.  
Table 6.1: Composition of optimised formulations  
Formulation components  1 2 3 
Alginate (%w/v) 3.14 3.14 3.14 
Glycerol (mL) 22.54 22.54 22.54 
Barium chloride 2-hydrate (%w/v) 10.00 10.00 10.00 
Ciprofloxacin (mg)  200 200 - 
Diclofenac sodium (mg)  - 500 - 
6.3.2. Preparation of culture and media 
Guidelines obtained from the National Committee on Clinical Laboratory Service (NCCLS) 
(2003) were followed ensuring accurate microbiological assay and transfer techniques. Stock 
cultures were stored at -20˚C. Subcultures were prepared in Trytone Soya Agar (TSA), 
incubated at 37˚C for 24 hours and checked for purity. Pure colonies were then isolated and 
further subcultured in TSA. Table 6.2 contains the strains of test organisms which were used 
in this study.  Weekly subcultures were kept for stock culture maintenance.  Media was 
prepared according to protocol provided by the supplier. Media components were weighed, 
dissolved in distilled water, autoclaved (Butterworth) for 15 minutes at 121˚C and pre-
incubated to confirm sterility.  
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Table 6.2: Microbial test organisms with corresponding Gram stains, incubation conditions 
and reference strains 
Test organism Gram 
stain 
Incubation conditions Reference 
strain 
Escherichia coli (E. coli) Negative Aerobic, 37˚C for 24hr ACC 8739 
Enterococcus faecalis (E. faecalis) Positive Aerobic, 37˚C for 24hr ATCC 29212 
Streptococcus mutans (S. mutans) Positive Anaerobic (candle jar), 37˚C for 24hr NCTC 10919 
6.3.3. Agar diffusion studies 
Agar plates were prepared as outlined in Chapter 3 Section 3.3.5 for plates inoculated with 
E. coli or E. faecalis cultures. The plates inoculated with S. Mutans were prepared with 
100µL of culture and 20mL of a 2.5%v/v sheep’s blood in Mueller Hilton Agar. Samples of 
fibres were transferred onto the solidified agar using sterile forceps to prevent contamination. 
Ciprofloxacin/diclofenac-loaded fibres were tested simultaneously with the drug-free fibres, 
which served as the control (Figure 6.2a). Agar diffusion studies were conducted in triplicate 
for each test microbe.  The plates were placed in the fridge for 1 hour, allowing the drug to 
diffuse from the fibre, after which they were incubated at 37˚C for 24 hours. 
Iodonitrotetrazolium chloride indicator dye (INT) (0.04mg/mL) solution was sprayed onto E. 
coli and E. faecalis inoculated plates to visualise the inhibition zones. INT in the presence of 
dehydrogenase changes colour to purple red. Dehydrogenase enzyme is present in 
metabolically active microorganisms.  The zone of inhibition was measured, from the fibre to 
the edge where microbial growth was visible, comparing fibres loaded with ciprofloxacin and 
diclofenac sodium to the control. Four readings were taken as represented in Figure 6.2b 
around the fibre as it is an irregular shape with an asymmetrical zone of inhibition. 
 
(a) Prior incubation (b) Post incubation 
 
 
Figure 6.2: A diagrammatic sketch representative of agar diffusion plates (a) prior to 
incubation and (b) post incubation with arrows measuring the anticipated zone of inhibition of 
drug-free (DF) to that of ciprofloxacin/diclofenac-loaded (DL) fibres 
 
 
DF DF DL DL 
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6.3.4. In vitro dissolution studies 
Dissolution apparatus used was as described in Chapter 3 Section 3.3.6. Samples were 
removed on day 1, 2, 4, 6, 8 and 10 withdrawing 4mL of solution which was retained at -4˚C 
for further antimicrobial analysis. For comparative purposes dissolution samples were 
collected from drug-free, ciprofloxacin-loaded as well as ciprofloxacin/diclofenac-loaded 
fibres in PBS pH 4 and 6.8. As previously discussed the pH range of the periodontal pocket 
is large and the behaviour of crosslinked alginate fibres varies considerably depending on 
pH.  
6.3.5. Minimum inhibitory concentration (MIC) assays 
The MIC micro-dilution bioassay (NCCLS, 2003) was used to quantitatively assess the 
antimicrobial activity of the PFD. Dissolution samples were diluted 1 in 10 with sterile water 
and vortexed prior to testing. Aseptically, 100µL of distilled water was added to each well of a 
96 well microtitre plate, followed by a further 100µL of dissolution sample (samples from day 
1, 2, etc) added to the first row of the microtitre plates. Serial dilutions were performed 
transferring 100µL of sample from the well above to the well below, each dilution halving the 
sample concentration in each well with every transfer, as in Figure 6.3. Each dissolution 
sample was tested in duplicate. Bacterial cultures were subcultured from stock agar plates 
and grown in Tryptone Soya broth overnight to confirm viability. Cultures were diluted 1:100 
in fresh Tryptone Soya broth, yielding an approximate inoculums size of 1 x 108 colony 
forming units (CFU)/mL. Each well was further inoculated with 100µl of bacterial culture.  
Plates were incubated for 24 hours at 37˚C. MIC plates inoculated with S. mutans were 
placed in an anaerobic candle jar and incubated for 24 hours. Prior to incubation, the 
microtitre plate was sealed with adhesive seal film to prevent loss of any volatile samples. 
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Figure 6.3: Schematic representation of MIC plate representing addition of sterile water to 
each of the 96 wells and dissolution samples from each sample time point added to the first 
row, followed by serial dilutions transferring 100µL from row to row, finally discarding 100µL 
from last row (DL – drug-loaded sample; DF – drug-free sample) 
 
Negative and positive controls were included in each assay as summarised in Table 6.3. The 
ciprofloxacin and diclofenac controls were prepared by dissolving the drug in sterile water 
with final concentrations of 0.1mg/mL. Equal quantities of the solutions were combined to 
test if the antimicrobial activity of ciprofloxacin was affected by diclofenac sodium. INT 
(0.04mg/mL) solution was prepared and 40µL added to each well. After 6 hours the MIC 
results were read as the lowest concentration of sample to inhibit microbial growth.  
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Table 6.3: Controls used to verify MIC results 
Positive controls Reason for inclusion 
Ciprofloxacin (0.01mg/mL)   To confirm activity of antibiotic used. 
Ciprofloxacin (0.005mg/mL)  and diclofenac 
sodium (0.005 mg/mL)   
To verify the antimicrobial activity of 
ciprofloxacin is maintained when combined 
with diclofenac sodium.  
Negative controls Reason for inclusion  
Drug-free fibre dissolution samples (1, 2, 4, 6, 
8, 10 days) 
To prove that the formulation without 
ciprofloxacin has antimicrobial activity.   
Diclofenac sodium (0.01mg/mL) To confirm that diclofenac sodium has no 
antimicrobial activity. 
PBS pH 4 & pH 6.8 To ensure that the buffer has no 
antimicrobial activity and that it is not 
contaminated.  
 
Broth (with culture) To verify that the broth can support the 
growth of microorganisms.  
Broth (without culture) To validate that the broth was not 
contaminated.  
6.4. Results and Discussion 
6.4.1. Qualitative studies assessed using agar diffusion assays 
Agar diffusion assays were used to investigate if the fibres contained sufficient ciprofloxacin 
and if the entrapped drug was released from the polymeric matrix to inhibit microbial growth. 
Ciprofloxacin/diclofenac-loaded fibres significantly inhibited the growth of all three test 
organisms while the control fibres showed no activity. The zones of inhibition are visually 
represented in Figure 6.4 and the mean measurements summerised in Table 6.4. The 
irregular zone of inhibition surrounding the fibre as well as the necessity to quantitatively 
measure the effectiveness of the fibre in releasing ciprofloxacin limits the use of this assay to 
qualitative purposes only.  
 Table 6.4: Mean zone of inhibition measurements for test organisms (N=3) 
Test organism Zone of inhibition (mm) 
E. coli (ACC 8739) 14.96 ± 0.94 
E. faecalis (ATCC 29212) 14.83 ± 0.32 
S. mutans (NCTC 10919) 17.79 ± 2.65 
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Figure 6.4: Agar diffusion assays comparing drug-free fibres (DF) to ciprofloxacin/diclofenac- 
loaded fibres (DL) inoculated with (a) E. coli, (b) E. faecalis and (c) S. mutans 
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6.4.2. Quantitative studies assessed using MIC assays 
The purpose of performing MIC analysis on the PFD was to determine if sufficient 
ciprofloxacin was released from the fibre at each time point. Furthermore, it was necessary to 
quantify the antimicrobial activity of the prolonged delivery device against the three test 
pathogens that were screened for activity in the diffusion assays.  The results are tabulated 
for comparison in Tables 6.5 and 6.6, representative of dissolution studies conducted in PBS 
pH 4 and 6.8 respectively. The study confirmed that sufficient ciprofloxacin was released 
from both ciprofloxacin- and ciprofloxacin/diclofenac-loaded fibres to inhibit growth of all 
three microorganisms. Therefore, the incorporation of diclofenac had no effect on the 
antimicrobial activity of the device. Both formulations had significantly more activity against 
E. coli (MIC range 0.1-0.7µg/mL) and E. faecalis (MIC range 0.2-1.1 µg/mL) compared to S. 
mutans (MIC range 0.7-2.1µg/mL). The MIC range for E. coli (0.1-0.4µg/mL for ciprofloxacin-
loaded and 0.5-0.8µg/mL for ciprofloxacin/diclofenac-loaded fibres) and E. Faecalis (0.2-
0.3µg/mL for ciprofloxacin-loaded fibres and 0.3-0.5 µg/mL for ciprofloxacin/diclofenac-
loaded fibres) is consistent throughout the 10 day sampling period. The MIC range for S. 
Mutans (0.4-1.0µg/mL for ciprofloxacin-loaded fibres and 0.7-2.1µg/mL for 
ciprofloxacin/diclofenac-loaded fibres) identified some variation from sampling times but was 
still within the ranges for MIC testing. Consistent MIC results over the testing period attest to 
steady concentrations of ciprofloxacin being released from one time point to another. Figure 
6.5a confirms that the MIC was maintained over the 10 days, its antimicrobial activity seems 
somewhat independent of the pH of the PBS, testing the fibres activity against E.coli. Similar 
results were attained when fibres were tested against E. faecalis and S. mutans, and thus 
only one test organism (E. coli) is represented in Figure 6.5 for the sake of brevity. The 
controls, represented in Figure 6.5b and Table 6.5, assisted in verifying the dissolution 
results. The PBS pH 4 and 6.8 as well as drug-free fibres demonstrated no inhibition of 
growth, confirming that the antimicrobial activity noted with the drug-loaded fibre is not 
attributed to the buffer or formulation components correspondingly. The broth showed no 
growth of microorganism compared to the broth inoculated with culture, which had growth 
throughout. This confirmed that the broth was not contaminated and it was able to support 
microbial growth. In comparison, the positive controls MIC values range was from 2.5-
10.0µg/mL for ciprofloxacin and 18.8-50.0µg/mL for ciprofloxacin/diclofenac combination at a 
ratio of 1:1. MIC results for the dissolution samples over the 10 day period tested, confirmed 
the efficacy of the sustainable release formulation comparable to the ciprofloxacin controls.   
It was verified that diclofenac has no antimicrobial activity, as no inhibition of growth was 
noted. However, when combined with ciprofloxacin it did not inhibit the ciprofloxacin’s 
antimicrobial activity.  
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Figure 6.5: MIC plates inoculated with E.coli, wells which changed colour to red after the 
addition of INT represented growth of bacteria while wells which remained colourless 
represented no bacterial growth, (a) dissolution samples in PBS pH 4 and 6.8 over 10 days 
(b) controls used for verification of results 
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Table 6.5: MIC results for ciprofloxacin-loaded and ciprofloxacin/diclofenac-loaded fibres 
from dissolution samples in PBS pH 4 over 10 days (NI – no inhibition) (NG – no growth) 
Samples Ciprofloxacin-loaded fibres  
MIC (µg/mL) 
Ciprofloxacin/diclofenac-loaded fibres 
MIC (µg/mL) 
 E. coli E. faecalis S. Mutans E. coli E. faecalis S. Mutans 
Day 1 0.2 0.3 0.8 0.5 0.4 0.7 
Day 2 0.4 0.2 0.9 0.6 0.6 1.2 
Day 4 0.2 0.4 1.0 0.7 1.1 1.4 
Day 6 0.1 0.4 0.6 0.8 0.8 1.7 
Day 8 0.3 0.2 0.6 0.5 0.4 1.9 
Day 10 0.1 0.2 0.4 0.5 0.5 2.1 
Controls:       
Ciprofloxacin 2.5 2.5 10.0 2.5 2.5 10.0 
Cipro/Diclo (1:1) 18.8 25.0 50.0 18.8 25.0 50.0 
Diclofenac  NI NI NI NI NI NI 
Drug free fibres (Day 1-10)  NI NI NI NI NI NI 
PBS pH 4 NI NI NI NI NI NI 
Broth with culture NI NI NI NI NI NI 
Broth  NG NG NG NG NG NG 
 
Table 6.6: MIC results for ciprofloxacin-loaded and ciprofloxacin/diclofenac-loaded fibres 
from dissolution samples in PBS pH 6.8 over 10 days (NI – no inhibition) (NG – no growth)  
Samples  Ciprofloxacin loaded-fibres 
MIC (µg/mL) 
Ciprofloxacin/diclofenac-loaded fibres 
MIC (µg/mL) 
 E. coli E. faecalis S. Mutans E. coli E. faecalis S. Mutans 
Day 1 0.2 0.2 0.8 0.4 0.4 0.8 
Day 2 0.2 0.2 0.9 0.5 0.5 1.0 
Day 4 0.2 0.2 1.0 0.4 0.4 0.8 
Day 6 0.2 0.2 1.0 0.3 0.3 0.6 
Day 8 0.3 0.3 1.0 0.5 0.5 0.9 
Day 10 0.4 0.3 1.0 0.5 0.5 1.0 
Controls:       
Ciprofloxacin 2.5 2.5 10.0 2.5 2.5 10.0 
Cipro/Diclo (1:1) 18.8 25.0 50.0 18.8 25.0 50.0 
Diclofenac  NI NI NI NI NI NI 
Drug free fibres (Day 1-10)  NI NI NI NI NI NI 
PBS pH 6.8 NI NI NI NI NI NI 
Broth with culture NI NI NI NI NI NI 
Broth  NG NG NG NG NG NG 
The results of this study were compared to ethyl cellulose films loaded with minocycline, 
whichn the methodology was discussed in Section 6.1, confirmed that the polymeric matrix 
itself did not have any antimicrobial activity and did not interfere with the antimicrobial activity 
of the loaded drug (Elkayam et al., 1988). Although this type of study provided qualitative 
results, the MIC assays provide a quantitative analysis of the ciprofloxacin’s release from the 
PFD over a 10 day period. 
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6.5. Concluding Remarks 
Antimicrobial activity of the PFD loaded with ciprofloxacin was confirmed through diffusion 
and MICs assays. Diffusion assays proved its usefulness as a screening tool to determine if 
sufficient drug is incorporated within the formulation as well as confirming activity against a 
variety of microorganisms. Once activity was noted, it was necessary to determine if 
ciprofloxacin is released from the fibre is in sufficient quantities to inhibit growth of the 
microorganisms through assessing the dissolution samples. Furthermore, the MIC assay 
confirmed that the antimicrobial activity was maintained when both ciprofloxacin and 
diclofenac sodium were simultaneously loaded within a fibre and the antimicrobial activity 
was not affected by the pH of the dissolution media.  
Review of the literature validated the incorporation of ciprofloxacin, as the model 
antimicrobial drug, within a polymeric matrix. Although this study did not test the drug-loaded 
fibre against causative pathogens such as A. actinomycetemcomitans and P. gingivalis, 
Wade (1989) verified that ciprofloxacin demonstrates activity against these causative 
periodontal pathogens. Due to limited access to other periodontal pathogens, it is suggested 
that in further research the fibres should be tested against an extensive range of 
microorganisms, including gram-negative anaerobes. Analysis against clinical strains of 
periodontal pathogens may also prove useful. In addition drug release studies in conjunction 
with antimicrobial studies are necessary to investigate the concentration of ciprofloxacin that 
needs to be released over the 10 day period.     
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CHAPTER 7 
CONCLUSIONS AND RECOMMENDATIONS 
7.1. Conclusions 
PD is a condition with worldwide prevalence that if left untreated it may lead to permanent 
tooth loss.  Known risk factors in SA such as HIV, diabetes and socio-economic status affect 
a large portion of the South African population.  This may lead to a situation where the 
presence of periodontal infections escalates substantially. With an already burdened health 
care system the need to develop innovative treatment options is clearly important. Numerous 
drug delivery devices are at various stages of drug development processes, with a few 
commercially available abroad but none of which are obtainable in South Africa. To date one 
study has been conducted locally, formulating tetracycline-loaded microparticles and tested 
in vitro for the treatment of PD (Govender et al., 2005).  Therefore further research into a 
locally developed and manufactured drug delivery system for the treatment of PD would be 
highly beneficial.  
Chemotherapeutic treatment of PD is normally used in conjunction with SRP and may be 
delivered systemically or locally. Locally drug delivery of many antimicrobial agents 
dominated periodontal research in the 1990’s (Chapple 2009). It has been reported that local 
drug delivery for the treatment of PD has failed to meet the therapeutic objectives (Chappel, 
2009; Fellman, 2010). At a symposium held to discuss the role of local drug delivery within 
the periodontal pocket, questions were raised regarding the intended patient recipients, 
choice of antimicrobial/antiseptic agents, use of the device in conjunction the mechanical 
intervention and physical characteristics of the device (Finkelman and Williams, 1998).  
Schwach-Abellaoui et al. (2000) recommended that a suitable delivery system intended for 
the treatment of periodontal diseases should meet the following criteria: 
• The polymer must be free from impurities, additives, stabilisers, catalyst residues and 
emulsifies that may be eluted from the device.  
• The physical, chemical and mechanical properties of the polymer should not be 
changed by the biological environment from a nondegradable device.  
• The device should be thermally and mechanically stable.  
• The device must be easily processed into the intended form i.e. film, fibre, gel, 
multiparticulate.  
• The device should not evoke an inflammatory, toxic or carcinogenic response.  
• The device should be prepared under sterile conditions or be sterilised afterwards.  
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These guidelines form the minimum requirements that any device should meet. The in vitro 
analysis of the device needs careful consideration to evaluate the physical and chemical 
properties in order for the device to meet the therapeutic requirements in vivo.  
The majority of the research has focused on the delivery of antimicrobial agents, with little 
information available regarding anti-inflammatory agents used in the treatment of PD (Addy 
and Renton-Harper, 1996). Reddy (2003) reviewed the use of NSAIDs in the treatment of PD 
and concluded that the clinical trial results correlated with treatment rationale.  Further 
research is required to determine the efficacy of NSAIDs in comparison to antimicrobials and 
mechanical debridement as well as determining the effect of NSAIDs delivered locally 
(Howell and Williams, 1993).  
This study designed a local delivery device for placement within the periodontal pocket 
releasing ciprofloxacin and diclofenac sodium over a 10-day period. The incorporation of 
both ciprofloxacin and diclofenac sodium was aimed at both the microbial and inflammatory 
aetiology of PD. The PFD formed a strong and flexible matrix demonstrating activity against 
E. coli, E. faecalis and S. mutans. Simulated molecular models confirmed the effect of 
formulation components and model drug on the tensile properties of the fibre. The results 
thus far are promising, therefore advocating further analysis of the fibres.  
7.2. Recommendations 
The extremes of pH measured in the periodontal pocket impacts drug release. Most studies 
conducted in formulating a device have failed to test the device in an acidic and more basic 
environment. Incorporation of a weak acidic drug, diclofenac sodium, and a weak basic drug, 
ciprofloxacin, within a pH responsive polymer, sodium alginate, led to pH responsive drug 
release.  The pH of the pocket needs to remain constant for steady drug release from the 
fibre. It is therefore proposed that a buffered gel, which could maintain the pH of the pocket 
at 6.8, could be co-administered with the fibre resulting in steady drug levels.  
The major challenge posed by the study was to formulate fibres of a consistent size and 
shape. The force applied to the plunger of the syringe was a difficult factor to control. Ideally 
a syringe pump should be used where the applied pressure could be held constant. A 
syringe pump was purchased, however it was not suitable as the alginate solution was 
viscous and the flow rate required exceeded the set limits of the pump. A suitable method to 
ensure that homogenous fibre is formed needs further consideration. 
In vitro dissolution apparatus used in testing the release properties of a local delivery device 
placed within the periodontal pocket vary from study to study as described in Chapter 3 
Section 3.4.5. Therefore, it has not been possible compare the drug release profiles of 
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various devices.  It is necessary to develop a suitable model to standardise dissolution 
studies.  
Incorporation of further polymers may enhance the physicochemical and physicomechanical 
properties of the device. Incorporation of mucoadhesive polymers may assist in securing the 
fibre within the pocket. To further optimise the release properties, nanoparticles could 
perhaps be suspended within the fibres releasing as the matrix swells and erodes.  
Antimicrobial activity of the drug-loaded fibres against the known causative periodontal 
pathogens, P. gingivalis, T. forsythensis, T. denticola, A. actinomycetemcomitans needs to 
be investigated. The fibres demonstrated excellent activity against E. faecalis, E. coli and S. 
Mutans using agar diffusion assays and MIC assays.  
A suitable method for securing the device within the pocket needs further consideration. The 
device could be secured in place with a biocompatible cyanoacylate glue. This is the 
mechanism used to secure the commercially available fibre, Actiste®. Alternative methods for 
securing the device in place should be investigated. The proposed methods are using a 
biodegradable stitch or developing a bioadhesive gel.  
No toxicology investigations have been conducted on the fibres as yet. Alginate and glycerol 
have been used extensively in formulation development. However, concern regarding barium 
chloride toxicity needs further investigation. Barium ions in solution may stimulate the heart 
muscle leading to ventricular fibrillation, which may result in death (Patnaik, 2003). The lethal 
dose of barium is estimated between 3-5g for an average adult (70kg) (Assimon et al., 1997). 
Barium cations have been used in development of numerous systems intended for human 
administration (Zekorn et al.; 1992; Klöck et al.; 1994; Bajpai et al., 2006). Although, a 
relatively high concentration of barium chloride was used in the crosslinking solution, the 
amount of cations crosslinked within the matrix needs to be determined. If the fibres were 
found to be toxic, the proposed solution would be to use a combination of crosslinking 
cations, perhaps salts incorporating zinc, aluminum and calcium ions. Furthermore, exposing 
the alginate crosslinked matrix to an acidic solution may retard erosion of the device (Bajpai 
and Sharma, 2004).   
If the device was found not to have any toxic affects the next stage in the development 
process would be testing in a suitable animal model. Weinberg and Bral (1999) compared 
animal models used in evaluation of the pathogenesis and treatment modalities in PD. The 
review concluded that both nonhuman primates (e.g. cynomolgus monkey) and dogs (e.g. 
beagles) should be used as animal models with regard to periodontal research as rodent 
models, such as hamsters and rats, have a different dental formula. 
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The study resulted in the formulation of a strong yet flexible fibre capable of entrapping a 
high percentage of model drugs. While it is acknowledged that the further research is 
necessary for this device to reach the next stage of the drug development process, 
nevertheless it is suggested that the results represent a valuable contribution towards the 
successful development of a biodegradable polymeric fibre for the treatment of periodontal 
disease.  In addition other applications of such a device warrant further investigations. 
Similar biocompatible drug-loaded fibres may be used as an implant, dental floss or as 
surgical sutures.     
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Appendix A: 
Flexural and extensibility testing of co-blended amphiphilic triethanolamine and transesterified epichlorohydrin-based 
alginate fibers 
Deanne Hazle, Viness Pillay*, Yahya E. Choonara, Lisa C. du Toit and Michael P. Danckwerts 
University of the Witwatersrand, Department of Pharmacy and Pharmacology, 7 York Road, Parktown, 2193, Johannesburg, 
South Africa 
*Correspondence: viness.pillay@wits.ac.za 
29th Annual Conference of the Academy of Pharmaceutical Sciences of South Africa, Hunters Rest Resort, Magaliesburg, 
Johannesburg, South Africa, September 22-26, 2008. 
Introduction  
The purpose of this study was to compare the physicochemical properties, elasticity and flexibility, of alginate fibres following 
the addition of various plasticizers.  
Methods 
Alginate fibers were prepared using a 4%w/v alginate solution crosslinked with 2%w/v barium chloride (BaCl2). Varying 
concentrations (7-10%) of plasticizers namely triethanolamine (TEA) and glycerine (GLY) were added to the alginate solution to 
form a homogenous mixture. Fibers were left to cure for 24 hours. The resultant alginate fibres were left to dry for 48 hours and 
were then cut into 70mm samples for standardization. A TA.XTplus Texture Analyzer (TA) was used for assessing the elasticity 
and flexibility of the fibres. A tensile grip was calibrated at a 60mm distance from the TA sample stage. A fiber was secured to 
both the lower and upper custom made tensile grips during testing at a data acquisition rate of 400pps. Force-Time profiles 
were plotted for each fibre tested revealing the effects of each the plasticizer in the formulation.  
Results 
Measurement of the distance to the fibre break-point indicated the elasticity with greater distances signifying more extensible 
fibre formulations. The maximum Force revealed the elastic limit or tensile strength of the various fibre formulations. 
Formulations B, C, D and E were more extensible (4.74-19.634mm) that Formulation A (Control) (4.12mm) where no plasticizer 
was included. Comparison of the results revealed that Formulation D fibres were the most extensible (238.03g of Force 
required). The breaking-point of the fibres indicated the flexibility. The Control formulations fractured immediately on the 
application of force. Formulations with added plasticizers demonstrated increased flexibility. Formulation B, C, D and E did not 
fracture under the same force applied and were significantly more extensible.  
Conclusions: Addition of TEA or GLY increased the elasticity and flexibility of the alginate fibres. Formulations comprising GLY 
demonstrated improved physicomechanical properties as compared to TEA formulations.  
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Appendix B: 
Characterization of co-blended amphiphilic transesterified epichlorohydrin-based alginate fibers for oramucosal 
delivery 
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Introduction 
This study involved the formulation of polymeric fibers for the site-specific delivery of metronidazole for the management of 
periodontitis. Prolonged release formulations within the gum cavity may improve patient compliance, reduce gastric degradation 
of drug and avoid extensive first-pass metabolism. 
Preparation and optimization of the metronidazole-loaded alginate fibers 
A metronidazole-alginate solution was crosslinked with BaCl2 into robust fibers. A plasticizer, glycerol (5-25mL), was then added 
to the solution as to increase the fiber flexibility. A Box-Behnken experimental design was employed to optimize the fiber 
formulation using various concentrations of alginate (2-4%w/v), BaCl2 (0.5-10%w/v) and glycerol (5-25mL). Fifteen formulations 
were generated and the results obtained for three of these are presented. 
Formulation Alginate BaCl2 Transesterified epichlorohydrin 
FA 2%w/v 10 %w/v 15mL 
FB 4%w/v 5.25%w/v 25mL 
FC 3%w/v 5.25%w/v 15mL 
Determination of the fiber fracture 
A Texture Analyzer (TA) determined the fiber fracture force. Samples (70mm) were placed between calibrated tensile grips 
60mm from the TA sample stage. Force-Time profiles revealed the influence of glycerol on the physicomechanical properties of 
the fibers. 
Assessment of fiber swelling and erosion 
Fibers were immersed in 100mL PBS (pH4, 37°C) and analyzed every 2 days over a 10 day period. Excess buffer was blotted 
and samples were weighed to determine the degree of swelling. Thereafter they were dried in an oven (30°C; 48hrs) until 
constant mass and re-weighed to determine the extent of erosion. 
Results 
Textural analysis revealed that FA fractured at a lower force (0.684N) compared to FC (0.777N) due to a decreased alginate 
concentration (2%w/v) that compromised fiber strength. FB fractured at the lowest force (0.678N) despite the higher alginate 
concentration. The increased glycerol reduced the fiber strength by acting as a plasticizer. FB swelled 201.33% of the original 
mass which was considerably higher than FA (87.12%) and FC (167.20%) also due to the higher alginate concentration. FC had 
the lowest extent of erosion after 10 days (36.52%) compared to FA (25.06%) and FB (23.53%) with an increased alginate 
concentration and reduced plasticizer volume. Increasing the alginate concentration enhanced the quantity binding sites 
available for ionotropic crosslinking with Ba2+, resulting in a highly interconnected and rigid fiber matrix. The addition of glycerol 
conversely reduced the degree of crosslinking, thus produced weaker flexible fibers through enhancement of the polymeric 
chain mobility.  
Conclusions 
Further studies are underway to assess the metronidazole release and improve the physicomechanical properties of the fiber 
system.  
Key words: co-blended amphiphilic transesterified epichlorohydrin-based alginate fibers 
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Periodontal disease (PD), a prevalent condition worldwide, is characterized as a chronic bacterial infection with cascading 
inflammatory reactions that if left untreated may lead to the permanent tooth loss. The aim of the study was to design, formulate 
and evaluate (in vitro) a novel polymeric matrix system to deliver an antimicrobial and anti-inflammatory drug over 10 days for 
the treatment of PD. Alginate combined with glycerol was crosslinked with barium cations forming a monolithic fiber 
incorporating ciprofloxacin and diclofenac sodium as the model antimicrobial and anti-inflammatory agents respectively. A 3-
Factor Box-Behnken Design was employed to statistically optimize the fibers according to their tensile properties and drug 
release. The optimized formulation (3.14%w/v alginate, 22.54mL glycerol and 10.00w/v barium chloride) was evaluated according 
to drug entrapment, drug release and hydration behavior at pH 4 and 6.8, vibrational transitions (FTIR), antimicrobial activity 
and tensile properties. Drug release at pH 4 occurred as a result of drug diffusing through the polymeric matrix however at pH 
6.8 the disruption of the fiber structure led to drug release as a consequence of the swelling and erosion of the matrix. 
Ciprofloxacin was sufficiently released from the drug-loaded fibers inhibiting growth of Escherichia coli, Enterococcus faecalis 
and Streptococcus mutans over 10 days. The physicomechanical and physicochemical properties were related to the degree of 
crosslinking, the effect of the plasticizer and the interaction of formulation components affecting the strength, flexibility and drug 
release from the matrix, which may be attributed to monomeric composition of polymer and the crosslinker ion present as well 
as the interactions with the plasticizer. The promising in vitro results advocate further analysis of the fibers.  
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